Non-integrating HIV-1 comprising mutant RT/IN proteins and the SARS-CoV-2 spike protein

REFERENCE TO SEQUENCE LISTING

This application includes one or more Sequence Listings pursuant to 37 C.F.R. 1.821 et seq., which are disclosed in computer-readable media (file name: 2650-0005US1_ST25.txt, created on May 18, 2020, and having a size of 206,750 bytes), which file is herein incorporated by reference in its entirety.

FIELD OF THE INVENTION

The present invention is directed to recombinant lentiviral particles that array the SARS-CoV-2 spike (S) protein on their surface (“SARS-CoV-2 S Protein Lentiviral Particles”), and that optionally comprise an additional copy of a polynucleotide encoding the SARS-CoV-2 spike (S) protein in their viral genome, and to methods for the production of such lentiviral particles. The invention particularly pertains to such SARS-CoV-2 S Protein Lentiviral Particles that have been engineered to be incapable of mediating the integration of their lentiviral genome into the chromosomes of infected cells and/or to be incapable of mediating the reverse transcription of their lentiviral genome. The present invention is also directed to “SARS-CoV-2 S Protein Lentiviral Vaccine” pharmaceutical compositions that comprise such SARS-CoV-2 S Protein Lentiviral Particles. The present invention is additionally directed to the use of such SARS-CoV-2 S Protein Lentiviral Vaccine pharmaceutical compositions for providing immunity to COVID-19 infection to humans and other mammals, either directly or as an inactivated form.

BACKGROUND OF THE INVENTION
I. Lentiviruses

Lentiviruses are members of the retroviridae family of viruses. They include primate and non-primate retroviruses (such as HIV and SIV (simian immunodeficiency virus), FIV (feline immunodeficiency virus), BIV (bovine immunodeficiency virus), CAEV (caprine arthritis-encephalitis virus), EIAV (equine infectious anemia virus) and visnavirus) (Escors, D. et al. (2011) “Lentiviral Vectors In Gene Therapy: Their Current Status And Future Potential,” Arch. Immunol. Ther. Exp. (Warsz.) 58(2):107-119). The most widely studied lentivirus is HIV-1, the causative agent of AIDS (Danforth, K. et al. (2017) “Global Mortality and Morbidity of HIV/AIDS,” In: MAJOR INFECTIOUS DISEASES, Vol. 6 (Holmes, K. K. et al. (Eds.)) The World Bank, Washington, D.C.; Engelman, A. et al. (2012) “The Structural Biology Of HIV-1: Mechanistic And Therapeutic Insights,” Nat. Rev. Microbiol. 10(4):279-290; Freed, E. O. (2015) “HIV-1 Assembly, Release And Maturation,” Nat. Rev. Microbiol. 13(8):484-496; Soliman, M. et al. (2017) “Mechanisms of HIV-1 Control,” Curr. HIV/AIDS Rep. 14(3):101-109; Elsinger, R. W. et al. (2018) “Ending the HIV/AIDS Pandemic,” Emerg. Infect. dis. 24(3):413-416).

Although wildtype lentiviruses are capable of causing disease, it has been possible to modify their genomes to produce lentiviral vectors and vaccines that have proven to be safe and effective in the laboratory and therapeutically (Keeler, A. M. et al. (2017) “Gene Therapy 2017: Progress and Future Directions,” Clin. Trasl. Sci. 10:242-248; Milone, M. C. et al. (2018) “Clinical Use of Lentiviral Vectors,” Leukemia 32:1529-1541; Escors, D. et al. (2011) “Lentiviral Vectors In Gene Therapy: Their Current Status And Future Potential,” Arch. Immunol. Ther. Exp. (Warsz.) 58(2):107-119; Schambach, A. et al. (2013) “Biosafety Features of Lentiviral Vectors,” Human Gene Ther. 24:132-142; Shirley, J. L. et al. (2020) “Immune Responses to Viral Gene Therapy Vectors,” Molec. Ther. 28(3):709-722). Lentiviruses have thus evolved into highly efficient vehicles for in vivo gene delivery (Chen, S.-H. et al. (2019) “Overview: Recombinant Viral Vectors as Neuroscience Tools,” Curr. Protoc. Neurosci. 87(1):e67:1-16; Lundstrom, K. (2019) “RNA Viruses as Tools in Gene Therapy and Vaccine Development.” Genes (Basel) 10(3):1-24).

The wildtype lentiviral genome consists of two linear, single-stranded, positive-sense RNA molecules of 9.75 kb, whose ends are flanked by long terminal repeated sequences (LTR). These 5′ and 3′ LTR sequences are required for viral transcription, reverse transcription, and integration of the viral genome. The lentiviral genome comprises at least nine genes: gag, pol, env, tat, rev, vpu, vpr, vif and nef (Hope, T. J. et al. (2000) “Structure, Expression, and Regulation of the HIV Genome,” HIV InSite Knowledge Base Chapter, pages 1-12). The basic structure of the lentivirus genome is shown in FIG. 1.

The lentiviral LTRs are composed of three subregions: U3 (for unique 3′ sequence), R (for repeated sequence), and U5 (for unique 5′ sequence) (Starcich, B. et al. (1985) “Characterization Of Long Terminal Repeat Sequences Of HTLV-III,” Science 227(4686):538-540). The U3 region is approximately 450-basepairs (bp) in length and is located at the 5′ end of each LTR. The U3 region contains cis-acting binding sites for cellular transcription factors. The R region of each LTR contains a 100-bp repeated sequence. Transcription begins at the first base of the R region and polyadenylation occurs immediately after the last base of R. The U5 region is 180-bp in length and contains the Tat binding site and packaging sequences of HIV. The 3′ end of the U5 region is defined by the location of a lysyl tRNA binding site. The lysyl tRNA acts as a primer for the reverse transcription of the lentivirus.

Transcription of the gag gene occurs in two reading frames at a ratio of approximately 20:1 due to a ribosomal frame-shifting event that is triggered by a specific cis-acting RNA motif in the distal region of the gag RNA. The more abundant gag transcript encodes a 55 kD Gag precursor protein that is cleaved into four smaller proteins, designated MA (matrix (p17)), CA (capsid (p24)), NC (nucleocapsid (p9)), and p6, by a virally encoded protease (p10; PRO)) (Gottlinger, H. G. et al. (1989) “Role Of Capsid Precursor Processing And Myristoylation In Morphogenesis And Infectivity Of Human Immunodeficiency Virus Type 1,” Proc. Natl. Acad. Sci. (U.S.A.) 86:5781-5785. The frame-shifting causes the less abundant gag transcript to include pol gene sequences, so that a 160 kD Gag-Pol fusion protein is expressed. This fusion protein is cleaved into Gag and Pol proteins by the viral protease (p10 (PRO)). The Pol cleavage product is further digested to yield the viral protease (p10 (PRO)), a reverse transcriptase (p50; RT) that is needed for the reverse transcription of the genomic RNA into DNA, an RNase H (p15), and an integrase (p31, IN)) that is needed to effect the integration of the lentivirus into the chromosome of infected cells. The env gene encodes 160 kD protein that is cleaved by cellular enzymes into a gp120 surface glycoprotein (SU) and a gp41 transmembrane protein (TM). These proteins associate with one another to form trimeric structures on the surface of the mature lentivirus. Tat encodes a transcriptional trans-activator critical for activating viral transcription. Rev encodes a 13-kD sequence-specific RNA binding protein that regulates the splicing and export of viral transcripts (Pollard, V. W. et al. (1998) “The HIV-1 Rev Protein,” Annu. Rev. Microbiol. 52:491-532). The rev and tat genes both contain untranscribed intervening sequences. Tat and rev are the first proteins to be synthesized following integration and are required to accelerate the production of viral mRNAs. The vpu, vpr, vif and nef genes encode accessory proteins, and are not required for viral replication in in vitro systems (Klimatcheva, E. et al. (1999) “Lentiviral Vectors And Gene Therapy,” Front. Biosci. 4:D481-D496). Among these gene, vpr is a virion-associated protein present only in primate lentiviruses. Vpr can act as a weak transcriptional trans-activator of the LTRs and participates in enabling infection of non-dividing cells (Heinzinger, N. K. et al. (1994) “The vpr Protein Of Human Immunodeficiency Virus Type 1 Influences Nuclear Localization Of Viral Nucleic Acids In Nondividing Host Cells,” Proc. Natl. Acad. Sci. (U.S.A.) 91(15):7311-7315). The 16-kD Vpu polypeptide is an integral membrane phosphoprotein that is primarily localized in the internal membranes of the cell. It functions to down-modulate CD4 and to enhance virion release (Willey, R. L. et al. (1992) “Human Immunodeficiency Virus Type 1 Vpu Protein Induces Rapid Degradation Of CD4,” J. Virol. 66(12):7193-7200; Schubert, U. et al. (1996) “The Two Biological Activities Of Human Immunodeficiency Virus Type 1 Vpu Protein Involve Two Separable Structural Domains,” J. Virol. 70(2):809-819). Nef acts post-translationally to decrease the cell-surface expression of CD4, the primary receptor for HIV (Foster, J. L. et al. (2011) “Mechanisms Of HIV-1 Nef Function And Intracellular Signaling,” J. Neuroimmune Pharmacol. 6(2):230-246; Garcia, J. V. et al. (1992) “Downregulation of Cell Surface CD4 by nef,” Res. Virol. 143(1):52-55). Vif is a 23-kD polypeptide that is essential for the replication of HIV in peripheral blood lymphocytes, macrophages, and certain cell lines (Strebel, K. et al. (1987) “The HIV ‘A’ (sor) Gene Product Is Essential For Virus Infectivity,” Nature 328(6132):728-730).

Located between the 5′-LTR and the gag gene is ψ, which is a region that serves as a signal for genome dimerization and packaging. In addition to these major genes, the viral genome also contains regulatory genes (tat and rev) as well as accessory genes (e.g., vif, vpr, vpu, p7, and nef).

Lentiviral particles are highly structured. FIG. 2 illustrates the structure of a wildtype lentivirus particle. The particle is composed of a central core that contains two copies of the viral RNA genome complexed with the nucleocapsid proteins. The central core also contains the viral integrase, reverse transcriptase, and accessory proteins. The central core is enclosed within a protein shell that is formed through the self-assembly of lentiviral p24 capsid proteins. A layer of matrix proteins surrounds the capsid shell. Envelope glycoproteins (env proteins) are incorporated into the matrix protein layer. When the virus is released from infected cells (“budding”), a portion of the cell's lipid membrane envelopes the matrix protein layer. The envelope glycoproteins extend beyond this lipid membrane envelope and are capable of binding to receptor molecules that are present on the surfaces of new potential host cells, thereby enabling the infection of such cells. The nature of a lentivirus' env proteins thus determines the lentivirus' host range (i.e., the species that the virus are capable of infecting) and tropism (i.e., the specific cell types that the virus is capable of infecting).

The Lentivirus lifecycle can be summarized by six major steps: First, envelope glycoproteins on the surface of the lentiviral particle bind to cell receptors, permitting the virus to enter into the cell. Then, the matrix and capsid proteins disassemble, releasing the viral genome and viral proteins into the cytoplasm of the infected cell. The reverse transcriptase then uses the viral RNA as a template for the synthesis of viral DNA. The viral DNA is then transported to the nucleus where it is integrated into the host genome via the action of viral integrase (Fanales-Belasio, E. et al. (2010) “HIV Virology And Pathogenetic Mechanisms Of Infection: A Brief Overview,” Ann. I. Super. Sanita. 46(1):5-14). The 5′ LTR of the integrated viral genome acts as a combined enhancer and promoter, enabling the host cell's RNA polymerase II to begin transcription of the viral genome. The 3′ LTR stabilizes newly synthesized transcripts by regulating their polyadenylation. Tat, Rev, and Nef proteins are produced that facilitate the production of other viral transcripts necessary for progression through the viral lifecycle (Wei, P. et al. (1998) “A Novel CDK9-Associated C-Type Cyclin Interacts Directly With HIV-1 Tat And Mediates Its High-Affinity, Loop-Specific Binding To TAR RNA,” Cell 92(4):451-462). Rev facilitates the nuclear export of the viral mRNA molecules by binding to a Rev-responsive element (RRE) on such transcripts (Malim, M. H. et al. (1989) “The HIV-1 Rev Trans-Activator Acts Through A Structured Target Sequence To Activate Nuclear Export Of Unspliced Viral mRNA,” Nature 338(6212):254-257). Finally, the exported viral genome and proteins are assembled at the cell's plasma membrane and released from the host cell (Fanales-Belasio, E. et al. (2010) “HIV Virology And Pathogenetic Mechanisms Of Infection: A Brief Overview,” Annali Dell'istituto Superiore Di Sanita. 46(1):5-14).

II. Lentiviral Vectors

Lentiviruses cannot be directly employed as vaccines because their capacity to integrate into cellular chromosomes of infected cells is potentially oncogenic. Thus, lentiviral vector systems have been developed that do not permit chromosomal integration to occur. Most recombinant lentivirus vectors are derived from HIV-1. In order to comport with the constraints that certain lentiviral elements, such as the LTRs, ψ, and RRE (Rev response element required for processing and transport of viral RNAs) are required in cis, whereas other lentiviral elements, such as genes: gag, pol, env, tat, rev, vpu, vpr, vif and nef function in trans, such vector systems entail the co-transfection of multiple plasmids.

Multiple generations of such lentiviral vector systems have been described (Pincha, M. et al. (2010) “Lentiviral Vectors For Immunization: An Inflammatory Field,” Expert Rev. Vaccines 9(3):309-321). Their basic principle is to avoid the formation of replication-competent species (Schambach, A. et al. (2013) “Biosafety Features of Lentiviral Vectors,” Human Gene Ther. 24:132-142). To accomplish these goals, sequences that encode lentiviral proteins are deleted from the transgene-containing vector, and sequences that are required for highly efficient packaging into nascent particles are moved to a separate plasmid. In order to be able to more easily vary tropism, sequences encoding the envelope protein are provided on a further plasmid.

Thus, in the first generation of lentiviral vectors, three vectors were employed to produce lentiviral particles:

(1) a packaging plasmid that encoded the required gag and pol sequences, the viral regulatory genes tat and rev and the accessory genes vif, vpr, vpu and nef;
(2) an envelope vector that encoded a non-lentiviral, heterogenous envelope protein (“pseudotyped” envelope protein) that determines the host range (tropism) of the lentiviral particle; and
(3) a transfer vector that comprised the 5′ and 3′ LTR sequences, W, the RRE, the central polypurine tract (cPPT) (derived from the Pol reading frame) that increases the efficiency of reverse transcription (RT), and a desired exogenous gene for expression (transgene) under the control of a promoter, such as the cytomegalovirus (CMV) immediate-early enhancer and promoter (Barrow, K. M. (2006) “Use Of The Cytomegalovirus Promoter For Transient And Stable Transgene Expression In Mouse Embryonic Stem Cells,” Methods Mol Biol. 329:283-294) or the Rous sarcoma virus (RSV) (Yaguchi, M. et al. (2013) “Characterization Of The Properties Of Seven Promoters In The Motor Cortex Of Rats And Monkeys After Lentiviral Vector-Mediated Gene Transfer,” Hum. Gene Ther. Methods 24(6):333-344).

Co-transfection with all three vectors thus results in the production of lentiviral particles that express the pseudo-envelope protein on their surfaces. By replacing the native lentiviral envelope protein with a heterogenous “pseudotyped” envelope protein, such vector systems alter the tropism of the lentivirus so that it targets desired host cells. For example, the native lentiviral envelope protein can be replaced with the vesicular stomatitis virus glycoprotein G (VSV-G) to create a pseudotyped lentiviral vectors having extensive host cell infectivity (see, Gruber, A. et al. (2000) “Dendritic Cells Transduced By Multiply Deleted HIV-1 Vectors Exhibit Normal Phenotypes And Functions And Elicit An HIV-Specific Cytotoxic T-Lymphocyte Response in vitro,” Blood 96:1327-1333; Zufferey, R. et al. (1997) “Multiply Attenuated Lentiviral Vector Achieves Efficient Gene Delivery in vivo,” Nat. Biotechnol. 15:871-875).

Second generation lentiviral vector systems deleted the four accessory genes, vif, vpr, vpu and nef, thereby improving the safety profile of the lentiviral vector, since any replication-competent lentivirus would be devoid of all virulence factors (Hope, T. J. et al. (2000) “Structure, Expression, and Regulation of the HIV Genome,” HIV InSite Knowledge Base Chapter, pages 1-12; Escors, D. et al. (2011) “Lentiviral Vectors In Gene Therapy: Their Current Status And Future Potential,” Arch. Immunol. Ther. Exp. (Warsz.) 58(2):107-119).

Third generation lentiviral systems further improved the safety profile of the lentiviral vector by deleting the U3 region of the 3′-LTR (Pincha, M. et al. (2010) “Lentiviral Vectors For Immunization: An Inflammatory Field,” Expert Rev. Vaccines 9(3):309-321). The deletion results in the Transcriptional Self-Inactivation (SIN) of potentially packageable viral genomes in transduced cells (Schambach, A. et al. (2013) “Biosafety Features of Lentiviral Vectors,” Human Gene Ther. 24:132-142; Yu, S. F. et al. (1986) “Self-Inactivating Retroviral Vectors Designed For Transfer Of Whole Genes Into Mammalian Cells,” Proc. Natl. Acad. Sci. (U.S.A.) 83(10):3194-3198; Miyoshi, H. (1998) “Development Of A Self-Inactivating Lentivirus Vector,” J. Virol. 72(10):8150-8157). Additionally, the rev gene (which encodes a gene product that promotes the transport of unspliced and singly spliced viral transcripts into the cytoplasm, thereby allowing late viral proteins to be produced) is expressed from a separate plasmid. The 5′ LTR is modified to delete its U3 region and to place the 5′ LTR under the control of a strong tat-independent constitutive promoter (Dull, T. et al. (1998) “A Third-Generation Lentivirus Vector With A Conditional Packaging System,” J. Virol. 72:8463-8471). FIG. 3 illustrates the four vectors of third generation lentiviral systems.

III. Lentiviral Vaccines

Lentiviral vectors have been primarily employed as delivery vehicles for gene therapy due to the low incidence of pre-existing anti-lentivirus immunity in the population and their capacity to integrate into the genome of recipient cells (thus providing persistent, long term expression of the therapeutic gene being delivered by the vector) (Keeler, A. M. et al. (2017) “Gene Therapy 2017: Progress and Future Directions,” Clin. Trasl. Sci. 10:242-248; Milone, M. C. et al. (2018) “Clinical Use of Lentiviral Vectors,” Leukemia 32:1529-1541; Shirley, J. L. et al. (2020) “Immune Responses to Viral Gene Therapy Vectors,” Molec. Ther. 28(3):709-722; Escors, D. et al. (2011) “Lentiviral Vectors In Gene Therapy: Their Current Status And Future Potential,” Arch. Immunol. Ther. Exp. (Warsz.) 58(2):107-119; Chen, S.-H. et al. (2019) “Overview: Recombinant Viral Vectors as Neuroscience Tools,” Curr. Protoc. Neurosci. 87(1):e67:1-16; Klimatcheva, E. et al. (1999) “Lentiviral Vectors And Gene Therapy,” Front. Biosci. 4:D481-D496).

The use of lentiviral vectors as vaccines for providing long term active immunity against pathogens has been encumbered by low infectivity (Huisman, W. et al. (2009) “Vaccine-Induced Enhancement Of Viral Infections,” Vaccine 27(4):505-512) and by concerns regarding that lentiviral integration into the chromosomes of recipient cells may be oncogenic. Although the risk of insertional mutagenesis is considered to be very low (Norton, T. D. et al. (2016) “Recent Advances in Lentiviral Vaccines for HIV-1 Infection,” Front. Immunol. 7:243:1-8), incidences of leukemia were observed when a retroviral vector derived from the Murine Moloney Leukemia Virus (MoMLV) was used in two SCID-X1 lentiviral gene therapy trials (Gaspar, H. B. et al. (2011) “Long-Term Persistence Of A Polyclonal T Cell Repertoire After Gene Therapy For X-Linked Severe Combined Immunodeficiency,” Sci. Transl. Med. 3:97ra79:1-7; Hacein-Bey-Abina, S. et al. (2003) “LMO2-Associated Clonal T Cell Proliferation In Two Patients After Gene Therapy For SCID-X1,” Science 302:415-419).

In order to address such concerns, integrase-defective lentiviral vectors (IDLV) have been developed (Fontana, J. M. et al. (2014) “Mucosal Immunization With Integrase Defective Lentiviral Vectors Protects Against Influenza Virus Challenge In Mice,” PLoS One 9(5):1-12; Banasik, M. B. et al. (2010) “Integrase-Defective Lentiviral Vectors: Progress And Applications,” Gene Ther 17:150-157; Michelini, Z. et al. (2009) “Development And Use Of SIV-Based Integrase Defective Lentiviral Vector For Immunization,” Vaccine (2009) 27(34):4622-4629; Norton, T. D. et al. (2016) “Recent Advances in Lentiviral Vaccines for HIV-1 Infection,” Front. Immunol. 7:243:1-8). A number of mutations in the HIV integrase gene have been described, particularly within the protein's catalytic triad (Banasik, M. B. et al. (2010) “Integrase-Defective Lentiviral Vectors: Progress And Applications,” Gene Ther 17:150-157). As a result, IDLV accumulate in the nuclei of transduced cells as stable, transcriptionally-active, episomal DNA circles that persist in slowly dividing and terminally differentiated cells. A single immunization with an IDLV capable of delivering influenza hemagglutinin (HA) and nucleoprotein (NP) antigens provided high and persistent levels of antiviral neutralizing antibodies in mice (Fontana, J. M. et al. (2014) “Mucosal Immunization With Integrase Defective Lentiviral Vectors Protects Against Influenza Virus Challenge In Mice,” PLoS One 9(5):1-12; Gallinaro, A. et al. (2018) “Integrase Defective Lentiviral Vector as a Vaccine Platform for Delivering Influenza Antigens,” Front. Immunol. 9:171). Measles virus glycoproteins (MVGs), hemagglutinin (H) and fusion (F), have also been used to pseudotype lentiviral vectors for vaccines targeting dendritic cells (Norton, T. D. et al. (2016) “Recent Advances in Lentiviral Vaccines for HIV-1 Infection,” Front. Immunol. 7:243:1-8). Lentiviral vectors that are designed to target dendritic cells have been developed as cancer vaccines (Arce, F. et al. (2011) “Targeting Lentiviral Vectors For Cancer Immunotherapy,” Curr. Cancer Ther. Rev. 7(4):248-260).

IV. SARS-CoV-2 Coronavirus

Coronaviruses (CoVs) are enveloped, single-stranded, RNA viruses that possess a positive-sense RNA genome of 26 to 32 kilobases in length. Coronaviruses belong to the subfamily Orthocoronavirinae in the family Coronaviridae and the order Nidovirales. Four genera of coronaviruses have been identified, namely, Alphacoronavirus (αCoV), Betacoronavirus (βCoV), Deltacoronavirus (δCoV), and Gammacoronavirus (γCoV) (Chan, J. F. et al. (2013) “Interspecies Transmission And Emergence Of Novel Viruses: Lessons From Bats And Birds,” Trends Microbiol. 21(10):544-555). Evolutionary analyses have shown that bats and rodents are the gene sources of most αCoVs and βCoVs, while avian species are the gene sources of most δCoVs and 7CoVs. Prior to 2019, only six coronavirus species were known to be pathogenic to humans. Four of these species were associated with mild clinical symptoms, but two coronaviruses, Severe Acute Respiratory Syndrome (SARS) coronavirus (SARS-CoV) (Marra, M. A. et al. (2003) “The Genome Sequence of the SARS-Associated Coronavirus,” Science 300(5624):1399-1404) and Middle East Respiratory Syndrome (MERS) coronavirus (MERS-CoV) (Mackay, I. M. (2015) “MERS Coronavirus: Diagnostics, Epidemiology And Transmission,” Virol. J. 12:222. doi: 10.1186/s12985-015-0439-5) were associated with human mortalities approaching 10% (Su, S. et al. (2016) “Epidemiology, Genetic Recombination, And Pathogenesis Of Coronaviruses,” Trends Microbiol. 24:490-502; Al Johani, S. et al. (2016) “MERS-CoV Diagnosis: An Update,” J. Infect. Public Health 9(3):216-219).

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a newly identified coronavirus species (the virus was previously provisionally named “2019 novel coronavirus” or “2019-nCoV”) (Fang, Y. et al. (2020) “Transmission Dynamics Of The COVID-19 Outbreak And Effectiveness Of Government Interventions: A Data-Driven Analysis,” J. Med. Virol. doi: 10.1002/jmv.25750; Zhao, W. M. et al. (2020) “The 2019 Novel Coronavirus Resource,” Yi Chuan. 42(2):212-221; Zhu, N. et al. (2020) “A Novel Coronavirus from Patients with Pneumonia in China, 2019,” New Engl. J. Med. 382(8):727-733).

The SARS-CoV-2 genome has been sequenced from at least 170 isolates. The reference sequence is GenBank NC_045512 (Wang, C. et al. (2020) “The Establishment Of Reference Sequence For SARS-CoV-2 And Variation Analysis,” J. Med. Virol. 92:667-674; Chan, J. F. et al. (2020) “Genomic Characterization Of The 2019 Novel Human-Pathogenic Coronavirus Isolated From A Patient With Atypical Pneumonia After Visiting Wuhan,” Emerg. Microbes. Infect. 9(1):221-236). Comparisons of the sequences of multiple isolates of the virus (MN988668 and NC_045512, isolated from Wuhan, China, and MN938384.1, MN975262.1, MN985325.1, MN988713.1, MN994467.1, MN994468.1, and MN997409.1) reveal greater than 99.99% identity (Sah, R. et al. (2020) “Complete Genome Sequence of a 2019 Novel Coronavirus (SARS-CoV-2) Strain Isolated in Nepal,” Microbiol. Resource Announcements 9(11): e00169-20, pages 1-3; Brüssow, H. (2020) “The Novel Coronavirus—A Snapshot of Current Knowledge,” Microbial Biotechnology 0:(0):1-6). The SARS-CoV-2 genome is highly similar to that of human SARS-CoV, with an overall nucleotide identity of approximately 82% (Chan, J. F. et al. (2020) “Genomic Characterization Of The 2019 Novel Human-Pathogenic Corona Virus Isolated From A Patient With Atypical Pneumonia After Visiting Wuhan,” Emerg Microbes Infect 9:221-236; Chan, J. F. et al. (2020) “Improved Molecular Diagnosis Of COVID-19 By The Novel, Highly Sensitive And Specific COVID-19-RdRp/Hel Real-Time Reverse Transcription-Polymerase Chain Reaction Assay Validated In Vitro And With Clinical Specimens,” J Clin. Microbiol. JCM.00310-20. doi: 10.1128/JCM.00310-20). Based on its homology to related coronaviruses, SARS-CoV-2 is predicted to encode 12 open reading frame (ORFs) coding regions (ORF1ab, S (spike), 3, E (envelope protein), M (matrix), 7, 8, 9, 10b, N, 13 and 14.

The coronavirus spike or S protein, which is arrayed on the virus surface, is considered crucial for determining host tropism and transmission capacity (Lu, G. et al. (2015) “Bat-To-Human: Spike Features Determining ‘Host Jump’ Of Coronaviruses SARS-CoV, MERS-CoV, And Beyond,” Trends Microbiol. 23:468-478; Wang, Q. et al. (2016) “MERS-CoV Spike Protein: Targets For Vaccines And Therapeutics,” Antiviral. Res. 133:165-177). Studies of the S protein of SARS-CoV have found it to be functionally cleaved into two subunits: an S1 domain that mediates receptor binding, and an S2 domain that mediates membrane fusion (He, Y. et al. (2004) “Receptor-Binding Domain Of SARS-CoV Spike Protein Induces Highly Potent Neutralizing Antibodies: Implication For Developing Subunit Vaccine,” Biochem. Biophys. Res. Commun. 324:773-781; Li, F. (2016) “Structure, Function, And Evolution Of Coronavirus Spike Proteins,” Annu. Rev. Virol. 3:237-261; He, Y. et al. (2004) “Receptor-Binding Domain Of SARS-CoV Spike Protein Induces Highly Potent Neutralizing Antibodies: Implication For Developing Subunit Vaccine, Biochem. Biophys. Res. Commun. 324:773-781). The S protein of SARS-CoV-2 shares 76% identity with the S protein of SARS-CoV (Lu, R. et al. (2020) “Genomic Characterisation And Epidemiology Of 2019 Novel Coronavirus: Implications For Virus Origins And Receptor Binding,” Lancet 395(10224):565-574). In light of such similarity, it has been proposed that these S proteins may have similar functions. FIG. 4 illustrates the structure of the SARS-CoV-2 viral particle. The structure is similar to that of lentiviruses in that a glycoprotein spike (the S protein) extends out of the viral particle and is responsible for viral tropism.

Patients infected with SARS-CoV-2 exhibit COVID-19, a condition characterized by fever and cough (Kong, I. et al. (2020) “Early Epidemiological and Clinical Characteristics of 28 Cases of Coronavirus Disease in South Korea,” Osong Public Health Res Perspect. 11(1):8-14). In approximately 20% of patients, COVID-19 progresses to a severe respiratory disease and pneumonia that has a mortality of 5-10% (1-2% overall mortality). No cure for COVID-19 yet exists, and no vaccine is currently available. These deficiencies are exacerbated by the wide susceptibility of individuals to infection (reflecting the absence of prior herd immunity). Since no therapies have been proven to be effective thus far, management of COVID-19 presently consists of a “Four-Anti and Two-Balance” strategy included antivirus, anti-shock, anti-hyoxemia, anti-secondary infection, and maintaining water, electrolyte and acid-base balance and micro-ecological balance (Xu, K. et al. (2020) “Management Of Corona Virus Disease-19 (COVID-19): The Zhejiang Experience,” Zhejiang Da Xue Bao Yi Xue Ban. 49(1):0). In 2020, COVID-19 became a pandemic accounting for over 300,000 ascribed deaths.

In sum, an urgent need exists for a vaccine that could protect populations from COVID-19. The present invention is directed to this and other goals.

SUMMARY OF THE INVENTION

In detail, the invention provides a lentiviral particle that comprises a recombinantly engineered lentiviral genome and that arrays a SARS-CoV-2 spike (S) protein on its surface.

The invention further provides the embodiment of such lentiviral particle wherein the recombinantly engineered lentiviral genome is non-integrating.

The invention further provides the embodiment of such lentiviral particle wherein the recombinantly engineered lentiviral genome is incapable of being reverse transcribed.

The invention further provides the embodiment of such lentiviral particle wherein the recombinantly engineered lentiviral genome is non-integrating and incapable of being reverse transcribed.

The invention further provides the embodiment of such lentiviral particles wherein the recombinantly engineered lentiviral genome encodes a heterologous transgene protein.

The invention further provides the embodiment of such lentiviral particles wherein the encoded heterologous transgene protein is an antibiotic resistance determinant, a reporter protein, a protein drug effective in treating SARS-CoV-2 infection, or a protein that comprises the epitope binding domain of an antibody that binds to a SARS-CoV-2 antigen.

The invention further provides the embodiment of such lentiviral particles wherein the encoded heterologous transgene protein is a SARS-CoV-2 protein.

The invention further provides the embodiment of such lentiviral particles wherein the encoded SARS-CoV-2 heterologous transgene protein is a SARS-CoV-2 Spike (S) protein or a SARS-CoV-2 Nucleocapsid (N) protein.

The invention further provides a vaccine for the treatment of COVID-19, wherein the vaccine comprises a prophylactically effective dose of a pharmaceutical composition that comprises any of the above-described lentiviral particles and a pharmaceutically acceptable carrier.

The invention further provides the embodiment of such vaccine wherein the recombinantly engineered lentiviral genome of the lentiviral particle is non-integrating.

The invention further provides the embodiment of such vaccine wherein the recombinantly engineered lentiviral genome of the lentiviral particle is incapable of being reverse transcribed.

The invention further provides the embodiment of such vaccine wherein the recombinantly engineered lentiviral genome of the lentiviral particle is non-integrating and incapable of being reverse transcribed.

The invention further provides the embodiment of such vaccine wherein the recombinantly engineered lentiviral genome of the lentiviral particle encodes a heterologous transgene protein.

The invention further provides the embodiment of such vaccines wherein the encoded heterologous transgene protein is a SARS-CoV-2 Spike (S) protein or a SARS-CoV-2 Nucleocapsid (N) protein.

The invention further provides the embodiment of such vaccines wherein the pharmaceutically acceptable carrier is adapted for intramuscular administration.

The invention further provides the embodiment of such vaccines wherein the pharmaceutically acceptable carrier is adapted for intranasal administration.

The invention further provides a method for producing any of the above-described recombinant lentiviral particles, wherein the method comprises:

(A) transfecting HEK293 cells with:

- (1) an LTR-containing vector that comprises a deleted 5′ LTR U3 region and a self-inactivating 3′ LTR region;
- (2) a packaging vector that comprises a polynucleotide that encodes the gag and pol proteins;
- (3) a REV vector that comprises a polynucleotide that encodes a rev protein; and
- (4) an envelope vector that comprises a polynucleotide that encodes a SARS-CoV-2 spike (S) protein; and
  
  (B) permitting the cells to produce the recombinant lentiviral particle.

The invention further provides the embodiment of such method wherein the packaging vector comprises a genome that encodes a mutated integrase, wherein the transfection produces a recombinant lentiviral particle that comprises a genome that is non-integrating.

The invention further provides the embodiment of such method wherein the packaging vector comprises a genome that encodes a mutated reverse transcriptase, wherein the transfection produces a recombinant lentiviral particle that comprises a genome that is incapable of being reverse transcribed.

The invention further provides the embodiment of such method wherein the packaging vector comprises a genome that additionally encodes a mutated integrase, wherein the transfection produces a recombinant lentiviral particle that comprises a genome that is non-integrating and incapable of being reverse transcribed.

The invention further provides the embodiment of such methods wherein the LTR-containing vector comprises the features of any of the LTR-containing vectors:

pLenti-SV40-puro (SEQ ID NO:27);

pLenti-SV40-puro (-att) (SEQ ID NO:28);

pLenti-CMV-IRES-empty (-att) (SEQ ID NO:67);

pLenti-CMV-IRES-Spike (SEQ ID NO:70);

pLenti-IgGκ-nCoV-Spike-CD8-TM (-att) (SEQ ID NO:83);

pLenti-IgGκ-nCoV-N-CD8-TM (-att) (SEQ ID NO:84); or

pLenti-IL-2 n-CoV-N(-att) (SEQ ID NO:85).

The invention further provides the embodiment of such methods wherein the packaging vector comprises the features of pGAG (SEQ ID NO:44).

The invention further provides the embodiment of such methods wherein the REV vector comprises the features of pREV (SEQ ID NO:49).

The invention further provides the embodiment of such methods wherein the envelope vector comprises the features of pCMV-SARS-CoV-2 S Protein (SEQ ID NO:61).

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 illustrates the structure of a wildtype lentivirus genome.

FIG. 2 illustrates the structure of a wildtype lentivirus particle.

FIG. 3 illustrates the four plasmids of third generation lentiviral systems: the transgene-containing vector, the packaging vector, the rev-expressing vector and the envelope protein containing vector. CMV and RSV denote the cytomegalovirus immediate-early enhancer and promoter and the Rous sarcoma virus (RSV) promoter, respectively.

FIG. 4 illustrates the structure of the SARS-CoV-2 viral particle.

FIG. 5 illustrates the structure of the four plasmids employed to produce the SARS-CoV-2 S Protein Lentiviral Vaccine compositions of the present invention.

FIG. 6 provides the structure of pLenti-SV40-puro (SEQ ID NO:27) (7705 nucleotide residues), which is an example of an LTR-containing vector of the present invention.

FIG. 7 provides the structure of pLenti-SV40-puro (-att) (SEQ ID NO:28) (7701 nucleotide residues), which is an example of an LTR-containing vector of the present invention.

FIG. 8 provides the structure of pLenti-CMV-IRES-empty (-att) (SEQ ID NO:67) (7267 nucleotide residues), which is an example of an LTR-containing vector of the present invention.

FIG. 9 provides the structure of pLenti-CMV-IRES-Spike (-att) (SEQ ID NO:70) (11060 nucleotide residues), which is an example of an LTR-containing vector of the present invention.

FIG. 10 provides the structure of pLenti-IgGκ-nCoV-Spike-CD8-TM (-att) (SEQ ID NO:83) (11381 nucleotide residues), which is an example of an LTR-containing vector of the present invention.

FIG. 11 provides the structure of pLenti-IgGκ-nCoV-N-CD8-TM (-att) (SEQ ID NO:84) (8819 nucleotide residues), which is an example of an LTR-containing vector of the present invention.

FIG. 12 provides the structure of pLenti-IL-2 n-CoV-N(-att) (SEQ ID NO:85) (8552 nucleotide residues), which is an example of an LTR-containing vector of the present invention.

FIG. 13 provides the structure of pGAG (SEQ ID NO:44) (11282 nucleotide residues), which is an example of a packaging vector of the present invention.

FIG. 14 provides the structure of pREV (SEQ ID NO:49) (5514 nucleotide residues), which is an example of a Rev-containing vector of the present invention.

FIG. 15 provides the structure of pCMV-SARS-CoV-2 S Protein (SEQ ID NO:61) (8602 nucleotide residues), which is an example of an envelope vector of the present invention.

DETAILED DESCRIPTION OF THE INVENTION

The SARS-CoV-2 S Protein Lentiviral Particles of the present invention are lentiviral particle that have been pseudotyped to express and/or array the spike (S) protein of SARS-CoV-2 on their outer surface so as to permit the SARS-CoV-2 S protein to be recognized as an antigen by the immune system of a “recipient subject” (e.g., a mammal, and especially, a human, a non-human primate, or a non-human mammal (e.g., a canine, feline, bovine, equine, ovine, porcine, rodent, bat, pangolin, etc.)). Such SARS-CoV-2 S Protein Lentiviral Particles can be used in SARS-CoV-2 S Protein Lentiviral Vaccine pharmaceutical compositions that can be administered to recipient subjects to thereby cause such subjects to elicit neutralizing antibodies against the SARS-CoV-2 S protein. The binding of such antibodies to SARS-CoV-2 viral particles decreases the infectivity of SARS-CoV-2 and/or the severity of COVID-19 in such recipients. As used herein, “SARS-CoV-2 infectivity” is defined as the capacity of SARS-CoV-2 to enter a host cell and exploit its resources to replicate and produce progeny infectious viral particles. SARS-CoV-2 infectivity will preferably be decreased by the SARS-CoV-2 S Protein Lentiviral Vaccine pharmaceutical compositions of the present invention by at least about one order of magnitude, by at least about two orders of magnitude, by at least about three orders of magnitude, by at least about four orders of magnitude, or by more than at least five orders of magnitude. In one embodiment, such administration is implemented so as to elicit secretory IgA2 antibodies. In a second embodiment, such administration is implemented so as to elicit IgM and/or IgG antibodies.

The present invention provides SARS-CoV-2 S Protein Lentiviral Particles that have been engineered to be incapable of mediating the integration of the lentiviral genome into the chromosomes of infected cells. As discussed above, and as illustrated in FIG. 2, mature lentiviral particles contain the lentiviral integrase protein (encoded by one of the pol gene transcripts). Thus, even though third generation lentiviral vector systems have moved the pol gene to a separate packaging vector, the lentiviral particles produced by such vector systems contain functional integrase proteins. Thus, the LTR-containing genome of the mature lentiviral particles produced by such vector systems is capable of being integrated into the chromosomes of infected cells. In contrast, as discussed below, in one embodiment, the present invention employs packaging vectors whose pol gene has been mutated to render the expressed integrase non-functional. As a consequence, the lentiviral particles that are produced do not contain functional integrase proteins. Accordingly, in such embodiment, the genome present in the LTR-containing vectors of the present invention are non-integrating. As used herein, a genome contained within a lentiviral particle is said to be “non-integrating” if the integrase present within such particle exhibits an ability to mediate integration into the chromosome of an infected cells that is at least two orders of magnitude, more preferably at least three orders of magnitude, more preferably still at least four orders of magnitude less than the ability of a wildtype lentiviral integrase, or most preferably, if integration is undetectable under conditions in which the integration of a wildtype lentiviral genome is detectable. SARS-CoV-2 S Protein Lentiviral Particles of the present invention that comprise such mutated integrase proteins are effectively incapable of inserting their genomes into the chromosomes of transfected cells, and are thus much less likely to cause oncogenic events. Accordingly, such SARS-CoV-2 S Protein Lentiviral Particles of the present invention are safer than wildtype lentiviral vectors.

The present invention also provides SARS-CoV-2 S Protein Lentiviral Particles that have been engineered to be incapable of mediating the reverse transcription of their genome. As discussed above, and as illustrated in FIG. 2, mature lentiviral particles contain the lentiviral reverse transcriptase protein (encoded by one of the pol gene transcripts). Thus, the LTR-containing genome of the mature lentiviral particles produced by such vector systems is capable of being reverse transcribed into DNA upon entry into infected cells. In contrast, as discussed below, in one embodiment, the present invention employs packaging vectors whose pol gene has been mutated to render the expressed reverse transcriptase non-functional. As a consequence, the lentiviral particles that are produced do not contain functional reverse transcriptase integrase. Accordingly, in such embodiment, the genome present in the LTR-containing vectors of the present invention are incapable of being reverse transcribed. As used herein, a genome contained within a lentiviral particle is said to be “incapable of being reverse transcribed” if the reverse transcriptase present within such particle exhibits an ability to mediate reverse transcription within infected cells that is at least two orders of magnitude, more preferably at least three orders of magnitude, more preferably still at least four orders of magnitude less than the ability of a wildtype lentiviral reverse transcriptase, or most preferably, if reverse transcription is undetectable under conditions in which the reverse transcription of a wildtype lentiviral genome is detectable. As discussed below, the lentiviral RT proteins of such lentiviral particles comprise mutations that block reverse transcriptase function. Reverse transcription is required in order for the lentiviral genome to integrate into the chromosomes of transfected cells. Thus, by being incapable of mediating reverse transcription, the SARS-CoV-2 S Protein Lentiviral Particles of the present invention are effectively incapable of inserting their genomes into the chromosomes of transfected cells, and are thus much less likely to cause oncogenic events than wildtype lentiviral particles. Accordingly, such SARS-CoV-2 S Protein Lentiviral Particles of the present invention are safer than wildtype lentiviral vectors.

Additionally, reverse transcription is required for lentiviral replication. Thus, the SARS-CoV-2 S Protein Lentiviral Particles of the present invention that are incapable of mediating reverse transcription are effectively incapable of self-propagation. The genomes of such lentiviral particles will thus be capable of being transcribed and of expressing viral proteins, but will in time passively diminish in recipient subjects (due to cellular aging, cell division, apoptosis, RNA processing and other natural processes). As such, the SARS-CoV-2 S Protein Lentiviral Particles of the present invention are much less likely to be associated with long term adverse consequences than wildtype lentiviral vectors.

The present invention specifically contemplates SARS-CoV-2 S Protein Lentiviral Particles that are both non-integrating and additionally incapable of mediating reverse transcription. Such lentiviral particles are synergistically safer than either lentiviral particles having non-integrating genomes or lentiviral particles having genomes that are incapable of mediating reverse transcription.

I. Preferred Vectors for Producing the SARS-CoV-2 S Protein Lentiviral Particles of the Present Invention

The SARS-CoV-2 S Protein Lentiviral Particles of the present invention are preferably produced by co-transfecting a cell with four plasmids (FIG. 5): (1) an LTR-Containing vector; (2) a packaging vector; (3) a REV vector; and (4) an envelope vector.

A. LTR-Containing Vectors of the Present Invention

1. Features and Components of the LTR-Containing Vectors of the Present Invention

As used herein, the term “LTR-containing vector” is intended to denote a vector that comprises at least one lentiviral LTR regions (which region may be intact, truncated, or contain an internal deletion, relative to a wildtype lentiviral LTR region). Such vectors will additionally comprise a promoter capable of mediating transcription of an R region and U5 region of a 5′ lentiviral LTR, a lentiviral ψ region, a lentiviral Rev response element (RRE), a lentiviral central polypurine tract and central termination sequence (cPPT/CTS), and a self-inactivating 3′ LTR region. The vectors: pLenti-SV40-puro (FIG. 6), pLenti-SV40-puro (-att) (FIG. 7), pLenti-CMV-IRES-empty (-att) (FIG. 8), pLenti-CMV-IRES-Spike (FIG. 9), pLenti-IgGκ-nCoV-Spike-CD8-TM (-att) (FIG. 10), pLenti-IgGκ-nCoV-N-CD8-TM (-att) (FIG. 11) and pLenti-IL-2 n-CoV-N(-att) (FIG. 12) illustrate the LTR-containing vectors of the present invention.

The LTR-containing vectors of the present invention comprise multiple preferred features. The first of such preferred features of the LTR vectors of the present invention is a first promoter (and an optional upstream transcriptional enhancer site) that will facilitate and mediate transcription in a mammalian host cell. Suitable promoters include the human cytomegalovirus (CMV) immediate early enhancer site and promoter, the EF1a promoter, the SV40 promoter, the human or murine PGK1 promoter, the α-fetoprotein promoter, the β-interferon promoter, the metallothionein II (MT II) promoter, the mouse mammary tumor virus (MMTV) promoter, the murine leukemia virus (MuLV) long terminal repeat promoter, the Ubc promoter, the human beta-actin promoter, the CAG promoter, the Rous sarcoma virus (RSV) promoter, the tetracycline response element (TRE) promoter, the Ca2+/calmodulin-dependent protein kinase II promoter, the human polymerase III RNA promoter, and the human or murine U6 small nuclear promoter (Colosimo, A. et al. (2000) “Transfer and Expression of Foreign Genes in Mammalian Cells,” BioTechniques 29(2):314-331; Addgene (2014) “Plasmids 101: The Promoter Region—Let's Go!,” Addgene). Illustrative polynucleotides for such purpose comprise the human cytomegalovirus (CMV) immediate early enhancer site and the CMV immediate early promoter site. An illustrative CMV immediate early enhancer site comprises the sequence (SEQ ID NO:1):

gacattgatt attgactagt tattaatagt aatcaattac

ggggtcatta gttcatagcc catatatgga gttccgcgtt

acataactta cggtaaatgg cccgcctggc tgaccgccca

acgacccccg cccattgacg tcaataatga cgtatgttcc

catagtaacg ccaataggga ctttccattg acgtcaatgg

gtggagtatt tacggtaaac tgcccacttg gcagtacatc

aagtgtatca tatgccaagt acgcccccta ttgacgtcaa

tgacggtaaa tggcccgcct ggcattatgc ccagtacatg

accttatggg actttcctac ttggcagtac atctacgtat

tagtcatcgc tattaccatg

A suitable variant CMV immediate early enhancer site comprises the sequence (SEQ ID NO:2) (differences are shown underlined):

gacattgatt attgactagt tattaatagt aatcaattac

ggggtcatta gttcatagcc catatatgga gttccgcgtt

acataactta cggtaaatgg cccgcctggc tgaccgccca

acgacccccg cccattgacg tcaataatga cgtatgttcc

catagtaacg ccaataggga ctttccattg acgtcaatgg

gtggagtatt tacggtaaac tgcccacttg gcagtacatc

aagtgtatca tatgccaagt ccgcccccta ttgacgtcaa

tgacggtaaa tggcccgcct ggcattatgc ccagtacatg

accttacggg actttcctac ttggcagtac atctacgtat

tagtcatcgc tattaccatg

Truncated variants of such illustrative CMV immediate early enhancer sites that lack the first 76 residues of SEQ ID NO:1 or SEQ ID NO:2 may alternatively be employed.

An illustrative CMV immediate early promoter site for the LTR-containing vectors of the present invention comprises the sequence (SEQ ID NO:3):

gtgatgcggt tttggcagta catcaatggg cgtggatagc

ggtttgactc acggggattt ccaagtctcc accccattga

cgtcaatggg agtttgtttt ggcaccaaaa tcaacgggac

tttccaaaat gtcgtaacaa ctccgcccca ttgacgcaaa

tgggcggtag gcgtgtacgg tgggaggtct atataagcag

A suitable variant CMV immediate early promoter site comprises the sequence (SEQ ID NO:4) (differences are shown underlined):

gtgatgcggt tttggcagta caccaatggg cgtggatagc

ggtttgactc acggggattt ccaagtctcc accccattga

cgtcaatggg agtttgtttt ggcaccaaaa tcaacgggac

tttccaaaat gtcgtaataa ccccgccccg ttgacgcaaa

tgggcggtag gcgtgtacgg tgggaggtct atataagcag

agct

Additional suitable CMV immediate early promoter sites (e.g., SEQ ID NO:52) are discussed below.

A further preferred feature of the LTR-containing vectors of the present invention is a lentiviral 5′ LTR region that has been truncated to delete its U3 region. The lentiviral 5′ LTR region is natively composed of a U3 region, an R region (SEQ ID NO:76) and a U5 region (SEQ ID NO:77).

SEQ ID NO: 76

gggtctctct ggttagacca gatctgagcc tgggagctct

ctggctaact agggaaccca ctgcttaagc ctcaataaag

cttgccttga gtgcttca

SEQ ID NO: 77

agtagtgtgt gcccgtctgt tgtgtgactc tggtaactag

agatccctca gaccctttta gtcagtgtgg aaaatctcta

gca

As discussed above, the deletion of the U3 region results in the transcriptional self-inactivation (SIN) of potentially packageable viral genomes in transduced cells. In preferred embodiments, such lentiviral 5′ LTR region is derived from the 5′ LTR of HIV-1, and comprises the sequence of SEQ ID NO:5, which is composed of an R region (SEQ ID NO:76) (shown in bold) and a U5 region (SEQ ID NO:77) (single underlined).

SEQ ID NO: 5

gggtctctct ggttagacca gatctgagcc tgggagctct

ctggctaact agggaaccca ctgcttaagc ctcaataaag

cttgccttga gtgcttcaag tagtgtgtgc ccgtctgttg

tgtgactctg gtaactagag atccctcaga cccttttagt

cagtgtggaa aatctctagc a

An alternative lentiviral 5′ LTR region lacks the two 3′ terminal residues of SEQ ID NO:5, and comprises the sequence of SEQ ID NO:68:

gggtctctct ggttagacca gatctgagcc tgggagctct

ctggctaact agggaaccca ctgcttaagc ctcaataaag

cttgccttga gtgcttca
ag tagtgtgtgc ccgtctgttg

tgtgactctg gtaactagag atccctcaga cccttttagt

cagtgtggaa aatctctag

A further preferred feature of the LTR-containing vectors of the present invention is a lentiviral ψ region. In preferred embodiments, such lentiviral ψ region is derived from HIV-1, and comprises the sequence of (SEQ ID NO:6):

ctctctcgac gcaggactcg gcttgctgaa gcgcgcacgg

caagaggcga ggggcggcga ctggtgagta cgccaaaaat

tttgactagc ggaggctaga aggagagaga tgggtgcgag

agcgtc

A further preferred feature of the LTR-containing vectors of the present invention is a lentiviral Rev response element (RRE), which allows for Rev-dependent mRNA export from the nucleus to the cytoplasm. In preferred embodiments, such lentiviral RRE region is derived from HIV-1, and comprises the sequence of (SEQ ID NO:7):

aggagctttg ttccttgggt tcttgggagc agcaggaagc

actatgggcg cagcgtcaat gacgctgacg gtacaggcca

gacaattatt gtctggtata gtgcagcagc agaacaattt

gctgagggct attgaggcgc aacagcatct gttgcaactc

acagtctggg gcatcaagca gctccaggca agaatcctgg

ctgtggaaag atacctaaag gatcaacagc tcct

A further preferred feature of the LTR-containing vectors of the present invention is a lentiviral central polypurine tract and central termination sequence (cPPT/CTS). In preferred embodiments, such lentiviral cPPT/CTS region is derived from HIV-1, and comprises the sequence of (SEQ ID NO:8):

ttttaaaaga aaagggggga ttggggggta cagtgcaggg

gaaagaatag tagacataat agcaacagac atacaaacta

aagaattaca aaaacaaatt acaaaaattc aaaatttt

In one embodiment, the LTR-containing vectors of the present invention will contain as a further preferred feature a second promoter that will be operably-linked to a non-lentiviral (i.e., “heterologous”) transgene, so as to be capable of mediating the transcription and expression of the protein encoded by such transgene in a mammalian host cell. Suitable promoters are described above, and particularly include the CMV promoter (with or without its enhancer site). However, an illustrative such second promoter is an SV40 promoter that comprises the sequence of (SEQ ID NO:9), and which comprises an SV40 origin of replication (shown underlined):

gtgtgtcagt tagggtgtgg aaagtcccca ggctccccag

caggcagaag tatgcaaagc atgcatctca attagtcagc

aaccaggtgt ggaaagtccc caggctcccc agcaggcaga

agtatgcaaa gcatgcatct caattagtca gcaaccatag

tcccgcccct aactccgccc atcccgcccc taactccgcc

cagttccgcc cattctccgc cccatggctg actaattttt

tttatttatg

cagaggccga ggccgcctcg gcctctgagc

tattccagaa gtagtgagga

ggcttttttg gaggcc
tagg

cttttgcaaa

In one embodiment, the second promoter will be a regulatable promoter, such that the extent of transcription in a transfected subject may be increased or decreased via the provision of an inducer or repressor agent. Any of numerous regulatable promoters, for example, the EF1a or CAG promoters or the tetracycline(tet) inducible systems (Dogbevia, G. K. et al. (2015) “Inducible And Combinatorial Gene Manipulation In Mouse Brain,” Front. Cell. Neurosci. 9:142:1-8; Dogbevia, G. K. et al. (2016) “Flexible, AAV-Equipped Genetic Modules for Inducible Control of Gene Expression in Mammalian Brain,” Molec. Ther. Nucl. Acids 5:e309:1-8) described in the art may be employed in such manner.

In one embodiment, such operably-linked heterologous transgene may encode an antibiotic resistance determinant, for example an N-acetyltransferase capable of providing recipient host cells with resistance to puromycin. An illustrative antibiotic resistance determinant for such purpose is the N-acetyltransferase of Streptomyces alboniger, which comprises the sequence (SEQ ID NO:10):

MTEYKPTVRL ATRDDVPRAV RTLAAAFADY PATRHTVDPD

RHIERVTELQ ELFLTRVGLD IGKVWVADDG AAVAVWTTPE

SVEAGAVFAE IGPRMAELSG SRLAAQQQME GLLAPHRPKE

PAWFLATVGV SPDHQGKGLG SAVVLPGVEA AERAGVPAFL

ETSAPRNLPF YERLGFTVTA DVEVPEGPRT WCMTRKPGA

An illustrative polynucleotide that encodes such N-acetyltransferase of Streptomyces alboniger comprises the sequence (SEQ ID NO:11):

atgaccgagt acaagcccac ggtgcgcctc gccacccgcg

acgacgtccc ccgggcagta cgcaccctcg ccgccgcgtt

cgccgactac cccgccacgc gccacaccgt cgatccagac

cgccacatcg agcgggtcac cgagctgcaa gaactcttcc

tcacgcgcgt cgggctcgac atcggcaagg tgtgggtcgc

ggacgacggc gccgcggtgg cggtctggac cacgccggag

agcgtcgaag cgggggcggt gttcgccgag atcggcccgc

gcatggccga gttgagcggt tcccggctgg ccgcgcagca

acagatggaa ggcctcctgg cgccgcaccg gcccaaggag

cccgcgtggt tcctggccac cgtcggcgtc tcgcccgacc

accagggcaa gggtctgggc agcgccgtcg tgctccccgg

agtggaggcg gccgagcgcg ccggggtgcc cgccttcctg

gagacctccg cgccccgcaa cctccccttc tacgagcggc

tcggcttcac cgtcaccgcc gacgtcgagg tgcccgaagg

accgcgcacc tggtgcatga cccgcaagcc cggtgcctga

In an alternative embodiment, such operably-linked heterologous transgene may encode a reporter protein, such that the presence of the LTR-containing vector in a recipient cell can be more readily assessed. Examples of suitable reporter genes are well-known and include β-galactosidase, β-glucuronidase, chloramphenicol acetyltransferase, green fluorescent protein, red fluorescent protein, luciferase, etc. (Al Ali, S. et al. (2016) “Use of Reporter Genes in the Generation of Vaccinia Virus-Derived Vectors,” Viruses 8(5):1-18; Thakur, B. et al. (2015) “Molecular Imaging of Therapeutic Potential of Reporter Probes,” Curr. Drug Targets 16(6):645-657; Ghim, C. M. et al. (2010) “The Art Of Reporter Proteins In Science: Past, Present And Future Applications,” BMB Rep. 43(7):451-460; Liu, A. M. et al. (2009) “Reporter Gene Assays,” Meth. Mol. Biol. 486:109-123; Jansson, J. K. (2003) “Marker And Reporter Genes: Illuminating Tools For Environmental Microbiologists,” Curr. Opin. Microbiol. 6(3):310-316; Lewis, J. C. et al. (1998) “Applications Of Reporter Genes,” Anal. Chem. 70(17):579A-585A).

In a further embodiment, such operably-linked heterologous transgene may encode a protein pharmaceutical agent, such as a protein drug (especially a protein drug that is effective in treating a coronavirus infection (especially SARS-CoV-2), e.g., β-interferon, griffithsin (GRFT), etc.) (Spiegel, M. et al. (2004) “The Antiviral Effect Of Interferon-Beta Against SARS-Coronavirus Is Not Mediated By mXA Protein,” J. Clin. Virol. 30(3):211-213; (O'Keefe, B. R. et al. (2010) “Broad-Spectrum in vitro Activity and in vivo Efficacy Of The Antiviral Protein Griffthsin Against Emerging Viruses Of The Family Coronaviridae,” J. Virol. 84(5):2511-2521), a protein that comprises the epitope binding domain of an antibody (e.g., an antibody light or heavy chain, a single chain antibody, etc.), especially a protein that comprises the epitope binding domain of an antibody that binds to a SARS-CoV-2 antigen). For example, a lentiviral particle that arrays the SARS-CoV-2 S protein on its surface will exhibit a tropism for cells that possess the cellular receptor capable of binding such protein. By administering such lentiviral particles that are additionally capable of transcribing a pharmaceutical agent effective against SARS-CoV-2, the present invention provides a means for targeting the pharmaceutical agent to loci of potential infection by actual SARS-CoV-2 viruses.

In a further embodiment, such operably-linked heterologous transgene may encode a viral protein, for example, an influenza HA protein (e.g., GenBank Accession Nos.: QJI52636.1, CY147342.1, etc.), a SARS-CoV S protein (e.g., GenBank Accession Nos.: AB263618.1, BAF42873.1, AAR23250.1, etc.), a MERS-CoV S protein (e.g., GenBank Accession Nos.: QGW51898.1, QGW51909.1, QGW51920.1, etc.), or a SARS-CoV-2 protein, and especially a SARS-CoV-2 S or N protein. In this embodiment of the invention, it is desired that the expressed viral protein be released by the transfected cell into the extracellular environment so that it may be detected by the immune system and aid in developing immunity against the virus. Thus, where the viral protein possesses an endoplasmic reticulum binding site, it is desirable that the encoding polynucleotide be truncated so as to not encode such site.

In a preferred embodiment, the polynucleotide that encodes the viral protein will be preceded by an in-frame signal sequence, such as the IL-2 signal sequence (SEQ ID NO:72):

MYRMQLLSCIALSLALVTNS,

or the IgGκ signal sequence (SEQ ID NO:81) (Guler-Gane, G. et al. (2016) “Overcoming the Refractory Expression of Secreted Recombinant Proteins in Mammalian Cells through Modification of the Signal Peptide and Adjacent Amino Acids,” Plos One 11(5):1-15)

MDMRVPAQLLGLLLLWLSGARC

so as to form a fusion protein. The IL-2 signal (SEQ ID NO:72) may be encoded by a polynucleotide that comprises the sequence (SEQ ID NO:73):

atgtacagga tgcaactcct gtcttgcatt gcactaagtc

ttgcacttgt cacaaacagt

The IgGκ signal sequence (SEQ ID NO:81) may be encoded by a polynucleotide that comprises the sequence (SEQ ID NO:82):

atggacatga gggtccctgc tcagctcctg gggctcctgc

tgctctggct ctcaggtgcc agatgt

The presence of such a signal sequence promotes secretion of the viral protein (Zhang, L. et al. (2005) “Alteration In The IL-2 Signal Peptide Affects Secretion Of Proteins in vitro And in vivo,” J. Gene Med. 7(3):354-365; Owji, H. et al. (2018) “A Comprehensive Review Of Signal Peptides: Structure, Roles, And Applications,” Eur. J. Cell. Biol. 97(6):422-441; Nothwehr, S. F. et al. (1990) “Targeting Of Proteins Into The Eukaryotic Secretory Pathway: Signal Peptide Structure/Function Relationships,” Bioessays 12(10):479-484). The in-frame signal sequence may be preceded by a consensus sequence for strong initiation of translation, such as a Kozak sequence, (Kozak, M. (1987) “An Analysis Of 5′-Noncoding Sequences From 699 Vertebrate Messenger RNAs,” Nucl. Acids Res. 15(20):8125-8148). An illustrative Kozak sequence is (SEQ ID NO:85)

gccaccatgg.

In a particularly preferred embodiment, such operably-linked heterologous transgene will encode all or part of one or more proteins of SARS-CoV-2, e.g., all or part of the SARS-CoV-2 S protein, all or part of the SARS-CoV-2 nucleocapsid (N) protein, etc. Alternatively, transfection can be conducted using two different LTR-containing vectors, one of which comprises a transgene that encodes all or a portion of the SARS-CoV-2 S gene and the second of which comprises a transgene that encodes all or a portion of the SARS-CoV-2 N gene. The resulting lentiviral particles will array a mixture of S and N proteins on their surface. For example, transfection may be conducted in the presence of the LTR-containing vector pLenti-CMV-IRES-Spike (-att) (FIG. 9) or pLenti-IgG-nCoV-Spike-CD8-TM (-att) (FIG. 10) and in the presence of the LTR-containing vector pLenti-IgGκ-nCoV-N-CD8-TM (FIG. 11) or pLenti-IL-2 n-CoV-N(-att) (FIG. 12).

Polynucleotides encoding SARS-CoV-2 S proteins are described below. The SARS-CoV-2 N protein has the sequence (SEQ ID NO:78):

MSDNGPQNQR NAPRITFGGP SDSTGSNQNG ERSGARSKQR

RPQGLPNNTA SWFTALTQHG KEDLKFPRGQ GVPINTNSSP

DDQIGYYRRA TRRIRGGDGK MKDLSPRWYF YYLGTGPEAG

LPYGANKDGI IWVATEGALN TPKDHIGTRN PANNAAIVLQ

LPQGTTLPKG FYAEGSRGGS QASSRSSSRS RNSSRNSTPG

SSRGTSPARM AGNGGDAALA LLLLDRLNQL ESKMSGKGQQ

QQGQTVTKKS AAEASKKPRQ KRTATKAYNV TQAFGRRGPE

QTQGNFGDQE LIRQGTDYKH WPQIAQFAPS ASAFFGMSRI

GMEVTPSGTW LTYTGAIKLD DKDPNFKDQV ILLNKHIDAY

KTFPPTEPKK DKKKKADETQ ALPQRQKKQQ TVTLLPAADL

DDFSKQLQQS MSSADSTQA

The SARS-CoV-2 N protein (SEQ ID NO:78) may be encoded by the polynucleotide sequence (SEQ ID NO:79):

atgtctgata atggacccca aaatcagcga aatgcacccc

gcattacgtt tggtggaccc tcagattcaa ctggcagtaa

ccagaatgga gaacgcagtg gggcgcgatc aaaacaacgt

cggccccaag gtttacccaa taatactgcg tcttggttca

ccgctctcac tcaacatggc aaggaagacc ttaaattccc

tcgaggacaa ggcgttccaa ttaacaccaa tagcagtcca

gatgaccaaa ttggctacta ccgaagagct accagacgaa

ttcgtggtgg tgacggtaaa atgaaagatc tcagtccaag

atggtatttc tactacctag gaactgggcc agaagctgga

cttccctatg gtgctaacaa agacggcatc atatgggttg

caactgaggg agccttgaat acaccaaaag atcacattgg

cacccgcaat cctgctaaca atgctgcaat cgtgctacaa

cttcctcaag gaacaacatt gccaaaaggc ttctacgcag

aagggagcag aggcggcagt caagcctctt ctcgttcctc

atcacgtagt cgcaacagtt caagaaattc aactccaggc

agcagtaggg gaacttctcc tgctagaatg gctggcaatg

gcggtgatgc tgctcttgct ttgctgctgc ttgacagatt

gaaccagctt gagagcaaaa tgtctggtaa aggccaacaa

caacaaggcc aaactgtcac taagaaatct gctgctgagg

cttctaagaa gcctcggcaa aaacgtactg ccactaaagc

atacaatgta acacaagctt tcggcagacg tggtccagaa

caaacccaag gaaattttgg ggaccaggaa ctaatcagac

aaggaactga ttacaaacat tggccgcaaa ttgcacaatt

tgcccccagc gcttcagcgt tcttcggaat gtcgcgcatt

ggcatggaag tcacaccttc gggaacgtgg ttgacctaca

caggtgccat caaattggat gacaaagatc caaatttcaa

agatcaagtc attttgctga ataagcatat tgacgcatac

aaaacattcc caccaacaga gcctaaaaag gacaaaaaga

agaaggctga tgaaactcaa gccttaccgc agagacagaa

gaaacagcaa actgtgactc ttcttcctgc tgcagatttg

gatgatttct ccaaacaatt gcaacaatcc atgagcagtg

ctgactcaac tcaggcc

or by a codon-optimized variant thereof (SEQ ID NO:80):

atgtctgata atggaccaca aaaccagcgc aatgctccga

ggataacatt cggtgggccc tccgactcta ctggaagcaa

tcaaaatggg gagcggtcag gagccaggtc taaacagagg

cgacctcagg ggctgcctaa taatactgcc agctggttca

ctgctctgac ccagcatggc aaggaggact tgaagttccc

caggggtcag ggtgtaccaa tcaacactaa ttcttcccca

gacgaccaga ttggttatta cagaagggct acccggagga

ttaggggagg ggatggcaag atgaaggatc ttagtccacg

ctggtatttt tactaccttg gtacaggacc agaggctgga

cttccttatg gagcaaacaa agatggaatc atctgggtgg

ccacggaggg agccctcaat accccaaaag accatatcgg

gacccggaac cccgccaata atgccgcgat agtactgcaa

ttgccccaag ggactactct gccaaaaggc ttttatgcag

aagggtctcg aggagggtct caggcctcca gtcgctcatc

ttcccggtcc agaaacagca gccggaattc cacacccggg

agtagcagag gcactagccc tgcacgaatg gctggcaatg

gaggagatgc cgcccttgca ctgctgcttc tggatcgcct

gaaccagttg gagtccaaaa tgagtggcaa ggggcagcaa

cagcagggcc agacagtcac caagaagtct gccgcagaag

cttccaaaaa gccaaggcag aagaggacag caactaaagc

ttataacgtg acgcaggctt tcggtaggcg gggaccagaa

cagacccagg gtaacttcgg cgatcaggag cttattagac

aggggacaga ctataaacac tggccccaga tcgcccaatt

tgcccccagt gcatccgcct tcttcgggat gagtagaatc

ggcatggagg tgactcctag tggcacgtgg ctcacctata

ccggcgctat caagcttgat gacaaagatc ctaatttcaa

agatcaggtc atactgctga ataagcacat tgacgcatac

aaaacctttc cccctaccga accgaagaag gacaagaaga

aaaaggccga tgagacgcaa gctctgcctc agaggcagaa

gaaacagcaa acagtcactc tgttgcctgc ggcggacctt

gatgactttt ctaaacagct gcagcagagt atgagcagcg

ccgactccac ccaggcg

Such vectors will thus cause the SARS-CoV-2 spike (S) protein or nucleocapsid (N) protein to be produced in infected cells. Export of such protein will thus serve to provide such antigens to recipient subjects so that they may elicit neutralizing antibodies to SARS-CoV-2 and become immunized to COVID-19. It is preferred that the polynucleotide be codon optimized for translation in human cells. When the transgene encodes the SARS-CoV-2 S protein, it is preferred that its sequence be different from the sequence of the SARS-CoV-2 S protein-encoding polynucleotide used in the envelope vectors of the present invention in order to minimize recombination between these two sequences. Thus, it is preferred to employ the codon-optimized polynucleotide sequence of SEQ ID NO:71 to encode the SARS-CoV-2 spike protein (SEQ ID NO:54) in the LTR-containing vector embodiment that expresses a SARS-CoV-2 spike protein transgene.

SEQ ID NO: 71

atgtttgtgt tcctggtgct gctgccactg gtgtccagcc

agtgtgtgaa cctgaccacc aggacccaac ttcctcctgc

ctacaccaac tccttcacca ggggagtcta ctaccctgac

aaggtgttca ggtcctctgt gctgcacagc acccaggacc

tgttcctgcc attcttcagc aatgtgacct ggttccatgc

catccatgtg tctggcacca atggcaccaa gaggtttgac

aaccctgtgc tgccattcaa tgatggagtc tactttgcca

gcacagagaa gagcaacatc atcaggggct ggatttttgg

caccaccctg gacagcaaga cccagtccct gctgattgtg

aacaatgcca ccaatgtggt gattaaggtg tgtgagttcc

agttctgtaa tgacccattc ctgggagtct actaccacaa

gaacaacaag tcctggatgg agtctgagtt cagggtctac

tcctctgcca acaactgtac ctttgaatat gtgagccaac

cattcctgat ggacttggag ggcaagcagg gcaacttcaa

gaacctgagg gagtttgtgt tcaagaacat tgatggctac

ttcaagattt acagcaaaca cacaccaatc aacctggtga

gggacctgcc acagggcttc tctgccttgg aaccactggt

ggacctgcca attggcatca acatcaccag gttccagacc

ctgctggctc tgcacaggtc ctacctgaca cctggagact

cctcctctgg ctggacagca ggagcagcag cctactatgt

gggctacctc caaccaagga ccttcctgct gaaatacaat

gagaatggca ccatcacaga tgctgtggac tgtgccctgg

acccactgtc tgagaccaag tgtaccctga aatccttcac

agtggagaag ggcatctacc agaccagcaa cttcagggtc

caaccaacag agagcattgt gaggtttcca aacatcacca

acctgtgtcc atttggagag gtgttcaatg ccaccaggtt

tgcctctgtc tatgcctgga acaggaagag gattagcaac

tgtgtggctg actactctgt gctctacaac tctgcctcct

tcagcacctt caagtgttat ggagtgagcc caaccaaact

gaatgacctg tgtttcacca atgtctatgc tgactccttt

gtgattaggg gagatgaggt gagacagatt gcccctggac

aaacaggcaa gattgctgac tacaactaca aactgcctga

tgacttcaca ggctgtgtga ttgcctggaa cagcaacaac

ctggacagca aggtgggagg caactacaac tacctctaca

gactgttcag gaagagcaac ctgaaaccat ttgagaggga

catcagcaca gagatttacc aggctggcag cacaccatgt

aatggagtgg agggcttcaa ctgttacttt ccactccaat

cctatggctt ccaaccaacc aatggagtgg gctaccaacc

atacagggtg gtggtgctgt cctttgaact gctccatgcc

cctgccacag tgtgtggacc aaagaagagc accaacctgg

tgaagaacaa gtgtgtgaac ttcaacttca atggactgac

aggcacagga gtgctgacag agagcaacaa gaagttcctg

ccattccaac agtttggcag ggacattgct gacaccacag

atgctgtgag ggacccacag accttggaga ttctggacat

cacaccatgt tcctttggag gagtgtctgt gattacacct

ggcaccaaca ccagcaacca ggtggctgtg ctctaccagg

atgtgaactg tactgaggtg cctgtggcta tccatgctga

ccaacttaca ccaacctgga gggtctacag cacaggcagc

aatgtgttcc agaccagggc tggctgtctg attggagcag

agcatgtgaa caactcctat gagtgtgaca tcccaattgg

agcaggcatc tgtgcctcct accagaccca gaccaacagc

ccaaggaggg caaggtctgt ggcaagccag agcatcattg

cctacacaat gagtctggga gcagagaact ctgtggctta

cagcaacaac agcattgcca tcccaaccaa cttcaccatc

tctgtgacca cagagattct gcctgtgagt atgaccaaga

cctctgtgga ctgtacaatg tatatctgtg gagacagcac

agagtgtagc aacctgctgc tccaatatgg ctccttctgt

acccaactta acagggctct gacaggcatt gctgtggaac

aggacaagaa cacccaggag gtgtttgccc aggtgaagca

gatttacaag acacctccaa tcaaggactt tggaggcttc

aacttcagcc agattctgcc tgacccaagc aagccaagca

agaggtcctt cattgaggac ctgctgttca acaaggtgac

cctggctgat gctggcttca tcaagcaata tggagactgt

ctgggagaca ttgctgccag ggacctgatt tgtgcccaga

agttcaatgg actgacagtg ctgcctccac tgctgacaga

tgagatgatt gcccaataca cctctgccct gctggctggc

accatcacct ctggctggac ctttggagca ggagcagccc

tccaaatccc atttgctatg cagatggctt acaggttcaa

tggcattgga gtgacccaga atgtgctcta tgagaaccag

aaactgattg ccaaccagtt caactctgcc attggcaaga

ttcaggactc cctgtccagc acagcctctg ccctgggcaa

actccaagat gtggtgaacc agaatgccca ggctctgaac

accctggtga agcaactttc cagcaacttt ggagccatct

cctctgtgct gaatgacatc ctgagcagac tggacaaggt

ggaggctgag gtccagattg acagactgat tacaggcaga

ctccaatccc tccaaaccta tgtgacccaa caacttatca

gggctgctga gattagggca tctgccaacc tggctgccac

caagatgagt gagtgtgtgc tgggacaaag caagagggtg

gacttctgtg gcaagggcta ccacctgatg agttttccac

agtctgcccc tcatggagtg gtgttcctgc atgtgaccta

tgtgcctgcc caggagaaga acttcaccac agcccctgcc

atctgccatg atggcaaggc tcactttcca agggagggag

tgtttgtgag caatggcacc cactggtttg tgacccagag

gaacttctat gaaccacaga ttatcaccac agacaacacc

tttgtgtctg gcaactgtga tgtggtgatt ggcattgtga

acaacacagt ctatgaccca ctccaacctg aactggactc

cttcaaggag gaactggaca aatacttcaa gaaccacacc

agccctgatg tggacctggg agacatctct ggcatcaatg

cctctgtggt gaacatccag aaggagattg acagactgaa

tgaggtggct aagaacctga atgagtccct gattgacctc

caagaactgg gcaaatatga acaatacatc aagtggccat

ggtacatctg gctgggcttc attgctggac tgattgccat

tgtgatggtg accataatgc tgtgttgtat gacctcctgt

tgttcctgtc tgaaaggctg ttgttcctgt ggctcctgtt

gtaag

The transgene may be fused to a transmembrane domain, such as the CD8 transmembrane domain in order to promote the anchoring of the transgene protein in the lentiviral membrane. The sequence of the CD8 transmembrane domain is (SEQ ID NO:87):

ALSNSIMYFS HFVPVFLPAK PTTTPAPRPP TPAPTIASQP

LSLRPEACRP AAGGAVHTRG LDFACDIYIW APLAGTCGVL

LLSLVIT

A polynucleotide that encodes the CD8 transmembrane domain comprises the sequence (SEQ ID NO:88).

gccctgagca actccatcat gtacttcagc cacttcgtgc

cggtcttcct gccagcgaag cccaccacga cgccagcgcc

gcgaccacca acaccggcgc ccaccatcgc gtcgcagccc

ctgtccctgc gcccagaggc gtgccggcca gcggcggggg

gcgcagtgca cacgaggggg ctggacttcg cctgtgatat

ctacatctgg gcgcccttgg ccgggacttg tggggtcctt

ctcctgtcac tggttatcac ctga

In a further embodiment, the LTR-containing vector of the present invention comprise the above-discussed second promoter and comprise a heterologous transgene that is not translated into a protein. For example, such LTR-containing vector may comprise a polynucleotide that upon transcription provides an siRNA molecule capable of silencing an essential SARS-CoV-2 gene (e.g., the SARS-CoV-2 reverse transcriptase or integrase) (Kanasty, R. et al. (2013) “Delivery Materials for siRNA Therapeutics,” Nat. Mater. 12(11):967-977; Selvam, C. (2017) “Therapeutic Potential Of Chemically Modified siRNA: Recent Trends,” Chem. Biol. Drug Des. 90(5):665-678; Gavrilov, K. et al. (2012) “Therapeutic siRNA: Principles, Challenges, And Strategies,” Yale J. Biol. Med. 85(2):187-200).

In a further alternative embodiment, illustrated by the LTR-containing vector pLenti-CMV-IRES-empty (-att) (FIG. 8), the LTR-containing vector of the present invention lack the above-discussed second promoter and/or lack a heterologous transgene.

A further preferred feature of the LTR-containing vectors of the present invention is a third promoter (and an optional upstream transcriptional enhancer site) that will facilitate and mediate transcription in a mammalian host cell. Promoters for suitable for such use are discussed above. An illustrative transcriptional enhancer site is the variant CMV immediate early enhancer site (SEQ ID NO:2) and the variant CMV immediate early promoter site (SEQ ID NO:4).

A further preferred feature of the LTR-containing vectors of the present invention is a first promoter that will direct transcription in a bacterial host. Suitable promoters include the T7 promoter, the T7 lac promoter, the Sp6 promoter, the araBAD promoter, the trp promoter, the lac promoter, the Ptac promoter, the lambda pL promoter, and the T3 promoter. Sources of such promoters are well known in the art (Zheng, C. et al. (2008) “Evaluation of Promoters for Use in Tissue-Specifc Gene Delivery,” In: GENE THERAPY PROTOCOLS, Humana Press; pp. 205-219; Pance, A. (2013) “Tailoring The Models Of Transcription,” Int. J. Mol. Sci. 14(4):7583-7597; Tolmachov, O. (2009) “Designing Plasmid Vectors;” Methods Mol. Biol. 542:117-129; Addgene (2014) “Plasmids 101: The Promoter Region—Let's Go!,” Addgene). An exemplary polynucleotide for such purpose comprises a T7 promoter site. An illustrative T7 promoter site comprises the sequence (SEQ ID NO:12):

taatacgactcactatagg.

A further preferred feature of the LTR-containing vectors of the present invention is an internal ribosome entry site (IRES), such as the internal ribosome entry site of the encephalomyocarditis virus (EMCV) (SEQ ID NO:69):

gagggcccgg aaacctggcc ctgtcttctt gacgagcatt

cctaggggtc tttcccctct cgccaaagga atgcaaggtc

tgttgaatgt cgtgaaggaa gcagttcctc tggaagcttc

ttgaagacaa acaacgtctg tagcgaccct ttgcaggcag

cggaaccccc cacctggcga caggtgcctc tgcggccaaa

agccacgtgt ataagataca cctgcaaagg cggcacaacc

ccagtgccac gttgtgagtt ggatagttgt ggaaagagtc

aaatggctct cctcaagcgt attcaacaag gggctgaagg

atgcccagaa ggtaccccat tgtatgggat ctgatctggg

gcctcggtgc acatgcttta catgtgttta gtcgaggtta

aaaaacgtct aggccccccg aaccacgggg acgtggtttt

cctttgaaaa acacgatgat aa

A further preferred, but optional, feature of the LTR-containing vectors of the present invention comprises one or more epitope tags that facilitate the recovery of product by immunoadsorption or affinity chromatography (Zhao, X. (2013) “Several Affinity Tags Commonly Used In Chromatographic Purification,” J. Anal. Meth. Chem. 2013:581093:1-8). Illustrative epitope tags include a Myc (human c-Myc oncogene) or FLAG® epitope tag, a combined Myc-FLAG® tag that comprises the sequence (SEQ ID NO:13):

EQKLISEEDL AANDILDYKD DDDKV

(the FLAG® epitope tag portion thereof is underlined) An exemplary polynucleotide encoding such combined epitope tag comprises the sequence (SEQ ID NO:14):

gagcagaaac tcatctcaga agaggatctg gcagcaaatg

atatcctgga ttacaaggat gacgacgata aggtt

A further preferred, but optional, feature of the LTR-containing vectors of the present invention comprises a LoxP site, which permits recombination in the presence of Cre recombinase (McLellan, M. A. (2017) “Cre-LoxP-Mediated Recombination: General Principles And Experimental Considerations,” Curr. Protoc. Mouse Biol. 7(1):1-12), and thus facilitates cloning and modification of the vector. An exemplary polynucleotide encoding such LoxP site comprises the sequence (SEQ ID NO:15):

ataacttcgtatagcatacattatacgaagttat.

A further preferred feature of the LTR-containing vectors of the present invention, optionally present when the LTR-containing vector comprises a heterologous transgene, comprises a woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) (Higashimoto, T. et al. (2007) “The Woodchuck Hepatitis Virus Post-Transcriptional Regulatory Element Reduces Readthrough Transcription From Retroviral Vectors,” Gene Ther. 14:1298-1304). An illustrative polynucleotide encoding such WPRE comprises the sequence (SEQ ID NO:16):

aatcaacctc tggattacaa aatttgtgaa agattgactg

gtattcttaa ctatgttgct ccttttacgc tatgtggata

cgctgcttta atgcctttgt atcatgctat tgcttcccgt

atggctttca ttttctcctc cttgtataaa tcctggttgc

tgtctcttta tgaggagttg tggcccgttg tcaggcaacg

tggcgtggtg tgcactgtgt ttgctgacgc aacccccact

ggttggggca ttgccaccac ctgtcagctc ctttccggga

ctttcgcttt ccccctccct attgccacgg cggaactcat

cgccgcctgc cttgcccgct gctggacagg ggctcggctg

ttgggcactg acaattccgt ggtgttgtcg gggaaatcat

cgtcctttcc ttggctgctc gcctgtgttg ccacctggat

tctgcgcggg acgtccttct gctacgtccc ttcggccctc

aatccagcgg accttccttc ccgcggcctg ctgccggctc

tgcggcctct tccgcgtctt cgccttcgcc ctcagacgag

tcggatctcc ctttgggccg cctccccgc

A further preferred feature of the LTR-containing vectors of the present invention, optionally present when the LTR-containing vector comprises a heterologous transgene, comprises a Factor Xa cleavage site that mediates the cleavage of fusion proteins by Factor Xa protease (Block, H. et al. (2015) “Proteolytic Affinity Tag Cleavage,” Methods Enzymol. 559:71-97). An illustrative polynucleotide encoding such Factor Xa cleavage site comprises the sequence (SEQ ID NO:17):

tcggccctcaat.

A further preferred optional feature of the LTR-containing vectors of the present invention comprises a primer binding site for sequencing. An illustrative polynucleotide encoding such a site is a KS primer binding site that comprises the sequence (SEQ ID NO:18):

cgaggtcgacggtatcg.

Preferably, the primer binding site is introduced into the strand of the vector that does not comprise the transgene-encoding sequences (i.e., it is introduced into the “second” strand of the vector).

A further preferred feature of the LTR-containing vectors of the present invention is a second lentiviral 5′ LTR region that has been truncated to delete its U3 region. In preferred embodiments, such lentiviral 5′ LTR region is derived from the 5′ LTR of HIV-1, and comprises the same sequence (SEQ ID NO:5) as the above-discussed first lentiviral 5′ LTR region.

A further preferred feature of the LTR-containing vectors of the present invention is an origin of replication capable of mediating the replication of the vector in prokaryotic cells. An exemplary origin or replication site for this purpose is the high-copy-number ColE1/pMB1/pBR322/pUC origin of replication that comprises the sequence of SEQ ID NO:19, and is preferably positioned on the second strand of the vector:

ttgagatcct ttttttctgc gcgtaatctg ctgcttgcaa

acaaaaaaac caccgctacc agcggtggtt tgtttgccgg

atcaagagct accaactctt tttccgaagg taactggctt

cagcagagcg cagataccaa atactgttct tctagtgtag

ccgtagttag gccaccactt caagaactct gtagcaccgc

ctacatacct cgctctgcta atcctgttac cagtggctgc

tgccagtggc gataagtcgt gtcttaccgg gttggactca

agacgatagt taccggataa ggcgcagcgg tcgggctgaa

cggggggttc gtgcacacag cccagcttgg agcgaacgac

ctacaccgaa ctgagatacc tacagcgtga gctatgagaa

agcgccacgc ttcccgaagg gagaaaggcg gacaggtatc

cggtaagcgg cagggtcgga acaggagagc gcacgaggga

gcttccaggg ggaaacgcct ggtatcttta tagtcctgtc

gggtttcgcc acctctgact tgagcgtcga tttttgtgat

gctcgtcagg ggggcggagc ctatggaaa

A variant of such high-copy-number ColE1/pMB1/pBR322/pUC origin of replication comprises the sequence (SEQ ID NO:20) (the difference with respect to SEQ ID NO:19 is underlined):

ttgagatcct ttttttctgc gcgtaatctg ctgcttgcaa

acaaaaaaac caccgctacc agcggtggtt tgtttgccgg

atcaagagct accaactctt tttccgaagg taactggctt

cagcagagcg cagataccaa atactgtcct tctagtgtag

ccgtagttag gccaccactt caagaactct gtagcaccgc

ctacatacct cgctctgcta atcctgttac cagtggctgc

tgccagtggc gataagtcgt gtcttaccgg gttggactca

agacgatagt taccggataa ggcgcagcgg tcgggctgaa

cggggggttc gtgcacacag cccagcttgg agcgaacgac

ctacaccgaa ctgagatacc tacagcgtga gctatgagaa

agcgccacgc ttcccgaagg gagaaaggcg gacaggtatc

cggtaagcgg cagggtcgga acaggagagc gcacgaggga

gcttccaggg ggaaacgcct ggtatcttta tagtcctgtc

gggtttcgcc acctctgact tgagcgtcga tttttgtgat

gctcgtcagg ggggcggagc ctatggaaa

A further preferred feature of the LTR-containing vectors of the present invention is a gene that encodes an antibiotic resistance determinant, such as AmpR, which confers resistance to ampicillin, carbenicillin, and related antibiotics to bacterial cells transfected with the vector. The antibiotic resistance determinant is operably controlled by a promoter, such as the AmpR promoter, and both polynucleotide sequences are preferably positioned on the second stand of the vector. An illustrative AmpR antibiotic resistance determinant comprises the sequence (SEQ ID NO:21) (signal sequence shown underlined):

MSIQHFRVAL
IPFFAAFCLP VFAEPETLVK VKDAEDQLGA

RVGYIELDLN SGKILESFRP EERFPMMSTF KVLLCGAVLS

RIDAGQEQLG RRIHYSQNDL VEYSPVTEKH LTDGMTVREL

CSAAITMSDN TAANLLLTTI GGPKELTAFL HNMGDHVTRL

DRWEPELNEA IPNDERDTTM PVAMATTLRK LLTGELLTLA

SRQQLIDWME ADKVAGPLLR SALPAGWFIA DKSGAGERGS

RGIIAALGPD GKPSRIVVIY TTGSQATMDE RNRQIAEIGA

SLIKHW

An illustrative polynucleotide that encodes the AmpR antibiotic resistance determinant of SEQ ID NO:21 has the sequence of SEQ ID NO:22:

atgagtattc aacatttccg tgtcgccctt attccctttt

ttgcggcatt ttgccttcct gtttttgctc acccagaaac

gctggtgaaa gtaaaagatg ctgaagatca gttgggtgca

cgagtgggtt acatcgaact ggatctcaac agcggtaaga

tccttgagag ttttcgcccc gaagaacgtt ttccaatgat

gagcactttt aaagttctgc tatgtggcgc ggtattatcc

cgtattgacg ccgggcaaga gcaactcggt cgccgcatac

actattctca gaatgacttg gttgagtact caccagtcac

agaaaagcat cttacggatg gcatgacagt aagagaatta

tgcagtgctg ccataaccat gagtgataac actgcggcca

acttacttct gacaacgatc ggaggaccga aggagctaac

cgcttttttg cacaacatgg gggatcatgt aactcgcctt

gatcgttggg aaccggagct gaatgaagcc ataccaaacg

acgagcgtga caccacgatg cctgtagcaa tggcaacaac

gttgcgcaaa ctattaactg gcgaactact tactctagct

tcccggcaac aattaataga ctggatggag gcggataaag

ttgcaggacc acttctgcgc tcggcccttc cggctggctg

gtttattgct gataaatctg gagccggtga gcgtgggtct

cgcggtatca ttgcagcact ggggccagat ggtaagccct

cccgtatcgt agttatctac acgacgggga gtcaggcaac

tatggatgaa cgaaatagac agatcgctga gataggtgcc

tcactgatta agcattgg

A variant AmpR antibiotic resistance determinant comprises the sequence (SEQ ID NO:23) (signal sequence shown underlined; difference between SEQ ID NO:21 shown double underlined):

MSIQHFRVAL IPFFAAFCLP VFAHPETLVK VKDAEDQLGA

RVGYIELDLN SGKILESFRP EERFPMMSTF KVLLCGAVLS

RVDAGQEQLG RRIHYSQNDL VEYSPVTEKH LTDGMTVREL

CSAAITMSDN TAANLLLTTI GGPKELTAFL HNMGDHVTRL

DRWEPELNEA IPNDERDTTM PAAMATTLRK LLTGELLTLA

SRQQLIDWME ADKVAGPLLR SALPAGWFIA DKSGAGERGS

RGIIAALGPD GKPSRIVVIY TTGSQATMDE RNRQIAEIGA

SLIKHW

An illustrative polynucleotide that encodes the variant AmpR antibiotic resistance determinant of SEQ ID NO:23 comprises the sequence (SEQ ID NO:24) (differences relative to SEQ ID NO:22 are underlined):

atgagtattc aacatttccg tgtcgccctt attccctttt

ttgcggcatt ttgccttcct gtttttgctc acccagaaac

gctggtgaaa gtaaaagatg ctgaagatca gttgggtgca

cgagtgggtt acatcgaact ggatctcaac agcggtaaga

tccttgagag ttttcgcccc gaagaacgtt ttccaatgat

gagcactttt aaagttctgc tatgtggcgc ggtattatcc

cgtgttgacg ccgggcaaga gcaactcggt cgccgcatac

actattctca gaatgacttg gttgagtact caccagtcac

agaaaagcat cttacggatg gcatgacagt aagagaatta

tgcagtgctg ccataaccat gagtgataac actgcggcca

acttacttct gacaacgatc ggaggaccga aggagctaac

cgcttttttg cacaacatgg gggatcatgt aactcgcctt

gatcgttggg aaccggagct gaatgaagcc ataccaaacg

acgagcgtga caccacgatg cctgcagcaa tggcaacaac

gttgcgcaaa ctattaactg gcgaactact tactctagct

tcccggcaac aattaataga ctggatggag gcggataaag

ttgcaggacc acttctgcgc tcggcccttc cggctggctg

gtttattgct gataaatctg gagccggtga gcgtgggtct

cgcggtatca ttgcagcact ggggccagat ggtaagccct

cccgtatcgt agttatctac acgacgggga gtcaggcaac

tatggatgaa cgaaatagac agatcgctga gataggtgcc

tcactgatta agcattgg

An illustrative AmpR promoter-containing polynucleotide has the sequence of SEQ ID NO:25:

cgcgggaccc ctatttgttt atttttctaa atacattcaa

atatgtatcc gctcatgaga caataaccct gataaatgct

tcaataatat tgaaaaagga agagt

A variant AmpR promoter-containing polynucleotide has the sequence of SEQ ID NO:26 (differences relative to SEQ ID NO:25 are underlined):

cgcggaaccc ctatttgttt atttttctaa atacattcaa

atatgtatcc gctcatgaga caataaccct gataaatgct

tcaataatat tgaaaaagga agagt

The double-stranded vector pLenti-SV40-puro (FIG. 6) (7,705 base pairs) is a preferred LTR-containing vector of the present invention that may be used with the packaging vectors, REV vectors and envelope vectors of the present invention to produce lentiviral particles that array a SARS-CoV-2 S protein on their surface. The double-stranded vector pLenti-SV40-puro (-att) (FIG. 7) (7,701 base pairs) is an alternate preferred LTR-containing vector of the present invention that may be used with the packaging, REV and envelope vectors of the present invention to produce lentiviral particles that array a SARS-CoV-2 S protein on their surface. Vector pLenti-SV40-puro (-att) differs in sequence from vector pLenti-SV40-puro in containing:

(1) a deletion of the CA residues found at positions 1013-1014 of SEQ ID NO:27, which positions correspond to the two 3′ terminal nucleotides of the 5′ LTR;
(2) a deletion of the TG residues found at positions 5391-5392 of SEQ ID NO:27, which correspond to residues 1-2 of the 3′ terminus of the U3 region;
(3) an A to C substitution at position 5426, which correspond to residues within the U3 region; and
(4) a C to G substitution at position 5428, which correspond to residues within the U3 region.

Such modifications further reduce the ability of the vector to integrate into a chromosome of a transfected mammalian cell.

The sequence of the native 3′ LTR U3 region is SEQ ID NO:62:

tggaagggct aattcactcc caacgaagac aagatatcct

tgatctgtgg atctaccaca cacaaggcta cttccctgat

tggcagaact acacaccagg gccagggatc agatatccac

tgacctttgg atggtgctac aagctagtac cagttgagca

agagaaggta gaagaagcca atgaaggaga gaacacccgc

ttgttacacc ctgtgagcct gcatgggatg gatgacccgg

agagagaagt attagagtgg aggtttgaca gccgcctagc

atttcatcac atggcccgag agctgcatcc ggagtacttc

aagaactgct gacatcgagc ttgctacaag ggactttccg

ctggggactt tccagggagg cgtggcctgg gcgggactgg

ggagtggcga gccctcagat cctgcatata agcagctgct

ttttgcctgt act

The U3 region of vector pLenti-SV40-puro (SEQ ID NO:63) comprises a deletion of 133 residues (corresponding to residues 312-444 of SEQ ID NO:62).

SEQ ID NO: 63:

tggaagggct aattcactcc caacgaagac aagatatcct

tgatctgtgg atctaccaca cacaaggcta cttccctgat

tggcagaact acacaccagg gccagggatc agatatccac

tgacctttgg atggtgctac aagctagtac cagttgagca

agagaaggta gaagaagcca atgaaggaga gaacacccgc

ttgttacacc ctgtgagcct gcatgggatg gatgacccgg

agagagaagt attagagtgg aggtttgaca gccgcctagc

atttcatcac atggcccgag agctgcatcc ggactgtact

The U3 region of vector pLenti-SV40-puro (-att) (SEQ ID NO:64) comprises a deletion of the first two U3 residues and substitutions at positions 36 and 38 relative to SEQ ID NO:62 (underlined below) and the deletion of 133 residues (corresponding to residues 312-444 of SEQ ID NO:62).

SEQ ID NO: 64:

gaagggct aattcactcc caacgaagac aagatctgct

tgatctgtgg atctaccaca cacaaggcta cttccctgat

tggcagaact acacaccagg gccagggatc agatatccac

tgacctttgg atggtgctac aagctagtac cagttgagca

agagaaggta gaagaagcca atgaaggaga gaacacccgc

ttgttacacc ctgtgagcct gcatgggatg gatgacccgg

agagagaagt attagagtgg aggtttgaca gccgcctagc

atttcatcac atggcccgag agctgcatcc ggactgtact

2. Illustrative LTR-Containing Vectors

(a) pLenti-SV40-Puro

The vector pLenti-SV40-puro (FIG. 6) illustrates the LTR-containing vectors of the present invention. The first strand of vector pLenti-SV40-puro has 7705 nucleotide residues and has the sequence of SEQ ID NO:27 (differences relative to the polynucleotide sequence of the first strand of vector pLenti-SV40-puro (-att) are underlined):

As will be noted, residues 237-616 of pLenti-SV40-puro (SEQ ID NO:27) correspond to the CMV immediate early enhancer site (SEQ ID NO:1). Residues 618-816 of SEQ ID NO:27 correspond to the CMV immediate early promoter site (SEQ ID NO:3). Residues 834-1014 of SEQ ID NO:27 correspond to the truncated lentiviral 5′ LTR region (SEQ ID NO:5). Residues 1061-1186 of SEQ ID NO:27 correspond to the lentiviral ψ region (SEQ ID NO:6). Residues 1683-1916 of SEQ ID NO:27 correspond to the lentiviral Rev response element (RRE) (SEQ ID NO:7). Residues 2443-2560 of SEQ ID NO:27 correspond to the lentiviral cPPT/CTS region (SEQ ID NO:8). Residues 2621-2950 of SEQ ID NO:27 correspond to the SV40 promoter and origin of replication (SEQ ID NO:9). Residues 3008-3607 of SEQ ID NO:27 correspond to a polynucleotide sequence (SEQ ID NO:11) that encodes the N-acetyltransferase of Streptomyces alboniger (SEQ ID NO:10). Residues 3640-4019 of SEQ ID NO:27 correspond to the variant CMV immediate early enhancer site (SEQ ID NO:2). Residues 4020-4223 of SEQ ID NO:27 correspond to the variant CMV immediate early promoter site (SEQ ID NO:4). Residues 4249-4267 of SEQ ID NO:27 correspond to a T7 promoter site (SEQ ID NO:12). Residues 4382-4453 of SEQ ID NO:27 correspond to a polynucleotide sequence (SEQ ID NO:14) that encodes a combined Myc (human c-Myc oncogene) and FLAG® epitope tag (SEQ ID NO:13). Residues 4505-4538 of SEQ ID NO:27 correspond to a LoxP site (SEQ ID NO:15). Residues 4594-5182 of SEQ ID NO:27 correspond to a woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) (SEQ ID NO:16). Residues 5065-5076 of SEQ ID NO:27 correspond to a Factor Xa cleavage site (SEQ ID NO:17). Residues 5185-5201 of SEQ ID NO:27 correspond to a polynucleotide whose sequence is complementary to the sequence a KS primer binding site (SEQ ID NO:18). Residues 5391-5891 correspond to a 5′ LTR that has been modified to be self-inactivating (SIN) of which residues 5391-5710 correspond to a modified U3 region (SEQ ID NO:62), residues 5711-5891 correspond to R and the U5 regions of the 5′ LTR (SEQ ID NO:5). Residues 5953-6541 of SEQ ID NO:27 correspond to a polynucleotide whose sequence is complementary to the sequence of the high-copy-number ColE1/pMB1/pBR322/pUC origin of replication (SEQ ID NO:19). Residues 6712-7572 of SEQ ID NO:27 correspond to a polynucleotide whose sequence is complementary to the sequence encoding the AmpR antibiotic resistance determinant (SEQ ID NO:22) (i.e., such encoding sequence is on the second strand of the vector). Residues 7573-7677 of SEQ ID NO:27 correspond to a polynucleotide whose sequence is complementary to the sequence of the AmpR promoter (SEQ ID NO:25) (i.e., such promoter sequence is on the second strand of the vector).

(b) pLenti-SV40-Puro (-Att)

The vector pLenti-SV40-puro (-att) (FIG. 7) further illustrates the LTR-containing vectors of the present invention. The first strand of vector pLenti-SV40-puro (-att) has 7701 nucleotide residues and has the sequence of SEQ ID NO:28:

As will be noted, residues 237-616 of pLenti-SV40-puro (-att) (SEQ ID NO:28) correspond to the CMV immediate early enhancer site (SEQ ID NO:1). Residues 618-816 of SEQ ID NO:28 correspond to the CMV immediate early promoter site (SEQ ID NO:3). Residues 834-1012 of SEQ ID NO:28 correspond to the truncated lentiviral 5′ LTR region (SEQ ID NO:68). Residues 1059-1184 of SEQ ID NO:28 correspond to the lentiviral ψ region (SEQ ID NO:6). Residues 1681-1914 of SEQ ID NO:28 correspond to the lentiviral Rev response element (RRE) (SEQ ID NO:7). Residues 2441-2558 of SEQ ID NO:28 correspond to the lentiviral cPPT/CTS region (SEQ ID NO:8). Residues 2619-2948 of SEQ ID NO:28 correspond to the SV40 promoter and origin of replication (SEQ ID NO:9). Residues 3006-3605 of SEQ ID NO:28 correspond to a polynucleotide sequence (SEQ ID NO:11) that encodes the N-acetyltransferase of Streptomyces alboniger (SEQ ID NO:10). Residues 3638-4017 of SEQ ID NO:28 correspond to the variant CMV immediate early enhancer site (SEQ ID NO:2). Residues 4018-4221 of SEQ ID NO:28 correspond to the variant CMV immediate early promoter site (SEQ ID NO:4). Residues 4247-4265 of SEQ ID NO:28 correspond to a T7 promoter site (SEQ ID NO:12). Residues 4380-4450 of SEQ ID NO:28 correspond to a polynucleotide sequence (SEQ ID NO:14) that encodes a combined Myc (human c-Myc oncogene) and FLAG® epitope tag (SEQ ID NO:13). Residues 4503-4536 of SEQ ID NO:28 correspond to a LoxP site (SEQ ID NO:15). Residues 4592-5180 of SEQ ID NO:28 correspond to a woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) (SEQ ID NO:16). Residues 5063-5074 of SEQ ID NO:28 correspond to a Factor Xa cleavage site (SEQ ID NO:17). Residues 5183-5199 of SEQ ID NO:28 correspond to a polynucleotide whose sequence is complementary to the sequence a KS primer binding site (SEQ ID NO:18). Residues 5389-5887 correspond to a 5′ LTR that has been modified to be self-inactivating (SIN) of which residues 5389-5706 correspond to a modified U3 region (SEQ ID NO:64), residues 5707-5888 correspond to R and the U5 regions of the 5′ LTR (SEQ ID NO:5). Residues 5949-6537 of SEQ ID NO:28 correspond to a polynucleotide whose sequence is complementary to the sequence of the high-copy-number ColE1/pMB1/pBR322/pUC origin of replication (SEQ ID NO:19). Residues 6708-7568 of SEQ ID NO:28 correspond to a polynucleotide whose sequence is complementary to the sequence encoding the AmpR antibiotic resistance determinant (SEQ ID NO:22) (i.e., such encoding sequence is on the second strand of the vector). Residues 7569-7673 of SEQ ID NO:28 correspond to a polynucleotide whose sequence is complementary to the sequence of the AmpR promoter (SEQ ID NO:25) (i.e., such promoter sequence is on the second strand of the vector).

The vector pLenti-CMV-IRES-empty (-att) (FIG. 8) further illustrates the LTR-containing vectors of the present invention. The first strand of vector pLenti-CMV-IRES-empty (-att) has 7267 nucleotide residues and has the sequence of SEQ ID NO:67:

As will be noted, residues 237-616 of pLenti-CMV-IRES-empty (-att) (SEQ ID NO:67) correspond to the CMV immediate early enhancer site (SEQ ID NO:1). Residues 618-816 of SEQ ID NO:67 correspond to the CMV immediate early promoter site (SEQ ID NO:3). Residues 834-1012 of SEQ ID NO:67 correspond to the alternative truncated lentiviral 5′ LTR region (SEQ ID NO:68). Residues 1059-1184 of SEQ ID NO:67 correspond to the lentiviral ψ region (SEQ ID NO:6). Residues 1681-1914 of SEQ ID NO:67 correspond to the lentiviral Rev response element (RRE) (SEQ ID NO:7). Residues 2441-2558 of SEQ ID NO:67 correspond to the lentiviral cPPT/CTS region (SEQ ID NO:8). Residues 2641-3020 of SEQ ID NO:67 correspond to the variant CMV immediate early enhancer site (SEQ ID NO:2). Residues 3021-3224 of SEQ ID NO:67 correspond to the variant CMV immediate early promoter site (SEQ ID NO:4). Residues 3250-3268 of SEQ ID NO:67 correspond to a T7 promoter site (SEQ ID NO:12). Residues 3391-3852 of SEQ ID NO:67 correspond to the internal ribosome entry site of the encephalomyocarditis virus (EMCV) (SEQ ID NO:69). Residues 3946-4020 of SEQ ID NO:67 correspond to a polynucleotide sequence (SEQ ID NO:14) that encodes a combined Myc (human c-Myc oncogene) and FLAG® epitope tag (SEQ ID NO:13). Residues 4069-4102 of SEQ ID NO:67 correspond to a LoxP site (SEQ ID NO:15). Residues 4158-4746 of SEQ ID NO:67 correspond to a woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) (SEQ ID NO:16). Residues 4629-4640 of SEQ ID NO:67 correspond to a Factor Xa cleavage site (SEQ ID NO:17). Residues 4749-4765 of SEQ ID NO:67 correspond to a polynucleotide whose sequence is complementary to the sequence a KS primer binding site (SEQ ID NO:18). Residues 4955-5453 correspond to a 5′ LTR that has been modified to be self-inactivating (SIN) of which residues 4955-5272 correspond to a modified U3 region (SEQ ID NO:64), residues 5273-5400 correspond to R and the U5 regions of the 5′ LTR (SEQ ID NO:5). Residues 5515-6103 of SEQ ID NO:67 correspond to a polynucleotide whose sequence is complementary to the sequence of the high-copy-number ColE1/pMB1/pBR322/pUC origin of replication (SEQ ID NO:19). Residues 6274-7134 of SEQ ID NO:67 correspond to a polynucleotide whose sequence is complementary to the sequence encoding the AmpR antibiotic resistance determinant (SEQ ID NO:22) (i.e., such encoding sequence is on the second strand of the vector). Residues 7135-7239 of SEQ ID NO:67 correspond to a polynucleotide whose sequence is complementary to the sequence of the AmpR promoter (SEQ ID NO:25) (i.e., such promoter sequence is on the second strand of the vector).

(d) pLenti-CMV-IRES-Spike (-Att)

The vector pLenti-CMV-IRES-Spike (-att) (FIG. 9) further illustrates the LTR-containing vectors of the present invention. The first strand of vector pLenti-CMV-IRES-Spike (-att) has 11060 nucleotide residues and has the sequence of SEQ ID NO:70:

gtcgacggat cgggagatct cccgatcccc tatggtgcac tctcagtaca
50

atctgctctg atgccgcata gttaagccag tatctgctcc ctgcttgtgt
100

gttggaggtc gctgagtagt gcgcgagcaa aatttaagct acaacaaggc
150

aaggcttgac cgacaattgc atgaagaatc tgcttagggt taggcgtttt
200

gcgctgcttc gcgatgtacg ggccagatat cgcgttgaca ttgattattg
250

actagttatt aatagtaatc aattacgggg tcattagttc atagcccata
300

tatggagttc cgcgttacat aacttacggt aaatggcccg cctggctgac
350

cgcccaacga cccccgccca ttgacgtcaa taatgacgta tgttcccata
400

gtaacgccaa tagggacttt ccattgacgt caatgggtgg agtatttacg
450

gtaaactgcc cacttggcag tacatcaagt gtatcatatg ccaagtacgc
500

cccctattga cgtcaatgac ggtaaatggc ccgcctggca ttatgcccag
550

tacatgacct tatgggactt tcctacttgg cagtacatct acgtattagt
600

catcgctatt accatggtga tgcggttttg gcagtacatc aatgggcgtg
650

gatagcggtt tgactcacgg ggatttccaa gtctccaccc cattgacgtc
700

aatgggagtt tgttttggca ccaaaatcaa cgggactttc caaaatgtcg
750

taacaactcc gccccattga cgcaaatggg cggtaggcgt gtacggtggg
800

aggtctatat aagcagcgcg ttttgcctgt actgggtctc tctggttaga
850

ccagatctga gcctgggagc tctctggcta actagggaac ccactgctta
900

agcctcaata aagcttgcct tgagtgcttc aagtagtgtg tgcccgtctg
950

ttgtgtgact ctggtaacta gagatccctc agaccctttt agtcagtgtg
1000

gaaaatctct aggtggcgcc cgaacaggga cttgaaagcg aaagggaaac
1050

cagaggagct ctctcgacgc aggactcggc ttgctgaagc gcgcacggca
1100

agaggcgagg ggcggcgact ggtgagtacg ccaaaaattt tgactagcgg
1150

aggctagaag gagagagatg ggtgcgagag cgtcagtatt aagcggggga
1200

gaattagatc gcgatgggaa aaaattcggt taaggccagg gggaaagaaa
1250

aaatataaat taaaacatat agtatgggca agcagggagc tagaacgatt
1300

cgcagttaat cctggcctgt tagaaacatc agaaggctgt agacaaatac
1350

tgggacagct acaaccatcc cttcagacag gatcagaaga acttagatca
1400

ttatataata cagtagcaac cctctattgt gtgcatcaaa ggatagagat
1450

aaaagacacc aaggaagctt tagacaagat agaggaagag caaaacaaaa
1500

gtaagaccac cgcacagcaa gcggccggcc gctgatcttc agacctggag
1550

gaggagatat gagggacaat tggagaagtg aattatataa atataaagta
1600

gtaaaaattg aaccattagg agtagcaccc accaaggcaa agagaagagt
1650

ggtgcagaga gaaaaaagag cagtgggaat aggagctttg ttccttgggt
1700

tcttgggagc agcaggaagc actatgggcg cagcgtcaat gacgctgacg
1750

gtacaggcca gacaattatt gtctggtata gtgcagcagc agaacaattt
1800

gctgagggct attgaggcgc aacagcatct gttgcaactc acagtctggg
1850

gcatcaagca gctccaggca agaatcctgg ctgtggaaag atacctaaag
1900

gatcaacagc tcctggggat ttggggttgc tctggaaaac tcatttgcac
1950

cactgctgtg ccttggaatg ctagttggag taataaatct ctggaacaga
2000

tttggaatca cacgacctgg atggagtggg acagagaaat taacaattac
2050

acaagcttaa tacactcctt aattgaagaa tcgcaaaacc agcaagaaaa
2100

gaatgaacaa gaattattgg aattagataa atgggcaagt ttgtggaatt
2150

ggtttaacat aacaaattgg ctgtggtata taaaattatt cataatgata
2200

gtaggaggct tggtaggttt aagaatagtt tttgctgtac tttctatagt
2250

gaatagagtt aggcagggat attcaccatt atcgtttcag acccacctcc
2300

caaccccgag gggacccgac aggcccgaag gaatagaaga agaaggtgga
2350

gagagagaca gagacagatc cattcgatta gtgaacggat cggcactgcg
2400

tgcgccaatt ctgcagacaa atggcagtat tcatccacaa ttttaaaaga
2450

aaagggggga ttggggggta cagtgcaggg gaaagaatag tagacataat
2500

agcaacagac atacaaacta aagaattaca aaaacaaatt acaaaaattc
2550

aaaattttcg ggtttattac agggacagca gagatccagt ttggttagta
2600

ccgggcccgc tctagacatg tccaatatga ccgccatgtt gacattgatt
2650

attgactagt tattaatagt aatcaattac ggggtcatta gttcatagcc
2700

catatatgga gttccgcgtt acataactta cggtaaatgg cccgcctggc
2750

tgaccgccca acgacccccg cccattgacg tcaataatga cgtatgttcc
2800

catagtaacg ccaataggga ctttccattg acgtcaatgg gtggagtatt
2850

tacggtaaac tgcccacttg gcagtacatc aagtgtatca tatgccaagt
2900

ccgcccccta ttgacgtcaa tgacggtaaa tggcccgcct ggcattatgc
2950

ccagtacatg accttacggg actttcctac ttggcagtac atctacgtat
3000

tagtcatcgc tattaccatg gtgatgcggt tttggcagta caccaatggg
3050

cgtggatagc ggtttgactc acggggattt ccaagtctcc accccattga
3100

cgtcaatggg agtttgtttt ggcaccaaaa tcaacgggac tttccaaaat
3150

gtcgtaataa ccccgccccg ttgacgcaaa tgggcggtag gcgtgtacgg
3200

tgggaggtct atataagcag agctcgttta gtgaaccgtc agaattttgt
3250

aatacgactc actatagggc ggccgggaat tcgtcgactg cccccccccc
3300

taacgttact ggccgaagcc gcttggaata aggccggtgt gcgtttgtct
3350

atatgttatt ttccaccata ttgccgtctt ttggcaatgt gagggcccgg
3400

aaacctggcc ctgtcttctt gacgagcatt cctaggggtc tttcccctct
3450

cgccaaagga atgcaaggtc tgttgaatgt cgtgaaggaa gcagttcctc
3500

tggaagcttc ttgaagacaa acaacgtctg tagcgaccct ttgcaggcag
3550

cggaaccccc cacctggcga caggtgcctc tgcggccaaa agccacgtgt
3600

ataagataca cctgcaaagg cggcacaacc ccagtgccac gttgtgagtt
3650

ggatagttgt ggaaagagtc aaatggctct cctcaagcgt attcaacaag
3700

gggctgaagg atgcccagaa ggtaccccat tgtatgggat ctgatctggg
3750

gcctcggtgc acatgcttta catgtgttta gtcgaggtta aaaaacgtct
3800

aggccccccg aaccacgggg acgtggtttt cctttgaaaa acacgatgat
3850

aatgatccgg taccgaggag atctgccgcc gcgatcgcca ccatgtacag
3900

gatgcaactc ctgtcttgca ttgcactaag tcttgcactt gtcacaaaca
3950

gtatgtttgt gttcctggtg ctgctgccac tggtgtccag ccagtgtgtg
4000

aacctgacca ccaggaccca acttcctcct gcctacacca actccttcac
4050

caggggagtc tactaccctg acaaggtgtt caggtcctct gtgctgcaca
4100

gcacccagga cctgttcctg ccattcttca gcaatgtgac ctggttccat
4150

gccatccatg tgtctggcac caatggcacc aagaggtttg acaaccctgt
4200

gctgccattc aatgatggag tctactttgc cagcacagag aagagcaaca
4250

tcatcagggg ctggattttt ggcaccaccc tggacagcaa gacccagtcc
4300

ctgctgattg tgaacaatgc caccaatgtg gtgattaagg tgtgtgagtt
4350

ccagttctgt aatgacccat tcctgggagt ctactaccac aagaacaaca
4400

agtcctggat ggagtctgag ttcagggtct actcctctgc caacaactgt
4450

acctttgaat atgtgagcca accattcctg atggacttgg agggcaagca
4500

gggcaacttc aagaacctga gggagtttgt gttcaagaac attgatggct
4550

acttcaagat ttacagcaaa cacacaccaa tcaacctggt gagggacctg
4600

ccacagggct tctctgcctt ggaaccactg gtggacctgc caattggcat
4650

caacatcacc aggttccaga ccctgctggc tctgcacagg tcctacctga
4700

cacctggaga ctcctcctct ggctggacag caggagcagc agcctactat
4750

gtgggctacc tccaaccaag gaccttcctg ctgaaataca atgagaatgg
4800

caccatcaca gatgctgtgg actgtgccct ggacccactg tctgagacca
4850

agtgtaccct gaaatccttc acagtggaga agggcatcta ccagaccagc
4900

aacttcaggg tccaaccaac agagagcatt gtgaggtttc caaacatcac
4950

caacctgtgt ccatttggag aggtgttcaa tgccaccagg tttgcctctg
5000

tctatgcctg gaacaggaag aggattagca actgtgtggc tgactactct
5050

gtgctctaca actctgcctc cttcagcacc ttcaagtgtt atggagtgag
5100

cccaaccaaa ctgaatgacc tgtgtttcac caatgtctat gctgactcct
5150

ttgtgattag gggagatgag gtgagacaga ttgcccctgg acaaacaggc
5200

aagattgctg actacaacta caaactgcct gatgacttca caggctgtgt
5250

gattgcctgg aacagcaaca acctggacag caaggtggga ggcaactaca
5300

actacctcta cagactgttc aggaagagca acctgaaacc atttgagagg
5350

gacatcagca cagagattta ccaggctggc agcacaccat gtaatggagt
5400

ggagggcttc aactgttact ttccactcca atcctatggc ttccaaccaa
5450

ccaatggagt gggctaccaa ccatacaggg tggtggtgct gtcctttgaa
5500

ctgctccatg cccctgccac agtgtgtgga ccaaagaaga gcaccaacct
5550

ggtgaagaac aagtgtgtga acttcaactt caatggactg acaggcacag
5600

gagtgctgac agagagcaac aagaagttcc tgccattcca acagtttggc
5650

agggacattg ctgacaccac agatgctgtg agggacccac agaccttgga
5700

gattctggac atcacaccat gttcctttgg aggagtgtct gtgattacac
5750

ctggcaccaa caccagcaac caggtggctg tgctctacca ggatgtgaac
5800

tgtactgagg tgcctgtggc tatccatgct gaccaactta caccaacctg
5850

gagggtctac agcacaggca gcaatgtgtt ccagaccagg gctggctgtc
5900

tgattggagc agagcatgtg aacaactcct atgagtgtga catcccaatt
5950

ggagcaggca tctgtgcctc ctaccagacc cagaccaaca gcccaaggag
6000

ggcaaggtct gtggcaagcc agagcatcat tgcctacaca atgagtctgg
6050

gagcagagaa ctctgtggct tacagcaaca acagcattgc catcccaacc
6100

aacttcacca tctctgtgac cacagagatt ctgcctgtga gtatgaccaa
6150

gacctctgtg gactgtacaa tgtatatctg tggagacagc acagagtgta
6200

gcaacctgct gctccaatat ggctccttct gtacccaact taacagggct
6250

ctgacaggca ttgctgtgga acaggacaag aacacccagg aggtgtttgc
6300

ccaggtgaag cagatttaca agacacctcc aatcaaggac tttggaggct
6350

tcaacttcag ccagattctg cctgacccaa gcaagccaag caagaggtcc
6400

ttcattgagg acctgctgtt caacaaggtg accctggctg atgctggctt
6450

catcaagcaa tatggagact gtctgggaga cattgctgcc agggacctga
6500

tttgtgccca gaagttcaat ggactgacag tgctgcctcc actgctgaca
6550

gatgagatga ttgcccaata cacctctgcc ctgctggctg gcaccatcac
6600

ctctggctgg acctttggag caggagcagc cctccaaatc ccatttgcta
6650

tgcagatggc ttacaggttc aatggcattg gagtgaccca gaatgtgctc
6700

tatgagaacc agaaactgat tgccaaccag ttcaactctg ccattggcaa
6750

gattcaggac tccctgtcca gcacagcctc tgccctgggc aaactccaag
6800

atgtggtgaa ccagaatgcc caggctctga acaccctggt gaagcaactt
6850

tccagcaact ttggagccat ctcctctgtg ctgaatgaca tcctgagcag
6900

actggacaag gtggaggctg aggtccagat tgacagactg attacaggca
6950

gactccaatc cctccaaacc tatgtgaccc aacaacttat cagggctgct
7000

gagattaggg catctgccaa cctggctgcc accaagatga gtgagtgtgt
7050

gctgggacaa agcaagaggg tggacttctg tggcaagggc taccacctga
7100

tgagttttcc acagtctgcc cctcatggag tggtgttcct gcatgtgacc
7150

tatgtgcctg cccaggagaa gaacttcacc acagcccctg ccatctgcca
7200

tgatggcaag gctcactttc caagggaggg agtgtttgtg agcaatggca
7250

cccactggtt tgtgacccag aggaacttct atgaaccaca gattatcacc
7300

acagacaaca cctttgtgtc tggcaactgt gatgtggtga ttggcattgt
7350

gaacaacaca gtctatgacc cactccaacc tgaactggac tccttcaagg
7400

aggaactgga caaatacttc aagaaccaca ccagccctga tgtggacctg
7450

ggagacatct ctggcatcaa tgcctctgtg gtgaacatcc agaaggagat
7500

tgacagactg aatgaggtgg ctaagaacct gaatgagtcc ctgattgacc
7550

tccaagaact gggcaaatat gaacaataca tcaagtggcc atggtacatc
7600

tggctgggct tcattgctgg actgattgcc attgtgatgg tgaccataat
7650

gctgtgttgt atgacctcct gttgttcctg tctgaaaggc tgttgttcct
7700

gtggctcctg ttgtaagtga acgcgtacgc ggccgctcga gcagaaactc
7750

atctcagaag aggatctggc agcaaatgat atcctggatt acaaggatga
7800

cgacgataag gtttaaacgg ccggccgcgg tctgtacaag taggattcgt
7850

cgagggacct aataacttcg tatagcatac attatacgaa gttatacatg
7900

tttaagggtt ccggttccac taggtacaat tcgatatcaa gcttatcgat
7950

aatcaacctc tggattacaa aatttgtgaa agattgactg gtattcttaa
8000

ctatgttgct ccttttacgc tatgtggata cgctgcttta atgcctttgt
8050

atcatgctat tgcttcccgt atggctttca ttttctcctc cttgtataaa
8100

tcctggttgc tgtctcttta tgaggagttg tggcccgttg tcaggcaacg
8150

tggcgtggtg tgcactgtgt ttgctgacgc aacccccact ggttggggca
8200

ttgccaccac ctgtcagctc ctttccggga ctttcgcttt ccccctccct
8250

attgccacgg cggaactcat cgccgcctgc cttgcccgct gctggacagg
8300

ggctcggctg ttgggcactg acaattccgt ggtgttgtcg gggaaatcat
8350

cgtcctttcc ttggctgctc gcctgtgttg ccacctggat tctgcgcggg
8400

acgtccttct gctacgtccc ttcggccctc aatccagcgg accttccttc
8450

ccgcggcctg ctgccggctc tgcggcctct tccgcgtctt cgccttcgcc
8500

ctcagacgag tcggatctcc ctttgggccg cctccccgca tcgataccgt
8550

cgacctcgat cgagacctag aaaaacatgg agcaatcaca agtagcaata
8600

cagcagctac caatgctgat tgtgcctggc tagaagcaca agaggaggag
8650

gaggtgggtt ttccagtcac acctcaggta cctttaagac caatgactta
8700

caaggcagct gtagatctta gccacttttt aaaagaaaag gggggacgaa
8750

gggctaattc actcccaacg aagacaagat ctgcttgatc tgtggatcta
8800

ccacacacaa ggctacttcc ctgattggca gaactacaca ccagggccag
8850

ggatcagata tccactgacc tttggatggt gctacaagct agtaccagtt
8900

gagcaagaga aggtagaaga agccaatgaa ggagagaaca cccgcttgtt
8950

acaccctgtg agcctgcatg ggatggatga cccggagaga gaagtattag
9000

agtggaggtt tgacagccgc ctagcatttc atcacatggc ccgagagctg
9050

catccggact gtactgggtc tctctggtta gaccagatct gagcctggga
9100

gctctctggc taactaggga acccactgct taagcctcaa taaagcttgc
9150

cttgagtgct tcaagtagtg tgtgcccgtc tgttgtgtga ctctggtaac
9200

tagagatccc tcagaccctt ttagtcagtg tggaaaatct ctagcagcat
9250

gtgagcaaaa ggccagcaaa aggccaggaa ccgtaaaaag gccgcgttgc
9300

tggcgttttt ccataggctc cgcccccctg acgagcatca caaaaatcga
9350

cgctcaagtc agaggtggcg aaacccgaca ggactataaa gataccaggc
9400

gtttccccct ggaagctccc tcgtgcgctc tcctgttccg accctgccgc
9450

ttaccggata cctgtccgcc tttctccctt cgggaagcgt ggcgctttct
9500

catagctcac gctgtaggta tctcagttcg gtgtaggtcg ttcgctccaa
9550

gctgggctgt gtgcacgaac cccccgttca gcccgaccgc tgcgccttat
9600

ccggtaacta tcgtcttgag tccaacccgg taagacacga cttatcgcca
9650

ctggcagcag ccactggtaa caggattagc agagcgaggt atgtaggcgg
9700

tgctacagag ttcttgaagt ggtggcctaa ctacggctac actagaagaa
9750

cagtatttgg tatctgcgct ctgctgaagc cagttacctt cggaaaaaga
9800

gttggtagct cttgatccgg caaacaaacc accgctggta gcggtggttt
9850

ttttgtttgc aagcagcaga ttacgcgcag aaaaaaagga tctcaagaag
9900

atcctttgat cttttctacg gggtctgacg ctcagtggaa cgaaaactca
9950

cgttaaggga ttttggtcat gagattatca aaaaggatct tcacctagat
10000

ccttttaaat taaaaatgaa gttttaaatc aatctaaagt atatatgagt
10050

aaacttggtc tgacagttac caatgcttaa tcagtgaggc acctatctca
10100

gcgatctgtc tatttcgttc atccatagtt gcctgactcc ccgtcgtgta
10150

gataactacg atacgggagg gcttaccatc tggccccagt gctgcaatga
10200

taccgcgaga cccacgctca ccggctccag atttatcagc aataaaccag
10250

ccagccggaa gggccgagcg cagaagtggt cctgcaactt tatccgcctc
10300

catccagtct attaattgtt gccgggaagc tagagtaagt agttcgccag
10350

ttaatagttt gcgcaacgtt gttgccattg ctacaggcat cgtggtgtca
10400

cgctcgtcgt ttggtatggc ttcattcagc tccggttccc aacgatcaag
10450

gcgagttaca tgatccccca tgttgtgcaa aaaagcggtt agctccttcg
10500

gtcctccgat cgttgtcaga agtaagttgg ccgcagtgtt atcactcatg
10550

gttatggcag cactgcataa ttctcttact gtcatgccat ccgtaagatg
10600

cttttctgtg actggtgagt actcaaccaa gtcattctga gaatagtgta
10650

tgcggcgacc gagttgctct tgcccggcgt caatacggga taataccgcg
10700

ccacatagca gaactttaaa agtgctcatc attggaaaac gttcttcggg
10750

gcgaaaactc tcaaggatct taccgctgtt gagatccagt tcgatgtaac
10800

ccactcgtgc acccaactga tcttcagcat cttttacttt caccagcgtt
10850

tctgggtgag caaaaacagg aaggcaaaat gccgcaaaaa agggaataag
10900

ggcgacacgg aaatgttgaa tactcatact cttccttttt caatattatt
10950

gaagcattta tcagggttat tgtctcatga gcggatacat atttgaatgt
11000

atttagaaaa ataaacaaat aggggtcccg cgcacatttc cccgaaaagt
11050

gccacctgac
11060

As will be noted, residues 237-616 of pLenti-CMV-IRES-Spike (-att) (SEQ ID NO:70) correspond to the CMV immediate early enhancer site (SEQ ID NO:1). Residues 618-816 of SEQ ID NO:70 correspond to the CMV immediate early promoter site (SEQ ID NO:3). Residues 834-1012 of SEQ ID NO:70 correspond to the alternative truncated lentiviral 5′ LTR region (SEQ ID NO:68). Residues 1059-1184 of SEQ ID NO:70 correspond to the lentiviral ψ region (SEQ ID NO:6). Residues 1681-1914 of SEQ ID NO:70 correspond to the lentiviral Rev response element (RRE) (SEQ ID NO:7). Residues 2441-2558 of SEQ ID NO:70 correspond to the lentiviral cPPT/CTS region (SEQ ID NO:8). Residues 2641-3020 of SEQ ID NO:70 correspond to the variant CMV immediate early enhancer site (SEQ ID NO:2). Residues 3021-3224 of SEQ ID NO:70 correspond to the variant CMV immediate early promoter site (SEQ ID NO:4). Residues 3250-3268 of SEQ ID NO:70 correspond to a T7 promoter site (SEQ ID NO:12). Residues 3391-3852 of SEQ ID NO:70 correspond to the internal ribosome entry site of the encephalomyocarditis virus (EMCV) (SEQ ID NO:69). Residues 3893-3952 of SEQ ID NO:70 correspond to a polynucleotide sequence (SEQ ID NO:73) that encodes an TL-2 signal sequence (SEQ ID NO:72). Residues 3953-7717 of SEQ ID NO:70 correspond to a polynucleotide sequence (SEQ ID NO:71) that encodes the SARS-CoV-2 spike protein (SEQ ID NO:54). Residues 5265-5282 (gcaacaacctggacagca; SEQ ID NO:74) correspond to a sequence that is complementary to a polynucleotide that encodes a tetracysteine peptide (CCPGCC; SEQ ID NO:75) that binds biarsenical labeling reagents. Residues 7739-7813 of SEQ ID NO:70 correspond to a polynucleotide sequence (SEQ ID NO:14) that encodes a combined Myc (human c-Myc oncogene) and FLAG® epitope tag (SEQ ID NO:13). Residues 7862-7895 of SEQ ID NO:70 correspond to a LoxP site (SEQ ID NO:15). Residues 7951-8539 of SEQ ID NO:70 correspond to a woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) (SEQ ID NO:16). Residues 8422-8433 of SEQ ID NO:70 correspond to a Factor Xa cleavage site (SEQ ID NO:17). Residues 8542-8558 of SEQ ID NO:70 correspond to a polynucleotide whose sequence is complementary to the sequence a KS primer binding site (SEQ ID NO:18). Residues 8748-9247 correspond to a 5′ LTR that has been modified to be self-inactivating (SIN) of which residues 8748-9065 correspond to a modified U3 region (SEQ ID NO:64), residues 9066-9247 correspond to R and the U5 regions of the 5′ LTR (SEQ ID NO:5). Residues 9308-9896 of SEQ ID NO:70 correspond to a polynucleotide whose sequence is complementary to the sequence of the high-copy-number ColE1/pMB1/pBR322/pUC origin of replication (SEQ ID NO:19). Residues 10067-10927 of SEQ ID NO:70 correspond to a polynucleotide whose sequence is complementary to the sequence encoding the AmpR antibiotic resistance determinant (SEQ ID NO:22) (i.e., such encoding sequence is on the second strand of the vector). Residues 10928-11032 of SEQ ID NO:70 correspond to a polynucleotide whose sequence is complementary to the sequence of the AmpR promoter (SEQ ID NO:25) (i.e., such promoter sequence is on the second strand of the vector).

(e) pLenti-IgGκ-nCoV-Spike-CD8-TM (-att)

The vector pLenti-IgGκ-nCoV-Spike-CD8-TM (-att) (FIG. 10) further illustrates the LTR-containing vectors of the present invention. The first strand of vector pLenti-IgGκ-nCoV-Spike-CD8-TM (-att) has 11381 nucleotide residues and has the sequence of SEQ ID NO:83:

gtcgacggat cgggagatct cccgatcccc tatggtgcac tctcagtaca
50

atctgctctg atgccgcata gttaagccag tatctgctcc ctgcttgtgt
100

gttggaggtc gctgagtagt gcgcgagcaa aatttaagct acaacaaggc
150

aaggcttgac cgacaattgc atgaagaatc tgcttagggt taggcgtttt
200

gcgctgcttc gcgatgtacg ggccagatat cgcgttgaca ttgattattg
250

actagttatt aatagtaatc aattacgggg tcattagttc atagcccata
300

tatggagttc cgcgttacat aacttacggt aaatggcccg cctggctgac
350

cgcccaacga cccccgccca ttgacgtcaa taatgacgta tgttcccata
400

gtaacgccaa tagggacttt ccattgacgt caatgggtgg agtatttacg
450

gtaaactgcc cacttggcag tacatcaagt gtatcatatg ccaagtacgc
500

cccctattga cgtcaatgac ggtaaatggc ccgcctggca ttatgcccag
550

tacatgacct tatgggactt tcctacttgg cagtacatct acgtattagt
600

catcgctatt accatggtga tgcggttttg gcagtacatc aatgggcgtg
650

gatagcggtt tgactcacgg ggatttccaa gtctccaccc cattgacgtc
700

aatgggagtt tgttttggca ccaaaatcaa cgggactttc caaaatgtcg
750

taacaactcc gccccattga cgcaaatggg cggtaggcgt gtacggtggg
800

aggtctatat aagcagcgcg ttttgcctgt actgggtctc tctggttaga
850

ccagatctga gcctgggagc tctctggcta actagggaac ccactgctta
900

agcctcaata aagcttgcct tgagtgcttc aagtagtgtg tgcccgtctg
950

ttgtgtgact ctggtaacta gagatccctc agaccctttt agtcagtgtg
1000

gaaaatctct aggtggcgcc cgaacaggga cttgaaagcg aaagggaaac
1050

cagaggagct ctctcgacgc aggactcggc ttgctgaagc gcgcacggca
1100

agaggcgagg ggcggcgact ggtgagtacg ccaaaaattt tgactagcgg
1150

aggctagaag gagagagatg ggtgcgagag cgtcagtatt aagcggggga
1200

gaattagatc gcgatgggaa aaaattcggt taaggccagg gggaaagaaa
1250

aaatataaat taaaacatat agtatgggca agcagggagc tagaacgatt
1300

cgcagttaat cctggcctgt tagaaacatc agaaggctgt agacaaatac
1350

tgggacagct acaaccatcc cttcagacag gatcagaaga acttagatca
1400

ttatataata cagtagcaac cctctattgt gtgcatcaaa ggatagagat
1450

aaaagacacc aaggaagctt tagacaagat agaggaagag caaaacaaaa
1500

gtaagaccac cgcacagcaa gcggccggcc gctgatcttc agacctggag
1550

gaggagatat gagggacaat tggagaagtg aattatataa atataaagta
1600

gtaaaaattg aaccattagg agtagcaccc accaaggcaa agagaagagt
1650

ggtgcagaga gaaaaaagag cagtgggaat aggagctttg ttccttgggt
1700

tcttgggagc agcaggaagc actatgggcg cagcgtcaat gacgctgacg
1750

gtacaggcca gacaattatt gtctggtata gtgcagcagc agaacaattt
1800

gctgagggct attgaggcgc aacagcatct gttgcaactc acagtctggg
1850

gcatcaagca gctccaggca agaatcctgg ctgtggaaag atacctaaag
1900

gatcaacagc tcctggggat ttggggttgc tctggaaaac tcatttgcac
1950

cactgctgtg ccttggaatg ctagttggag taataaatct ctggaacaga
2000

tttggaatca cacgacctgg atggagtggg acagagaaat taacaattac
2050

acaagcttaa tacactcctt aattgaagaa tcgcaaaacc agcaagaaaa
2100

gaatgaacaa gaattattgg aattagataa atgggcaagt ttgtggaatt
2150

ggtttaacat aacaaattgg ctgtggtata taaaattatt cataatgata
2200

gtaggaggct tggtaggttt aagaatagtt tttgctgtac tttctatagt
2250

gaatagagtt aggcagggat attcaccatt atcgtttcag acccacctcc
2300

caaccccgag gggacccgac aggcccgaag gaatagaaga agaaggtgga
2350

gagagagaca gagacagatc cattcgatta gtgaacggat cggcactgcg
2400

tgcgccaatt ctgcagacaa atggcagtat tcatccacaa ttttaaaaga
2450

aaagggggga ttggggggta cagtgcaggg gaaagaatag tagacataat
2500

agcaacagac atacaaacta aagaattaca aaaacaaatt acaaaaattc
2550

aaaattttcg ggtttattac agggacagca gagatccagt ttggttagta
2600

ccgggcccgc tctagacatg tccaatatga ccgccatgtt gacattgatt
2650

attgactagt tattaatagt aatcaattac ggggtcatta gttcatagcc
2700

catatatgga gttccgcgtt acataactta cggtaaatgg cccgcctggc
2750

tgaccgccca acgacccccg cccattgacg tcaataatga cgtatgttcc
2800

catagtaacg ccaataggga ctttccattg acgtcaatgg gtggagtatt
2850

tacggtaaac tgcccacttg gcagtacatc aagtgtatca tatgccaagt
2900

ccgcccccta ttgacgtcaa tgacggtaaa tggcccgcct ggcattatgc
2950

ccagtacatg accttacggg actttcctac ttggcagtac atctacgtat
3000

tagtcatcgc tattaccatg gtgatgcggt tttggcagta caccaatggg
3050

cgtggatagc ggtttgactc acggggattt ccaagtctcc accccattga
3100

cgtcaatggg agtttgtttt ggcaccaaaa tcaacgggac tttccaaaat
3150

gtcgtaataa ccccgccccg ttgacgcaaa tgggcggtag gcgtgtacgg
3200

tgggaggtct atataagcag agctcgttta gtgaaccgtc agaattttgt
3250

aatacgactc actatagggc ggccgggaat tcgtcgactg cccccccccc
3300

taacgttact ggccgaagcc gcttggaata aggccggtgt gcgtttgtct
3350

atatgttatt ttccaccata ttgccgtctt ttggcaatgt gagggcccgg
3400

aaacctggcc ctgtcttctt gacgagcatt cctaggggtc tttcccctct
3450

cgccaaagga atgcaaggtc tgttgaatgt cgtgaaggaa gcagttcctc
3500

tggaagcttc ttgaagacaa acaacgtctg tagcgaccct ttgcaggcag
3550

cggaaccccc cacctggcga caggtgcctc tgcggccaaa agccacgtgt
3600

ataagataca cctgcaaagg cggcacaacc ccagtgccac gttgtgagtt
3650

ggatagttgt ggaaagagtc aaatggctct cctcaagcgt attcaacaag
3700

gggctgaagg atgcccagaa ggtaccccat tgtatgggat ctgatctggg
3750

gcctcggtgc acatgcttta catgtgttta gtcgaggtta aaaaacgtct
3800

aggccccccg aaccacgggg acgtggtttt cctttgaaaa acacgatgat
3850

aatgatccgg taccgaggag atctgccgcc gcgatcgcca ccatggacat
3900

gagggtccct gctcagctcc tggggctcct gctgctctgg ctctcaggtg
3950

ccagatgtat gtttgtgttc ctggtgctgc tgccactggt gtccagccag
4000

tgtgtgaacc tgaccaccag gacccaactt cctcctgcct acaccaactc
4050

cttcaccagg ggagtctact accctgacaa ggtgttcagg tcctctgtgc
4100

tgcacagcac ccaggacctg ttcctgccat tcttcagcaa tgtgacctgg
4150

ttccatgcca tccatgtgtc tggcaccaat ggcaccaaga ggtttgacaa
4200

ccctgtgctg ccattcaatg atggagtcta ctttgccagc acagagaaga
4250

gcaacatcat caggggctgg atttttggca ccaccctgga cagcaagacc
4300

cagtccctgc tgattgtgaa caatgccacc aatgtggtga ttaaggtgtg
4350

tgagttccag ttctgtaatg acccattcct gggagtctac taccacaaga
4400

acaacaagtc ctggatggag tctgagttca gggtctactc ctctgccaac
4450

aactgtacct ttgaatatgt gagccaacca ttcctgatgg acttggaggg
4500

caagcagggc aacttcaaga acctgaggga gtttgtgttc aagaacattg
4550

atggctactt caagatttac agcaaacaca caccaatcaa cctggtgagg
4600

gacctgccac agggcttctc tgccttggaa ccactggtgg acctgccaat
4650

tggcatcaac atcaccaggt tccagaccct gctggctctg cacaggtcct
4700

acctgacacc tggagactcc tcctctggct ggacagcagg agcagcagcc
4750

tactatgtgg gctacctcca accaaggacc ttcctgctga aatacaatga
4800

gaatggcacc atcacagatg ctgtggactg tgccctggac ccactgtctg
4850

agaccaagtg taccctgaaa tccttcacag tggagaaggg catctaccag
4900

accagcaact tcagggtcca accaacagag agcattgtga ggtttccaaa
4950

catcaccaac ctgtgtccat ttggagaggt gttcaatgcc accaggtttg
5000

cctctgtcta tgcctggaac aggaagagga ttagcaactg tgtggctgac
5050

tactctgtgc tctacaactc tgcctccttc agcaccttca agtgttatgg
5100

agtgagccca accaaactga atgacctgtg tttcaccaat gtctatgctg
5150

actcctttgt gattagggga gatgaggtga gacagattgc ccctggacaa
5200

acaggcaaga ttgctgacta caactacaaa ctgcctgatg acttcacagg
5250

ctgtgtgatt gcctggaaca gcaacaacct ggacagcaag gtgggaggca
5300

actacaacta cctctacaga ctgttcagga agagcaacct gaaaccattt
5350

gagagggaca tcagcacaga gatttaccag gctggcagca caccatgtaa
5400

tggagtggag ggcttcaact gttactttcc actccaatcc tatggcttcc
5450

aaccaaccaa tggagtgggc taccaaccat acagggtggt ggtgctgtcc
5500

tttgaactgc tccatgcccc tgccacagtg tgtggaccaa agaagagcac
5550

caacctggtg aagaacaagt gtgtgaactt caacttcaat ggactgacag
5600

gcacaggagt gctgacagag agcaacaaga agttcctgcc attccaacag
5650

tttggcaggg acattgctga caccacagat gctgtgaggg acccacagac
5700

cttggagatt ctggacatca caccatgttc ctttggagga gtgtctgtga
5750

ttacacctgg caccaacacc agcaaccagg tggctgtgct ctaccaggat
5800

gtgaactgta ctgaggtgcc tgtggctatc catgctgacc aacttacacc
5850

aacctggagg gtctacagca caggcagcaa tgtgttccag accagggctg
5900

gctgtctgat tggagcagag catgtgaaca actcctatga gtgtgacatc
5950

ccaattggag caggcatctg tgcctcctac cagacccaga ccaacagccc
6000

aaggagggca aggtctgtgg caagccagag catcattgcc tacacaatga
6050

gtctgggagc agagaactct gtggcttaca gcaacaacag cattgccatc
6100

ccaaccaact tcaccatctc tgtgaccaca gagattctgc ctgtgagtat
6150

gaccaagacc tctgtggact gtacaatgta tatctgtgga gacagcacag
6200

agtgtagcaa cctgctgctc caatatggct ccttctgtac ccaacttaac
6250

agggctctga caggcattgc tgtggaacag gacaagaaca cccaggaggt
6300

gtttgcccag gtgaagcaga tttacaagac acctccaatc aaggactttg
6350

gaggcttcaa cttcagccag attctgcctg acccaagcaa gccaagcaag
6400

aggtccttca ttgaggacct gctgttcaac aaggtgaccc tggctgatgc
6450

tggcttcatc aagcaatatg gagactgtct gggagacatt gctgccaggg
6500

acctgatttg tgcccagaag ttcaatggac tgacagtgct gcctccactg
6550

ctgacagatg agatgattgc ccaatacacc tctgccctgc tggctggcac
6600

catcacctct ggctggacct ttggagcagg agcagccctc caaatcccat
6650

ttgctatgca gatggcttac aggttcaatg gcattggagt gacccagaat
6700

gtgctctatg agaaccagaa actgattgcc aaccagttca actctgccat
6750

tggcaagatt caggactccc tgtccagcac agcctctgcc ctgggcaaac
6800

tccaagatgt ggtgaaccag aatgcccagg ctctgaacac cctggtgaag
6850

caactttcca gcaactttgg agccatctcc tctgtgctga atgacatcct
6900

gagcagactg gacaaggtgg aggctgaggt ccagattgac agactgatta
6950

caggcagact ccaatccctc caaacctatg tgacccaaca acttatcagg
7000

gctgctgaga ttagggcatc tgccaacctg gctgccacca agatgagtga
7050

gtgtgtgctg ggacaaagca agagggtgga cttctgtggc aagggctacc
7100

acctgatgag ttttccacag tctgcccctc atggagtggt gttcctgcat
7150

gtgacctatg tgcctgccca ggagaagaac ttcaccacag cccctgccat
7200

ctgccatgat ggcaaggctc actttccaag ggagggagtg tttgtgagca
7250

atggcaccca ctggtttgtg acccagagga acttctatga accacagatt
7300

atcaccacag acaacacctt tgtgtctggc aactgtgatg tggtgattgg
7350

cattgtgaac aacacagtct atgacccact ccaacctgaa ctggactcct
7400

tcaaggagga actggacaaa tacttcaaga accacaccag ccctgatgtg
7450

gacctgggag acatctctgg catcaatgcc tctgtggtga acatccagaa
7500

ggagattgac agactgaatg aggtggctaa gaacctgaat gagtccctga
7550

ttgacctcca agaactgggc aaatatgaac aatacatcaa gtggccatgg
7600

tacatctggc tgggcttcat tgctggactg attgccattg tgatggtgac
7650

cataatgctg tgttgtatga cctcctgttg ttcctgtctg aaaggctgtt
7700

gttcctgtgg ctcctgttgt aagtttgatg aggatgactc tgaacctgtg
7750

ctgaaaggag tgaaactgca ctacaccgcc ctgagcaact ccatcatgta
7800

cttcagccac ttcgtgccgg tcttcctgcc agcgaagccc accacgacgc
7850

cagcgccgcg accaccaaca ccggcgccca ccatcgcgtc gcagcccctg
7900

tccctgcgcc cagaggcgtg ccggccagcg gcggggggcg cagtgcacac
7950

gagggggctg gacttcgcct gtgatatcta catctgggcg cccttggccg
8000

ggacttgtgg ggtccttctc ctgtcactgg ttatcacctg aacgcgtacg
8050

cggccgctcg agcagaaact catctcagaa gaggatctgg cagcaaatga
8100

tatcctggat tacaaggatg acgacgataa ggtttaaacg gccggccgcg
8150

gtctgtacaa gtaggattcg tcgagggacc taataacttc gtatagcata
8200

cattatacga agttatacat gtttaagggt tccggttcca ctaggtacaa
8250

ttcgatatca agcttatcga taatcaacct ctggattaca aaatttgtga
8300

aagattgact ggtattctta actatgttgc tccttttacg ctatgtggat
8350

acgctgcttt aatgcctttg tatcatgcta ttgcttcccg tatggctttc
8400

attttctcct ccttgtataa atcctggttg ctgtctcttt atgaggagtt
8450

gtggcccgtt gtcaggcaac gtggcgtggt gtgcactgtg tttgctgacg
8500

caacccccac tggttggggc attgccacca cctgtcagct cctttccggg
8550

actttcgctt tccccctccc tattgccacg gcggaactca tcgccgcctg
8600

ccttgcccgc tgctggacag gggctcggct gttgggcact gacaattccg
8650

tggtgttgtc ggggaaatca tcgtcctttc cttggctgct cgcctgtgtt
8700

gccacctgga ttctgcgcgg gacgtccttc tgctacgtcc cttcggccct
8750

caatccagcg gaccttcctt cccgcggcct gctgccggct ctgcggcctc
8800

ttccgcgtct tcgccttcgc cctcagacga gtcggatctc cctttgggcc
8850

gcctccccgc atcgataccg tcgacctcga tcgagaccta gaaaaacatg
8900

gagcaatcac aagtagcaat acagcagcta ccaatgctga ttgtgcctgg
8950

ctagaagcac aagaggagga ggaggtgggt tttccagtca cacctcaggt
9000

acctttaaga ccaatgactt acaaggcagc tgtagatctt agccactttt
9050

taaaagaaaa ggggggacga agggctaatt cactcccaac gaagacaaga
9100

tctgcttgat ctgtggatct accacacaca aggctacttc cctgattggc
9150

agaactacac accagggcca gggatcagat atccactgac ctttggatgg
9200

tgctacaagc tagtaccagt tgagcaagag aaggtagaag aagccaatga
9250

aggagagaac acccgcttgt tacaccctgt gagcctgcat gggatggatg
9300

acccggagag agaagtatta gagtggaggt ttgacagccg cctagcattt
9350

catcacatgg cccgagagct gcatccggac tgtactgggt ctctctggtt
9400

agaccagatc tgagcctggg agctctctgg ctaactaggg aacccactgc
9450

ttaagcctca ataaagcttg ccttgagtgc ttcaagtagt gtgtgcccgt
9500

ctgttgtgtg actctggtaa ctagagatcc ctcagaccct tttagtcagt
9550

gtggaaaatc tctagcagca tgtgagcaaa aggccagcaa aaggccagga
9600

accgtaaaaa ggccgcgttg ctggcgtttt tccataggct ccgcccccct
9650

gacgagcatc acaaaaatcg acgctcaagt cagaggtggc gaaacccgac
9700

aggactataa agataccagg cgtttccccc tggaagctcc ctcgtgcgct
9750

ctcctgttcc gaccctgccg cttaccggat acctgtccgc ctttctccct
9800

tcgggaagcg tggcgctttc tcatagctca cgctgtaggt atctcagttc
9850

ggtgtaggtc gttcgctcca agctgggctg tgtgcacgaa ccccccgttc
9900

agcccgaccg ctgcgcctta tccggtaact atcgtcttga gtccaacccg
9950

gtaagacacg acttatcgcc actggcagca gccactggta acaggattag
10000

cagagcgagg tatgtaggcg gtgctacaga gttcttgaag tggtggccta
10050

actacggcta cactagaaga acagtatttg gtatctgcgc tctgctgaag
10100

ccagttacct tcggaaaaag agttggtagc tcttgatccg gcaaacaaac
10150

caccgctggt agcggtggtt tttttgtttg caagcagcag attacgcgca
10200

gaaaaaaagg atctcaagaa gatcctttga tcttttctac ggggtctgac
10250

gctcagtgga acgaaaactc acgttaaggg attttggtca tgagattatc
10300

aaaaaggatc ttcacctaga tccttttaaa ttaaaaatga agttttaaat
10350

caatctaaag tatatatgag taaacttggt ctgacagtta ccaatgctta
10400

atcagtgagg cacctatctc agcgatctgt ctatttcgtt catccatagt
10450

tgcctgactc cccgtcgtgt agataactac gatacgggag ggcttaccat
10500

ctggccccag tgctgcaatg ataccgcgag acccacgctc accggctcca
10550

gatttatcag caataaacca gccagccgga agggccgagc gcagaagtgg
10600

tcctgcaact ttatccgcct ccatccagtc tattaattgt tgccgggaag
10650

ctagagtaag tagttcgcca gttaatagtt tgcgcaacgt tgttgccatt
10700

gctacaggca tcgtggtgtc acgctcgtcg tttggtatgg cttcattcag
10750

ctccggttcc caacgatcaa ggcgagttac atgatccccc atgttgtgca
10800

aaaaagcggt tagctccttc ggtcctccga tcgttgtcag aagtaagttg
10850

gccgcagtgt tatcactcat ggttatggca gcactgcata attctcttac
10900

tgtcatgcca tccgtaagat gcttttctgt gactggtgag tactcaacca
10950

agtcattctg agaatagtgt atgcggcgac cgagttgctc ttgcccggcg
11000

tcaatacggg ataataccgc gccacatagc agaactttaa aagtgctcat
11050

cattggaaaa cgttcttcgg ggcgaaaact ctcaaggatc ttaccgctgt
11100

tgagatccag ttcgatgtaa cccactcgtg cacccaactg atcttcagca
11150

tcttttactt tcaccagcgt ttctgggtga gcaaaaacag gaaggcaaaa
11200

tgccgcaaaa aagggaataa gggcgacacg gaaatgttga atactcatac
11250

tcttcctttt tcaatattat tgaagcattt atcagggtta ttgtctcatg
11300

agcggataca tatttgaatg tatttagaaa aataaacaaa taggggtccc
11350

gcgcacattt ccccgaaaag tgccacctga c
11381

As will be noted, residues 237-616 of pLenti-IgGκ-nCoV-Spike-CD8-TM (-att) (SEQ ID NO:83) correspond to the CMV immediate early enhancer site (SEQ ID NO:1). Residues 618-816 of SEQ ID NO:83 correspond to the CMV immediate early promoter site (SEQ ID NO:3). Residues 834-1012 of SEQ ID NO:83 correspond to the alternative truncated lentiviral 5′ LTR region (SEQ ID NO:68). Residues 1059-1184 of SEQ ID NO:83 correspond to the lentiviral ψ region (SEQ ID NO:6). Residues 1681-1914 of SEQ ID NO:83 correspond to the lentiviral Rev response element (RRE) (SEQ ID NO:7). Residues 2441-2558 of SEQ ID NO:83 correspond to the lentiviral cPPT/CTS region (SEQ ID NO:8). Residues 2641-3020 of SEQ ID NO:83 correspond to the variant CMV immediate early enhancer site (SEQ ID NO:2). Residues 3021-3224 of SEQ ID NO:83 correspond to the variant CMV immediate early promoter site (SEQ ID NO:4). Residues 3250-3268 of SEQ ID NO:83 correspond to a T7 promoter site (SEQ ID NO:12). Residues 3391-3852 of SEQ ID NO:83 correspond to the internal ribosome entry site of the encephalomyocarditis virus (EMCV) (SEQ ID NO:69). Residues 3887-3896 of SEQ ID NO:83 correspond to a Kozak sequence (SEQ ID NO:85). Residues 3893-3958 of SEQ ID NO:83 correspond to an IgGκ signal sequence (SEQ ID NO:81). Residues 3959-7777 of SEQ ID NO:83 correspond to a polynucleotide sequence (SEQ ID NO:71) that encodes the SARS-CoV-2 spike protein (SEQ ID NO:54). Residues 5265-5282

(gcaacaacctggacagca, SEQ ID NO: 74)

correspond to a sequence that is complementary to a polynucleotide that encodes a tetracysteine peptide (CCPGCC; SEQ ID NO:75) that binds biarsenical labeling reagents. Residues 7778-8041 of SEQ ID NO:83 correspond to a polynucleotide (SEQ ID NO:88) that encodes a CD8 transmembrane domain (SEQ ID NO:87). Residues 8060-8134 of SEQ ID NO:83 correspond to a polynucleotide sequence (SEQ ID NO:14) that encodes a combined Myc (human c-Myc oncogene) and FLAG® epitope tag (SEQ ID NO:13). Residues 8183-8216 of SEQ ID NO:83 correspond to a LoxP site (SEQ ID NO:15). Residues 8272-8860 of SEQ ID NO:83 correspond to a woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) (SEQ ID NO:16). Residues 8743-8754 of SEQ ID NO:83 correspond to a Factor Xa cleavage site (SEQ ID NO:17). Residues 8863-8879 of SEQ ID NO:83 correspond to a polynucleotide whose sequence is complementary to the sequence a KS primer binding site (SEQ ID NO:18). Residues 9069-9568 correspond to a 5′ LTR that has been modified to be self-inactivating (SIN) of which residues 9069-9386 correspond to a modified U3 region (SEQ ID NO:64), residues 9387-9568 correspond to Rand the U5 regions of the 5′ LTR (SEQ ID NO:5). Residues 9629-10,217 of SEQ ID NO:83 correspond to a polynucleotide whose sequence is complementary to the sequence of the high-copy-number ColE1/pMB1/pBR322/pUC origin of replication (SEQ ID NO:19). Residues 10388-11248 of SEQ ID NO:83 correspond to a polynucleotide whose sequence is complementary to the sequence encoding the AmpR antibiotic resistance determinant (SEQ ID NO:22) (i.e., such encoding sequence is on the second strand of the vector). Residues 11249-11353 of SEQ ID NO:83 correspond to a polynucleotide whose sequence is complementary to the sequence of the AmpR promoter (SEQ ID NO:25) (i.e., such promoter sequence is on the second strand of the vector).

(f) pLenti-IgGκ-nCoV-N-CD8-TM (-att)

The vector pLenti-IgGκ-nCoV-N-CD8-TM (-att) (FIG. 11) further illustrates the LTR-containing vectors of the present invention. The first strand of vector has 8819 nucleotide residues and has the sequence of SEQ ID NO:84:

gtcgacggat cgggagatct cccgatcccc tatggtgcac tctcagtaca
50

atctgctctg atgccgcata gttaagccag tatctgctcc ctgcttgtgt
100

gttggaggtc gctgagtagt gcgcgagcaa aatttaagct acaacaaggc
150

aaggcttgac cgacaattgc atgaagaatc tgcttagggt taggcgtttt
200

gcgctgcttc gcgatgtacg ggccagatat cgcgttgaca ttgattattg
250

actagttatt aatagtaatc aattacgggg tcattagttc atagcccata
300

tatggagttc cgcgttacat aacttacggt aaatggcccg cctggctgac
350

cgcccaacga cccccgccca ttgacgtcaa taatgacgta tgttcccata
400

gtaacgccaa tagggacttt ccattgacgt caatgggtgg agtatttacg
450

gtaaactgcc cacttggcag tacatcaagt gtatcatatg ccaagtacgc
500

cccctattga cgtcaatgac ggtaaatggc ccgcctggca ttatgcccag
550

tacatgacct tatgggactt tcctacttgg cagtacatct acgtattagt
600

catcgctatt accatggtga tgcggttttg gcagtacatc aatgggcgtg
650

gatagcggtt tgactcacgg ggatttccaa gtctccaccc cattgacgtc
700

aatgggagtt tgttttggca ccaaaatcaa cgggactttc caaaatgtcg
750

taacaactcc gccccattga cgcaaatggg cggtaggcgt gtacggtggg
800

aggtctatat aagcagcgcg ttttgcctgt actgggtctc tctggttaga
850

ccagatctga gcctgggagc tctctggcta actagggaac ccactgctta
900

agcctcaata aagcttgcct tgagtgcttc aagtagtgtg tgcccgtctg
950

ttgtgtgact ctggtaacta gagatccctc agaccctttt agtcagtgtg
1000

gaaaatctct aggtggcgcc cgaacaggga cttgaaagcg aaagggaaac
1050

cagaggagct ctctcgacgc aggactcggc ttgctgaagc gcgcacggca
1100

agaggcgagg ggcggcgact ggtgagtacg ccaaaaattt tgactagcgg
1150

aggctagaag gagagagatg ggtgcgagag cgtcagtatt aagcggggga
1200

gaattagatc gcgatgggaa aaaattcggt taaggccagg gggaaagaaa
1250

aaatataaat taaaacatat agtatgggca agcagggagc tagaacgatt
1300

cgcagttaat cctggcctgt tagaaacatc agaaggctgt agacaaatac
1350

tgggacagct acaaccatcc cttcagacag gatcagaaga acttagatca
1400

ttatataata cagtagcaac cctctattgt gtgcatcaaa ggatagagat
1450

aaaagacacc aaggaagctt tagacaagat agaggaagag caaaacaaaa
1500

gtaagaccac cgcacagcaa gcggccggcc gctgatcttc agacctggag
1550

gaggagatat gagggacaat tggagaagtg aattatataa atataaagta
1600

gtaaaaattg aaccattagg agtagcaccc accaaggcaa agagaagagt
1650

ggtgcagaga gaaaaaagag cagtgggaat aggagctttg ttccttgggt
1700

tcttgggagc agcaggaagc actatgggcg cagcgtcaat gacgctgacg
1750

gtacaggcca gacaattatt gtctggtata gtgcagcagc agaacaattt
1800

gctgagggct attgaggcgc aacagcatct gttgcaactc acagtctggg
1850

gcatcaagca gctccaggca agaatcctgg ctgtggaaag atacctaaag
1900

gatcaacagc tcctggggat ttggggttgc tctggaaaac tcatttgcac
1950

cactgctgtg ccttggaatg ctagttggag taataaatct ctggaacaga
2000

tttggaatca cacgacctgg atggagtggg acagagaaat taacaattac
2050

acaagcttaa tacactcctt aattgaagaa tcgcaaaacc agcaagaaaa
2100

gaatgaacaa gaattattgg aattagataa atgggcaagt ttgtggaatt
2150

ggtttaacat aacaaattgg ctgtggtata taaaattatt cataatgata
2200

gtaggaggct tggtaggttt aagaatagtt tttgctgtac tttctatagt
2250

gaatagagtt aggcagggat attcaccatt atcgtttcag acccacctcc
2300

caaccccgag gggacccgac aggcccgaag gaatagaaga agaaggtgga
2350

gagagagaca gagacagatc cattcgatta gtgaacggat cggcactgcg
2400

tgcgccaatt ctgcagacaa atggcagtat tcatccacaa ttttaaaaga
2450

aaagggggga ttggggggta cagtgcaggg gaaagaatag tagacataat
2500

agcaacagac atacaaacta aagaattaca aaaacaaatt acaaaaattc
2550

aaaattttcg ggtttattac agggacagca gagatccagt ttggttagta
2600

ccgggcccgc tctagacatg tccaatatga ccgccatgtt gacattgatt
2650

attgactagt tattaatagt aatcaattac ggggtcatta gttcatagcc
2700

catatatgga gttccgcgtt acataactta cggtaaatgg cccgcctggc
2750

tgaccgccca acgacccccg cccattgacg tcaataatga cgtatgttcc
2800

catagtaacg ccaataggga ctttccattg acgtcaatgg gtggagtatt
2850

tacggtaaac tgcccacttg gcagtacatc aagtgtatca tatgccaagt
2900

ccgcccccta ttgacgtcaa tgacggtaaa tggcccgcct ggcattatgc
2950

ccagtacatg accttacggg actttcctac ttggcagtac atctacgtat
3000

tagtcatcgc tattaccatg gtgatgcggt tttggcagta caccaatggg
3050

cgtggatagc ggtttgactc acggggattt ccaagtctcc accccattga
3100

cgtcaatggg agtttgtttt ggcaccaaaa tcaacgggac tttccaaaat
3150

gtcgtaataa ccccgccccg ttgacgcaaa tgggcggtag gcgtgtacgg
3200

tgggaggtct atataagcag agctcgttta gtgaaccgtc agaattttgt
3250

aatacgactc actatagggc ggccgggaat tcgtcgactg cccccccccc
3300

taacgttact ggccgaagcc gcttggaata aggccggtgt gcgtttgtct
3350

atatgttatt ttccaccata ttgccgtctt ttggcaatgt gagggcccgg
3400

aaacctggcc ctgtcttctt gacgagcatt cctaggggtc tttcccctct
3450

cgccaaagga atgcaaggtc tgttgaatgt cgtgaaggaa gcagttcctc
3500

tggaagcttc ttgaagacaa acaacgtctg tagcgaccct ttgcaggcag
3550

cggaaccccc cacctggcga caggtgcctc tgcggccaaa agccacgtgt
3600

ataagataca cctgcaaagg cggcacaacc ccagtgccac gttgtgagtt
3650

ggatagttgt ggaaagagtc aaatggctct cctcaagcgt attcaacaag
3700

gggctgaagg atgcccagaa ggtaccccat tgtatgggat ctgatctggg
3750

gcctcggtgc acatgcttta catgtgttta gtcgaggtta aaaaacgtct
3800

aggccccccg aaccacgggg acgtggtttt cctttgaaaa acacgatgat
3850

aatgatccgg taccgaggag atctgccgcc gcgatcgcca ccatggacat
3900

gagggtccct gctcagctcc tggggctcct gctgctctgg ctctcaggtg
3950

ccagatgtat gtctgataat ggaccccaaa atcagcgaaa tgcaccccgc
4000

attacgtttg gtggaccctc agattcaact ggcagtaacc agaatggaga
4050

acgcagtggg gcgcgatcaa aacaacgtcg gccccaaggt ttacccaata
4100

atactgcgtc ttggttcacc gctctcactc aacatggcaa ggaagacctt
4150

aaattccctc gaggacaagg cgttccaatt aacaccaata gcagtccaga
4200

tgaccaaatt ggctactacc gaagagctac cagacgaatt cgtggtggtg
4250

acggtaaaat gaaagatctc agtccaagat ggtatttcta ctacctagga
4300

actgggccag aagctggact tccctatggt gctaacaaag acggcatcat
4350

atgggttgca actgagggag ccttgaatac accaaaagat cacattggca
4400

cccgcaatcc tgctaacaat gctgcaatcg tgctacaact tcctcaagga
4450

acaacattgc caaaaggctt ctacgcagaa gggagcagag gcggcagtca
4500

agcctcttct cgttcctcat cacgtagtcg caacagttca agaaattcaa
4550

ctccaggcag cagtagggga acttctcctg ctagaatggc tggcaatggc
4600

ggtgatgctg ctcttgcttt gctgctgctt gacagattga accagcttga
4650

gagcaaaatg tctggtaaag gccaacaaca acaaggccaa actgtcacta
4700

agaaatctgc tgctgaggct tctaagaagc ctcggcaaaa acgtactgcc
4750

actaaagcat acaatgtaac acaagctttc ggcagacgtg gtccagaaca
4800

aacccaagga aattttgggg accaggaact aatcagacaa ggaactgatt
4850

acaaacattg gccgcaaatt gcacaatttg cccccagcgc ttcagcgttc
4900

ttcggaatgt cgcgcattgg catggaagtc acaccttcgg gaacgtggtt
4950

gacctacaca ggtgccatca aattggatga caaagatcca aatttcaaag
5000

atcaagtcat tttgctgaat aagcatattg acgcatacaa aacattccca
5050

ccaacagagc ctaaaaagga caaaaagaag aaggctgatg aaactcaagc
5100

cttaccgcag agacagaaga aacagcaaac tgtgactctt cttcctgctg
5150

cagatttgga tgatttctcc aaacaattgc aacaatccat gagcagtgct
5200

gactcaactc aggccgccct gagcaactcc atcatgtact tcagccactt
5250

cgtgccggtc ttcctgccag cgaagcccac cacgacgcca gcgccgcgac
5300

caccaacacc ggcgcccacc atcgcgtcgc agcccctgtc cctgcgccca
5350

gaggcgtgcc ggccagcggc ggggggcgca gtgcacacga gggggctgga
5400

cttcgcctgt gatatctaca tctgggcgcc cttggccggg acttgtgggg
5450

tccttctcct gtcactggtt atcacctgaa cgcgtacgcg gccgctcgag
5500

cagaaactca tctcagaaga ggatctggca gcaaatgata tcctggatta
5550

caaggatgac gacgataagg tttaaacggc cggccgcggt ctgtacaagt
5600

aggattcgtc gagggaccta ataacttcgt atagcataca ttatacgaag
5650

ttatacatgt ttaagggttc cggttccact aggtacaatt cgatatcaag
5700

cttatcgata atcaacctct ggattacaaa atttgtgaaa gattgactgg
5750

tattcttaac tatgttgctc cttttacgct atgtggatac gctgctttaa
5800

tgcctttgta tcatgctatt gcttcccgta tggctttcat tttctcctcc
5850

ttgtataaat cctggttgct gtctctttat gaggagttgt ggcccgttgt
5900

caggcaacgt ggcgtggtgt gcactgtgtt tgctgacgca acccccactg
5950

gttggggcat tgccaccacc tgtcagctcc tttccgggac tttcgctttc
6000

cccctcccta ttgccacggc ggaactcatc gccgcctgcc ttgcccgctg
6050

ctggacaggg gctcggctgt tgggcactga caattccgtg gtgttgtcgg
6100

ggaaatcatc gtcctttcct tggctgctcg cctgtgttgc cacctggatt
6150

ctgcgcggga cgtccttctg ctacgtccct tcggccctca atccagcgga
6200

ccttccttcc cgcggcctgc tgccggctct gcggcctctt ccgcgtcttc
6250

gccttcgccc tcagacgagt cggatctccc tttgggccgc ctccccgcat
6300

cgataccgtc gacctcgatc gagacctaga aaaacatgga gcaatcacaa
6350

gtagcaatac agcagctacc aatgctgatt gtgcctggct agaagcacaa
6400

gaggaggagg aggtgggttt tccagtcaca cctcaggtac ctttaagacc
6450

aatgacttac aaggcagctg tagatcttag ccacttttta aaagaaaagg
6500

ggggacgaag ggctaattca ctcccaacga agacaagatc tgcttgatct
6550

gtggatctac cacacacaag gctacttccc tgattggcag aactacacac
6600

cagggccagg gatcagatat ccactgacct ttggatggtg ctacaagcta
6650

gtaccagttg agcaagagaa ggtagaagaa gccaatgaag gagagaacac
6700

ccgcttgtta caccctgtga gcctgcatgg gatggatgac ccggagagag
6750

aagtattaga gtggaggttt gacagccgcc tagcatttca tcacatggcc
6800

cgagagctgc atccggactg tactgggtct ctctggttag accagatctg
6850

agcctgggag ctctctggct aactagggaa cccactgctt aagcctcaat
6900

aaagcttgcc ttgagtgctt caagtagtgt gtgcccgtct gttgtgtgac
6950

tctggtaact agagatccct cagacccttt tagtcagtgt ggaaaatctc
7000

tagcagcatg tgagcaaaag gccagcaaaa ggccaggaac cgtaaaaagg
7050

ccgcgttgct ggcgtttttc cataggctcc gcccccctga cgagcatcac
7100

aaaaatcgac gctcaagtca gaggtggcga aacccgacag gactataaag
7150

ataccaggcg tttccccctg gaagctccct cgtgcgctct cctgttccga
7200

ccctgccgct taccggatac ctgtccgcct ttctcccttc gggaagcgtg
7250

gcgctttctc atagctcacg ctgtaggtat ctcagttcgg tgtaggtcgt
7300

tcgctccaag ctgggctgtg tgcacgaacc ccccgttcag cccgaccgct
7350

gcgccttatc cggtaactat cgtcttgagt ccaacccggt aagacacgac
7400

ttatcgccac tggcagcagc cactggtaac aggattagca gagcgaggta
7450

tgtaggcggt gctacagagt tcttgaagtg gtggcctaac tacggctaca
7500

ctagaagaac agtatttggt atctgcgctc tgctgaagcc agttaccttc
7550

ggaaaaagag ttggtagctc ttgatccggc aaacaaacca ccgctggtag
7600

cggtggtttt tttgtttgca agcagcagat tacgcgcaga aaaaaaggat
7650

ctcaagaaga tcctttgatc ttttctacgg ggtctgacgc tcagtggaac
7700

gaaaactcac gttaagggat tttggtcatg agattatcaa aaaggatctt
7750

cacctagatc cttttaaatt aaaaatgaag ttttaaatca atctaaagta
7800

tatatgagta aacttggtct gacagttacc aatgcttaat cagtgaggca
7850

cctatctcag cgatctgtct atttcgttca tccatagttg cctgactccc
7900

cgtcgtgtag ataactacga tacgggaggg cttaccatct ggccccagtg
7950

ctgcaatgat accgcgagac ccacgctcac cggctccaga tttatcagca
8000

ataaaccagc cagccggaag ggccgagcgc agaagtggtc ctgcaacttt
8050

atccgcctcc atccagtcta ttaattgttg ccgggaagct agagtaagta
8100

gttcgccagt taatagtttg cgcaacgttg ttgccattgc tacaggcatc
8150

gtggtgtcac gctcgtcgtt tggtatggct tcattcagct ccggttccca
8200

acgatcaagg cgagttacat gatcccccat gttgtgcaaa aaagcggtta
8250

gctccttcgg tcctccgatc gttgtcagaa gtaagttggc cgcagtgtta
8300

tcactcatgg ttatggcagc actgcataat tctcttactg tcatgccatc
8350

cgtaagatgc ttttctgtga ctggtgagta ctcaaccaag tcattctgag
8400

aatagtgtat gcggcgaccg agttgctctt gcccggcgtc aatacgggat
8450

aataccgcgc cacatagcag aactttaaaa gtgctcatca ttggaaaacg
8500

ttcttcgggg cgaaaactct caaggatctt accgctgttg agatccagtt
8550

cgatgtaacc cactcgtgca cccaactgat cttcagcatc ttttactttc
8600

accagcgttt ctgggtgagc aaaaacagga aggcaaaatg ccgcaaaaaa
8650

gggaataagg gcgacacgga aatgttgaat actcatactc ttcctttttc
8700

aatattattg aagcatttat cagggttatt gtctcatgag cggatacata
8750

tttgaatgta tttagaaaaa taaacaaata ggggtcccgc gcacatttcc
8800

ccgaaaagtg ccacctgac
8819

As will be noted, residues 237-616 of pLenti-IgGκ-nCoV-N-CD8-TM (-att) (SEQ ID NO:84) correspond to the CMV immediate early enhancer site (SEQ ID NO:1). Residues 618-816 of SEQ ID NO:84 correspond to the CMV immediate early promoter site (SEQ ID NO:3). Residues 834-1012 of SEQ ID NO:84 correspond to the truncated lentiviral 5′ LTR region (SEQ ID NO:68). Residues 1059-1184 of SEQ ID NO:84 correspond to the lentiviral ψ region (SEQ ID NO:6). Residues 1681-1914 of SEQ ID NO:84 correspond to the lentiviral Rev response element (RRE) (SEQ ID NO:7). Residues 2441-2558 of SEQ ID NO:84 correspond to the lentiviral cPPT/CTS region (SEQ ID NO:8). Residues 2641-3020 of SEQ ID NO:84 correspond to the variant CMV immediate early enhancer site (SEQ ID NO:2). Residues 3021-3224 of SEQ ID NO:84 correspond to the variant CMV immediate early promoter site (SEQ ID NO:4). Residues 3250-3268 of SEQ ID NO:84 correspond to a T7 promoter site (SEQ ID NO:12). Residues 3391-3852 of SEQ ID NO:84 correspond to the internal ribosome entry site of the encephalomyocarditis virus (EMCV) (SEQ ID NO:69). Residues 3887-3896 of SEQ ID NO:84 correspond to a Kozak sequence (SEQ ID NO:85). Residues 3899-3958 of SEQ ID NO:84 correspond to an IgGκ signal sequence (SEQ ID NO:81). Residues 3959-5215 of SEQ ID NO:84 correspond to a polynucleotide sequence (SEQ ID NO:79) that encodes the SARS-CoV-2 N protein (SEQ ID NO:54). Residues 5216-5479 of SEQ ID NO:84 correspond to a polynucleotide (SEQ ID NO:88) that encodes a CD8 transmembrane domain (SEQ ID NO:87). Residues 5498-5572 of SEQ ID NO:84 correspond to a polynucleotide sequence (SEQ ID NO:14) that encodes a combined Myc (human c-Myc oncogene) and FLAG® epitope tag (SEQ ID NO:13). Residues 5621-5624 of SEQ ID NO:84 correspond to a LoxP site (SEQ ID NO:15). Residues 5710-6298 of SEQ ID NO:84 correspond to a woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) (SEQ ID NO:16). Residues 6181-6192 of SEQ ID NO:84 correspond to a Factor Xa cleavage site (SEQ ID NO:17). Residues 6301-6317 of SEQ ID NO:84 correspond to a polynucleotide whose sequence is complementary to the sequence a KS primer binding site (SEQ ID NO:18). Residues 6507-7005 correspond to a 5′ LTR that has been modified to be self-inactivating (SIN) of which residues 6507-6824 correspond to a modified U3 region (SEQ ID NO:64), residues 6825-7005 correspond to R and the U5 regions of the 5′ LTR (SEQ ID NO:5). Residues 7067-7655 of SEQ ID NO:84 correspond to a polynucleotide whose sequence is complementary to the sequence of the high-copy-number ColE1/pMB1/pBR322/pUC origin of replication (SEQ ID NO:19). Residues 7826-9696 of SEQ ID NO:84 correspond to a polynucleotide whose sequence is complementary to the sequence encoding the AmpR antibiotic resistance determinant (SEQ ID NO:22) (i.e., such encoding sequence is on the second strand of the vector). Residues 8687-8791 of SEQ ID NO:84 correspond to a polynucleotide whose sequence is complementary to the sequence of the AmpR promoter (SEQ ID NO:25) (i.e., such promoter sequence is on the second strand of the vector).

(g) pLenti-IL2-nCoV-N(-att)

The vector pLenti-IL2-nCoV-N(-att) (FIG. 12) further illustrates the LTR-containing vectors of the present invention. The first strand of vector pLenti-IL2-nCoV-N(-att) has 8552 nucleotide residues and has the sequence of SEQ ID NO:85:

gtcgacggat cgggagatct cccgatcccc tatggtgcac tctcagtaca
50

atctgctctg atgccgcata gttaagccag tatctgctcc ctgcttgtgt
100

gttggaggtc gctgagtagt gcgcgagcaa aatttaagct acaacaaggc
150

aaggcttgac cgacaattgc atgaagaatc tgcttagggt taggcgtttt
200

gcgctgcttc gcgatgtacg ggccagatat cgcgttgaca ttgattattg
250

actagttatt aatagtaatc aattacgggg tcattagttc atagcccata
300

tatggagttc cgcgttacat aacttacggt aaatggcccg cctggctgac
350

cgcccaacga cccccgccca ttgacgtcaa taatgacgta tgttcccata
400

gtaacgccaa tagggacttt ccattgacgt caatgggtgg agtatttacg
450

gtaaactgcc cacttggcag tacatcaagt gtatcatatg ccaagtacgc
500

cccctattga cgtcaatgac ggtaaatggc ccgcctggca ttatgcccag
550

tacatgacct tatgggactt tcctacttgg cagtacatct acgtattagt
600

catcgctatt accatggtga tgcggttttg gcagtacatc aatgggcgtg
650

gatagcggtt tgactcacgg ggatttccaa gtctccaccc cattgacgtc
700

aatgggagtt tgttttggca ccaaaatcaa cgggactttc caaaatgtcg
750

taacaactcc gccccattga cgcaaatggg cggtaggcgt gtacggtggg
800

aggtctatat aagcagcgcg ttttgcctgt actgggtctc tctggttaga
850

ccagatctga gcctgggagc tctctggcta actagggaac ccactgctta
900

agcctcaata aagcttgcct tgagtgcttc aagtagtgtg tgcccgtctg
950

ttgtgtgact ctggtaacta gagatccctc agaccctttt agtcagtgtg
1000

gaaaatctct aggtggcgcc cgaacaggga cttgaaagcg aaagggaaac
1050

cagaggagct ctctcgacgc aggactcggc ttgctgaagc gcgcacggca
1100

agaggcgagg ggcggcgact ggtgagtacg ccaaaaattt tgactagcgg
1150

aggctagaag gagagagatg ggtgcgagag cgtcagtatt aagcggggga
1200

gaattagatc gcgatgggaa aaaattcggt taaggccagg gggaaagaaa
1250

aaatataaat taaaacatat agtatgggca agcagggagc tagaacgatt
1300

cgcagttaat cctggcctgt tagaaacatc agaaggctgt agacaaatac
1350

tgggacagct acaaccatcc cttcagacag gatcagaaga acttagatca
1400

ttatataata cagtagcaac cctctattgt gtgcatcaaa ggatagagat
1450

aaaagacacc aaggaagctt tagacaagat agaggaagag caaaacaaaa
1500

gtaagaccac cgcacagcaa gcggccggcc gctgatcttc agacctggag
1550

gaggagatat gagggacaat tggagaagtg aattatataa atataaagta
1600

gtaaaaattg aaccattagg agtagcaccc accaaggcaa agagaagagt
1650

ggtgcagaga gaaaaaagag cagtgggaat aggagctttg ttccttgggt
1700

tcttgggagc agcaggaagc actatgggcg cagcgtcaat gacgctgacg
1750

gtacaggcca gacaattatt gtctggtata gtgcagcagc agaacaattt
1800

gctgagggct attgaggcgc aacagcatct gttgcaactc acagtctggg
1850

gcatcaagca gctccaggca agaatcctgg ctgtggaaag atacctaaag
1900

gatcaacagc tcctggggat ttggggttgc tctggaaaac tcatttgcac
1950

cactgctgtg ccttggaatg ctagttggag taataaatct ctggaacaga
2000

tttggaatca cacgacctgg atggagtggg acagagaaat taacaattac
2050

acaagcttaa tacactcctt aattgaagaa tcgcaaaacc agcaagaaaa
2100

gaatgaacaa gaattattgg aattagataa atgggcaagt ttgtggaatt
2150

ggtttaacat aacaaattgg ctgtggtata taaaattatt cataatgata
2200

gtaggaggct tggtaggttt aagaatagtt tttgctgtac tttctatagt
2250

gaatagagtt aggcagggat attcaccatt atcgtttcag acccacctcc
2300

caaccccgag gggacccgac aggcccgaag gaatagaaga agaaggtgga
2350

gagagagaca gagacagatc cattcgatta gtgaacggat cggcactgcg
2400

tgcgccaatt ctgcagacaa atggcagtat tcatccacaa ttttaaaaga
2450

aaagggggga ttggggggta cagtgcaggg gaaagaatag tagacataat
2500

agcaacagac atacaaacta aagaattaca aaaacaaatt acaaaaattc
2550

aaaattttcg ggtttattac agggacagca gagatccagt ttggttagta
2600

ccgggcccgc tctagacatg tccaatatga ccgccatgtt gacattgatt
2650

attgactagt tattaatagt aatcaattac ggggtcatta gttcatagcc
2700

catatatgga gttccgcgtt acataactta cggtaaatgg cccgcctggc
2750

tgaccgccca acgacccccg cccattgacg tcaataatga cgtatgttcc
2800

catagtaacg ccaataggga ctttccattg acgtcaatgg gtggagtatt
2850

tacggtaaac tgcccacttg gcagtacatc aagtgtatca tatgccaagt
2900

ccgcccccta ttgacgtcaa tgacggtaaa tggcccgcct ggcattatgc
2950

ccagtacatg accttacggg actttcctac ttggcagtac atctacgtat
3000

tagtcatcgc tattaccatg gtgatgcggt tttggcagta caccaatggg
3050

cgtggatagc ggtttgactc acggggattt ccaagtctcc accccattga
3100

cgtcaatggg agtttgtttt ggcaccaaaa tcaacgggac tttccaaaat
3150

gtcgtaataa ccccgccccg ttgacgcaaa tgggcggtag gcgtgtacgg
3200

tgggaggtct atataagcag agctcgttta gtgaaccgtc agaattttgt
3250

aatacgactc actatagggc ggccgggaat tcgtcgactg cccccccccc
3300

taacgttact ggccgaagcc gcttggaata aggccggtgt gcgtttgtct
3350

atatgttatt ttccaccata ttgccgtctt ttggcaatgt gagggcccgg
3400

aaacctggcc ctgtcttctt gacgagcatt cctaggggtc tttcccctct
3450

cgccaaagga atgcaaggtc tgttgaatgt cgtgaaggaa gcagttcctc
3500

tggaagcttc ttgaagacaa acaacgtctg tagcgaccct ttgcaggcag
3550

cggaaccccc cacctggcga caggtgcctc tgcggccaaa agccacgtgt
3600

ataagataca cctgcaaagg cggcacaacc ccagtgccac gttgtgagtt
3650

ggatagttgt ggaaagagtc aaatggctct cctcaagcgt attcaacaag
3700

gggctgaagg atgcccagaa ggtaccccat tgtatgggat ctgatctggg
3750

gcctcggtgc acatgcttta catgtgttta gtcgaggtta aaaaacgtct
3800

aggccccccg aaccacgggg acgtggtttt cctttgaaaa acacgatgat
3850

aatgatccgg taccgaggag atctgccgcc gcgatcgcca ccatgtacag
3900

gatgcaactc ctgtcttgca ttgcactaag tcttgcactt gtcacaaaca
3950

gtatgtctga taatggaccc caaaatcagc gaaatgcacc ccgcattacg
4000

tttggtggac cctcagattc aactggcagt aaccagaatg gagaacgcag
4050

tggggcgcga tcaaaacaac gtcggcccca aggtttaccc aataatactg
4100

cgtcttggtt caccgctctc actcaacatg gcaaggaaga ccttaaattc
4150

cctcgaggac aaggcgttcc aattaacacc aatagcagtc cagatgacca
4200

aattggctac taccgaagag ctaccagacg aattcgtggt ggtgacggta
4250

aaatgaaaga tctcagtcca agatggtatt tctactacct aggaactggg
4300

ccagaagctg gacttcccta tggtgctaac aaagacggca tcatatgggt
4350

tgcaactgag ggagccttga atacaccaaa agatcacatt ggcacccgca
4400

atcctgctaa caatgctgca atcgtgctac aacttcctca aggaacaaca
4450

ttgccaaaag gcttctacgc agaagggagc agaggcggca gtcaagcctc
4500

ttctcgttcc tcatcacgta gtcgcaacag ttcaagaaat tcaactccag
4550

gcagcagtag gggaacttct cctgctagaa tggctggcaa tggcggtgat
4600

gctgctcttg ctttgctgct gcttgacaga ttgaaccagc ttgagagcaa
4650

aatgtctggt aaaggccaac aacaacaagg ccaaactgtc actaagaaat
4700

ctgctgctga ggcttctaag aagcctcggc aaaaacgtac tgccactaaa
4750

gcatacaatg taacacaagc tttcggcaga cgtggtccag aacaaaccca
4800

aggaaatttt ggggaccagg aactaatcag acaaggaact gattacaaac
4850

attggccgca aattgcacaa tttgccccca gcgcttcagc gttcttcgga
4900

atgtcgcgca ttggcatgga agtcacacct tcgggaacgt ggttgaccta
4950

cacaggtgcc atcaaattgg atgacaaaga tccaaatttc aaagatcaag
5000

tcattttgct gaataagcat attgacgcat acaaaacatt cccaccaaca
5050

gagcctaaaa aggacaaaaa gaagaaggct gatgaaactc aagccttacc
5100

gcagagacag aagaaacagc aaactgtgac tcttcttcct gctgcagatt
5150

tggatgattt ctccaaacaa ttgcaacaat ccatgagcag tgctgactca
5200

actcaggcct aaacgcgtac gcggccgctc gagcagaaac tcatctcaga
5250

agaggatctg gcagcaaatg atatcctgga ttacaaggat gacgacgata
5300

aggtttaaac ggccggccgc ggtctgtaca agtaggattc gtcgagggac
5350

ctaataactt cgtatagcat acattatacg aagttataca tgtttaaggg
5400

ttccggttcc actaggtaca attcgatatc aagcttatcg ataatcaacc
5450

tctggattac aaaatttgtg aaagattgac tggtattctt aactatgttg
5500

ctccttttac gctatgtgga tacgctgctt taatgccttt gtatcatgct
5550

attgcttccc gtatggcttt cattttctcc tccttgtata aatcctggtt
5600

gctgtctctt tatgaggagt tgtggcccgt tgtcaggcaa cgtggcgtgg
5650

tgtgcactgt gtttgctgac gcaaccccca ctggttgggg cattgccacc
5700

acctgtcagc tcctttccgg gactttcgct ttccccctcc ctattgccac
5750

ggcggaactc atcgccgcct gccttgcccg ctgctggaca ggggctcggc
5800

tgttgggcac tgacaattcc gtggtgttgt cggggaaatc atcgtccttt
5850

ccttggctgc tcgcctgtgt tgccacctgg attctgcgcg ggacgtcctt
5900

ctgctacgtc ccttcggccc tcaatccagc ggaccttcct tcccgcggcc
5950

tgctgccggc tctgcggcct cttccgcgtc ttcgccttcg ccctcagacg
6000

agtcggatct ccctttgggc cgcctccccg catcgatacc gtcgacctcg
6050

atcgagacct agaaaaacat ggagcaatca caagtagcaa tacagcagct
6100

accaatgctg attgtgcctg gctagaagca caagaggagg aggaggtggg
6150

ttttccagtc acacctcagg tacctttaag accaatgact tacaaggcag
6200

ctgtagatct tagccacttt ttaaaagaaa aggggggacg aagggctaat
6250

tcactcccaa cgaagacaag atctgcttga tctgtggatc taccacacac
6300

aaggctactt ccctgattgg cagaactaca caccagggcc agggatcaga
6350

tatccactga cctttggatg gtgctacaag ctagtaccag ttgagcaaga
6400

gaaggtagaa gaagccaatg aaggagagaa cacccgcttg ttacaccctg
6450

tgagcctgca tgggatggat gacccggaga gagaagtatt agagtggagg
6500

tttgacagcc gcctagcatt tcatcacatg gcccgagagc tgcatccgga
6550

ctgtactggg tctctctggt tagaccagat ctgagcctgg gagctctctg
6600

gctaactagg gaacccactg cttaagcctc aataaagctt gccttgagtg
6650

cttcaagtag tgtgtgcccg tctgttgtgt gactctggta actagagatc
6700

cctcagaccc ttttagtcag tgtggaaaat ctctagcagc atgtgagcaa
6750

aaggccagca aaaggccagg aaccgtaaaa aggccgcgtt gctggcgttt
6800

ttccataggc tccgcccccc tgacgagcat cacaaaaatc gacgctcaag
6850

tcagaggtgg cgaaacccga caggactata aagataccag gcgtttcccc
6900

ctggaagctc cctcgtgcgc tctcctgttc cgaccctgcc gcttaccgga
6950

tacctgtccg cctttctccc ttcgggaagc gtggcgcttt ctcatagctc
7000

acgctgtagg tatctcagtt cggtgtaggt cgttcgctcc aagctgggct
7050

gtgtgcacga accccccgtt cagcccgacc gctgcgcctt atccggtaac
7100

tatcgtcttg agtccaaccc ggtaagacac gacttatcgc cactggcagc
7150

agccactggt aacaggatta gcagagcgag gtatgtaggc ggtgctacag
7200

agttcttgaa gtggtggcct aactacggct acactagaag aacagtattt
7250

ggtatctgcg ctctgctgaa gccagttacc ttcggaaaaa gagttggtag
7300

ctcttgatcc ggcaaacaaa ccaccgctgg tagcggtggt ttttttgttt
7350

gcaagcagca gattacgcgc agaaaaaaag gatctcaaga agatcctttg
7400

atcttttcta cggggtctga cgctcagtgg aacgaaaact cacgttaagg
7450

gattttggtc atgagattat caaaaaggat cttcacctag atccttttaa
7500

attaaaaatg aagttttaaa tcaatctaaa gtatatatga gtaaacttgg
7550

tctgacagtt accaatgctt aatcagtgag gcacctatct cagcgatctg
7600

tctatttcgt tcatccatag ttgcctgact ccccgtcgtg tagataacta
7650

cgatacggga gggcttacca tctggcccca gtgctgcaat gataccgcga
7700

gacccacgct caccggctcc agatttatca gcaataaacc agccagccgg
7750

aagggccgag cgcagaagtg gtcctgcaac tttatccgcc tccatccagt
7800

ctattaattg ttgccgggaa gctagagtaa gtagttcgcc agttaatagt
7850

ttgcgcaacg ttgttgccat tgctacaggc atcgtggtgt cacgctcgtc
7900

gtttggtatg gcttcattca gctccggttc ccaacgatca aggcgagtta
7950

catgatcccc catgttgtgc aaaaaagcgg ttagctcctt cggtcctccg
8000

atcgttgtca gaagtaagtt ggccgcagtg ttatcactca tggttatggc
8050

agcactgcat aattctctta ctgtcatgcc atccgtaaga tgcttttctg
8100

tgactggtga gtactcaacc aagtcattct gagaatagtg tatgcggcga
8150

ccgagttgct cttgcccggc gtcaatacgg gataataccg cgccacatag
8200

cagaacttta aaagtgctca tcattggaaa acgttcttcg gggcgaaaac
8250

tctcaaggat cttaccgctg ttgagatcca gttcgatgta acccactcgt
8300

gcacccaact gatcttcagc atcttttact ttcaccagcg tttctgggtg
8350

agcaaaaaca ggaaggcaaa atgccgcaaa aaagggaata agggcgacac
8400

ggaaatgttg aatactcata ctcttccttt ttcaatatta ttgaagcatt
8450

tatcagggtt attgtctcat gagcggatac atatttgaat gtatttagaa
8500

aaataaacaa ataggggtcc cgcgcacatt tccccgaaaa gtgccacctg
8550

ac
8552

As will be noted, residues 237-616 of pLenti-IL2-nCoV-N(-att) (SEQ ID NO:85) correspond to the CMV immediate early enhancer site (SEQ ID NO:1). Residues 618-816 of SEQ ID NO:85 correspond to the CMV immediate early promoter site (SEQ ID NO:3). Residues 834-1012 of SEQ ID NO:85 correspond to the truncated lentiviral 5′ LTR region (SEQ ID NO:68). Residues 1059-1184 of SEQ ID NO:85 correspond to the lentiviral ψ region (SEQ ID NO:6). Residues 1681-1914 of SEQ ID NO:85 correspond to the lentiviral Rev response element (RRE) (SEQ ID NO:7). Residues 2441-2558 of SEQ ID NO:85 correspond to the lentiviral cPPT/CTS region (SEQ ID NO:8). Residues 2641-3020 of SEQ ID NO:85 correspond to the variant CMV immediate early enhancer site (SEQ ID NO:2). Residues 3021-3224 of SEQ ID NO:85 correspond to the variant CMV immediate early promoter site (SEQ ID NO:4). Residues 3250-3268 of SEQ ID NO:85 correspond to a T7 promoter site (SEQ ID NO:12). Residues 3391-3852 of SEQ ID NO:85 correspond to the internal ribosome entry site of the encephalomyocarditis virus (EMCV) (SEQ ID NO:69). Residues 3893-3952 of SEQ ID NO:85 correspond to a polynucleotide (SEQ ID NO:73) that encodes an IL-2 signal sequence (SEQ ID NO:72). Residues 3953-5209 of SEQ ID NO:85 correspond to a polynucleotide sequence (SEQ ID NO:79) that encodes the SARS-CoV-2 N protein (SEQ ID NO:54). Residues 5231-5302 of SEQ ID NO:85 correspond to a polynucleotide sequence (SEQ ID NO:14) that encodes a combined Myc (human c-Myc oncogene) and FLAG® epitope tag (SEQ ID NO:13). Residues 5354-5387 of SEQ ID NO:85 correspond to a LoxP site (SEQ ID NO:15). Residues 5443-6031 of SEQ ID NO:85 correspond to a woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) (SEQ ID NO:16). Residues 5914-5925 of SEQ ID NO:85 correspond to a Factor Xa cleavage site (SEQ ID NO:17).

Residues 6034-6050 of SEQ ID NO:85 correspond to a polynucleotide whose sequence is complementary to the sequence a KS primer binding site (SEQ ID NO:18). Residues 6240-6738 correspond to a 5′ LTR that has been modified to be self-inactivating (SIN) of which residues 6240-6557 correspond to a modified U3 region (SEQ ID NO:64), residues 6558-6738 correspond to R and the U5 regions of the 5′ LTR (SEQ ID NO:5). Residues 6800-7388 of SEQ ID NO:85 correspond to a polynucleotide whose sequence is complementary to the sequence of the high-copy-number ColE1/pMB1/pBR322/pUC origin of replication (SEQ ID NO:19). Residues 7559-8419 of SEQ ID NO:85 correspond to a polynucleotide whose sequence is complementary to the sequence encoding the AmpR antibiotic resistance determinant (SEQ ID NO:22) (i.e., such encoding sequence is on the second strand of the vector). Residues 8420-8524 of SEQ ID NO:85 correspond to a polynucleotide whose sequence is complementary to the sequence of the AmpR promoter (SEQ ID NO:25) (i.e., such promoter sequence is on the second strand of the vector).

B. Packaging Vectors of the Present Invention

As used herein, the term “packaging vector” is intended to denote a vector that comprises a polynucleotide that encodes a gag protein, a polynucleotide that encodes a pol protein, a Rev response element (RRE), and a promoter sufficient to mediate the transcription of such genes in a mammalian cell.

Most preferably, the packaging vector of the present invention will be a double-stranded DNA plasmid. The structure of a preferred packaging vector (pGAG) is shown in FIG. 13, and comprises 11,282 base pairs. The preferred packaging vectors of the present invention comprise multiple features.

A first preferred feature of the packaging vectors of the present invention is an origin of replication capable of mediating the replication of the vector in prokaryotic cells, such as the high-copy-number ColE1/pMB1/pBR322/pUC origin of replication. Illustrative polynucleotides that comprise such an origin of replication are described above (e.g., SEQ ID NO:19, SEQ ID NO:20).

A further preferred feature of the packaging vectors of the present invention is a promoter (and an optional upstream transcriptional enhancer site) that will facilitate and mediate transcription in a mammalian host cell. Exemplary polynucleotides that comprise such an upstream transcriptional enhancer site include SEQ ID NO:1, SEQ ID NO:2, and their above-described truncated variants, such as the truncated variants SEQ ID NO:29 and SEQ ID NO:30:

SEQ ID NO: 29:

cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc

cccgcccatt gacgtcaata atgacgtatg ttcccatagt aacgccaata

gggactttcc attgacgtca atgggtggag tatttacggt aaactgccca

cttggcagta catcaagtgt atcatatgcc aagtacgccc cctattgacg

tcaatgacgg taaatggccc gcctggcatt atgcccagta catgacctta

tgggactttc ctacttggca gtacatctac gtattagtca tcgctattac

catg

SEQ ID NO: 30:

cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc

cccgcccatt gacgtcaata atgacgtatg ttcccatagt aacgccaata

gggactttcc attgacgtca atgggtggag tatttacggt aaactgccca

cttggcagta catcaagtgt atcatatgcc aagtccgccc cctattgacg

tcaatgacgg taaatggccc gcctggcatt atgcccagta catgacctta

c
gggactttc ctacttggca gtacatctac gtattagtca tcgctattac

catg

Illustrative polynucleotides that comprise suitable promoter sites are described above, and include SEQ ID NO:3 and SEQ ID NO:4. Additional suitable promoter sites include the following variants of the CMV immediate early promoter site:

SEQ ID NO: 31

gtgatgcggt tttggcagta catcaatggg cgtggatagc ggtttgactc

acggggattt ccaagtctcc accccattga cgtcaatggg agtttgtttt

ggcaccaaaa tcaacgggac tttccaaaat gtcgtaacaa ctccgcccca

ttgacgcaaa tgggcggtag gcgtgtacgg tgggaggtct atataagcag

agct

SEQ ID NO: 32

gtgatgcggt tttggcagta caccaatggg cgtggatagc ggtttgactc

acggggattt ccaagtctcc accccattga cgtcaatggg agtttgtttt

ggcaccaaaa tcaacgggac tttccaaaat gtcgtaataa ccccgccccg

ttgacgcaaa tgggcggtag gcgtgtacgg tgggaggtct atataagcag

A further preferred feature of the packaging vectors of the present invention is a promoter that will facilitate and mediate transcription in a bacterial host. Illustrative polynucleotides, such as the exemplary T7 promoter site (SEQ ID NO:12) are described above.

A central feature of the packaging vectors of the present invention is a polynucleotide that encodes a gag protein, such as the HIV-1 gag protein (SEQ ID NO:33):

MGARASVLSG GELDRWEKIR LRPGGKKKYK LKHIVWASRE

LERFAVNPGL LETSEGCRQI LGQLQPSLQT GSEELRSLYN

TVATLYCVHQ RIEIKDTKEA LDKIEEEQNK SKKKAQQAAA

DTGHSNQVSQ NYPIVQNIQG QMVHQAISPR TLNAWVKVVE

EKAFSPEVIP MFSALSEGAT PQDLNTMLNT VGGHQAAMQM

LKETINEEAA EWDRVHPVHA GPIAPGQMRE PRGSDIAGTT

STLQEQIGWM TNNPPIPVGE IYKRWIILGL NKIVRMYSPT

SILDIRQGPK EPFRDYVDRF YKTLRAEQAS QEVKNWMTET

LLVQNANPDC KTILKALGPA ATLEEMMTAC QGVGGPGHKA

RVLAEAMSQV TNSATIMMQR GNFRNQRKIV KCFNCGKEGH

TARNCRAPRK KGCWKCGKEG HQMKDCTERQ ANFLGKIWPS

YKGRPGNFLQ SRPEPTAPPE ESFRSGVETT TPPQKQEPID

KELYPLTSLR SLFGNDPSSQ

An illustrative polynucleotide that encodes the HIV-1 gag protein is SEQ ID NO:34:

atgggtgcga gagcgtcagt attaagcggg ggagaattag atcgatggga

aaaaattcgg ttaaggccag ggggaaagaa aaaatataaa ttaaaacata

tagtatgggc aagcagggag ctagaacgat tcgcagttaa tcctggcctg

ttagaaacat cagaaggctg tagacaaata ctgggacagc tacaaccatc

ccttcagaca ggatcagaag aacttagatc attatataat acagtagcaa

ccctctattg tgtgcatcaa aggatagaga taaaagacac caaggaagct

ttagacaaga tagaggaaga gcaaaacaaa agtaagaaaa aagcacagca

agcagcagct gacacaggac acagcaatca ggtcagccaa aattacccta

tagtgcagaa catccagggg caaatggtac atcaggccat atcacctaga

actttaaatg catgggtaaa agtagtagaa gagaaggctt tcagcccaga

agtgataccc atgttttcag cattatcaga aggagccacc ccacaagatt

taaacaccat gctaaacaca gtggggggac atcaagcagc catgcaaatg

ttaaaagaga ccatcaatga ggaagctgca gaatgggata gagtgcatcc

agtgcatgca gggcctattg caccaggcca gatgagagaa ccaaggggaa

gtgacatagc aggaactact agtacccttc aggaacaaat aggatggatg

acaaataatc cacctatccc agtaggagaa atttataaaa gatggataat

cctgggatta aataaaatag taagaatgta tagccctacc agcattctgg

acataagaca aggaccaaaa gaacccttta gagactatgt agaccggttc

tataaaactc taagagccga gcaagcttca caggaggtaa aaaattggat

gacagaaacc ttgttggtcc aaaatgcgaa cccagattgt aagactattt

taaaagcatt gggaccagcg gctacactag aagaaatgat gacagcatgt

cagggagtag gaggacccgg ccataaggca agagttttgg ctgaagcaat

gagccaagta acaaattcag ctaccataat gatgcagaga ggcaatttta

ggaaccaaag aaagattgtt aagtgtttca attgtggcaa agaagggcac

acagccagaa attgcagggc ccctaggaaa aagggctgtt ggaaatgtgg

aaaggaagga caccaaatga aagattgtac tgagagacag gctaattttt

tagggaagat ctggccttcc tacaagggaa ggccagggaa ttttcttcag

agcagaccag agccaacagc cccaccagaa gagagcttca ggtctggggt

agagacaaca actccccctc agaagcagga gccgatagac aaggaactgt

atcctttaac ttccctcaga tcactctttg gcaacgaccc ctcgtcacaa

A further central feature of the packaging vectors of the present invention is a polynucleotide that encodes a pol protein, such as the HIV-1 pol protein (SEQ ID NO:35):

MSLPGRWKPK MIGGIGGFIK VRQYDQILIE ICGHKAIGTV LVGPTPVNII

GRNLLTQIGC TLNFPISPIE TVPVKLKPGM DGPKVKQWPL TEEKIKALVE

ICTEMEKEGK ISKIGPENPY NTPVFAIKKK DSTKWRKLVD FRELNKRTQD

FWEVQLGIPH PAGLKKKKSV TVLDVGDAYF SVPLDEDFRK YTAFTIPSIN

NETPGIRYQY NVLPQGWKGS PAIFQSSMTK ILEPFRKQNP DIVIYQYMDD

LYVGSDLEIG QHRTKIEELR QHLLRWGLTT PDKKHQKEPP FLWMGYELHP

DKWTVQPIVL PEKDSWTVND IQKLVGKLNW ASQIYPGIKV RQLCKLLRGT

KALTEVIPLT EEAELELAEN REILKEPVHG VYYDPSKDLI AEIQKQGQGQ

WTYQIYQEPF KNLKTGKYAR MRGAHTNDVK QLTEAVQKIT TESIVIWGKT

PKFKLPIQKE TWETWWTEYW QATWIPEWEF VNTPPLVKLW YQLEKEPIVG

AETFYVDGAA NRETKLGKAG YVTNRGRQKV VTLTDTTNQK TELQAIYLAL

QDSGLEVNIV TDSQYALGII QAQPDQSESE LVNQIIEQLI KKEKVYLAWV

PAHKGIGGNE QVDKLVSAGI RKVLFLDGID KAQDEHEKYH SNWRAMASDF

NLPPVVAKEI VASCDKCQLK GEAMHGQVDC SPGIWQLDCT HLEGKVILVA

VHVASGYIEA EVIPAETGQE TAYFLLKLAG RWPVKTIHTD NGSNFTSATV

KAACWWAGIK QEFGIPYNPQ SQGVVESMNK ELKKIIGQVR DQAEHLKTAV

QMAVFIHNFK RKGGIGGYSA GERIVDIIAT DIQTKELQKQ ITKIQNFRVY

YRDSRNPLWK GPAKLLWKGE GAVVIQDNSD IKVVPRRKAK IIRDYGKQMA

GDDCVASRQD ED

An illustrative polynucleotide that encodes the HIV-1 pol protein has the sequence of SEQ ID NO:36:

atgagtttgc caggaagatg gaaaccaaaa atgatagggg gaattggagg

ttttatcaaa gtaagacagt atgatcagat actcatagaa atctgtggac

ataaagctat aggtacagta ttagtaggac ctacacctgt caacataatt

ggaagaaatc tgttgactca gattggttgc actttaaatt ttcccattag

ccctattgag actgtaccag taaaattaaa gccaggaatg gatggcccaa

aagttaaaca atggccattg acagaagaaa aaataaaagc attagtagaa

atttgtacag agatggaaaa ggaagggaaa atttcaaaaa ttgggcctga

aaatccatac aatactccag tatttgccat aaagaaaaaa gacagtacta

aatggagaaa attagtagat ttcagagaac ttaataagag aactcaagac

ttctgggaag ttcaattagg aataccacat cccgcagggt taaaaaagaa

aaaatcagta acagtactgg atgtgggtga tgcatatttt tcagttccct

tagatgaaga cttcaggaaa tatactgcat ttaccatacc tagtataaac

aatgagacac cagggattag atatcagtac aatgtgcttc cacagggatg

gaaaggatca ccagcaatat tccaaagtag catgacaaaa atcttagagc

cttttagaaa acaaaatcca gacatagtta tctatcaata catggatgat

ttgtatgtag gatctgactt agaaataggg cagcatagaa caaaaataga

ggagctgaga caacatctgt tgaggtgggg acttaccaca ccagacaaaa

aacatcagaa agaacctcca ttcctttgga tgggttatga actccatcct

gataaatgga cagtacagcc tatagtgctg ccagaaaaag acagctggac

tgtcaatgac atacagaagt tagtggggaa attgaattgg gcaagtcaga

tttacccagg gattaaagta aggcaattat gtaaactcct tagaggaacc

aaagcactaa cagaagtaat accactaaca gaagaagcag agctagaact

ggcagaaaac agagagattc taaaagaacc agtacatgga gtgtattatg

acccatcaaa agacttaata gcagaaatac agaagcaggg gcaaggccaa

tggacatatc aaatttatca agagccattt aaaaatctga aaacaggaaa

atatgcaaga atgaggggtg cccacactaa tgatgtaaaa caattaacag

aggcagtgca aaaaataacc acagaaagca tagtaatatg gggaaagact

cctaaattta aactgcccat acaaaaggaa acatgggaaa catggtggac

agagtattgg caagccacct ggattcctga gtgggagttt gttaataccc

ctcctttagt gaaattatgg taccagttag agaaagaacc catagtagga

gcagaaacct tctatgtaga tggggcagct aacagggaga ctaaattagg

aaaagcagga tatgttacta atagaggaag acaaaaagtt gtcaccctaa

ctgacacaac aaatcagaag actgagttac aagcaattta tctagctttg

caggattcgg gattagaagt aaacatagta acagactcac aatatgcatt

aggaatcatt caagcacaac cagatcaaag tgaatcagag ttagtcaatc

aaataataga gcagttaata aaaaaggaaa aggtctatct ggcatgggta

ccagcacaca aaggaattgg aggaaatgaa caagtagata aattagtcag

tgctggaatc aggaaagtac tatttttaga tggaatagat aaggcccaag

atgaacatga gaaatatcac agtaattgga gagcaatggc tagtgatttt

aacctgccac ctgtagtagc aaaagaaata gtagccagct gtgataaatg

tcagctaaaa ggagaagcca tgcatggaca agtagactgt agtccaggaa

tatggcaact agattgtaca catttagaag gaaaagttat cctggtagca

gttcatgtag ccagtggata tatagaagca gaagttattc cagcagaaac

agggcaggaa acagcatatt ttcttttaaa attagcagga agatggccag

taaaaacaat acatacagac aatggcagca atttcaccag tgctacggtt

aaggccgcct gttggtgggc gggaatcaag caggaatttg gaattcccta

caatccccaa agtcaaggag tagtagaatc tatgaataaa gaattaaaga

aaattatagg acaggtaaga gatcaggctg aacatcttaa gacagcagta

caaatggcag tattcatcca caattttaaa agaaaagggg ggattggggg

gtacagtgca
ggggaaagaa tagtagacat aatagcaaca gacatacaaa

ctaaagaatt
acaaaaacaa attacaaaaa ttcaaaattt tcgggtttat

tacagggaca gcagaaatcc actttggaaa ggaccagcaa agctcctctg

gaaaggtgaa ggggcagtag taatacaaga taatagtgac ataaaagtag

tgccaagaag aaaagcaaag atcattaggg attatggaaa acagatggca

ggtgatgatt gtgtggcaag tagacaggat gaggat

The pol-encoding polynucleotide (SEQ ID NO:36) includes a central polypurine tract and central termination sequence (cPPT/CTS) (SEQ ID NO:8) (underlined above).

Improved safety can be obtained by employing a modified polynucleotide that encodes a pol protein that is substantially incapable of mediating reverse transcription of the lentiviral genome. Polynucleotides capable of encoding such proteins include modifications that encode D249V, D250V substitutions in the pol protein. The D249V and D250V substitutions attenuate the ability of the reverse transcriptase to mediate the reverse transcription of the lentiviral RNA into DNA. Thus, these mutations attenuate the ability of the lentiviral sequences to replicate.

Further improvements to safety can be obtained by employing a modified polynucleotide that encodes an IN integrase protein that is substantially incapable of mediating the reverse transcription of the lentiviral RNA into DNA. The amino acid sequence of the IN integrase protein is (SEQ ID NO:65):

FLDGIDKAQD EHEKYHSNWR AMASDFNLPP VVAKEIVASC DKCQLKGEAM

HGQVDCSPGI WQLDCTHLEG KVILVAVHVA SGYIEAEVIP AETGQETAYF

LLKLAGRWPV KTIHTDNGSN FTSATVKAAC WWAGIKQEFG IPYNPQSQGV

VESMNKELKK IIGQVRDQAE HLKTAVQMAV FIHNFKRKGG IGGYSAGERI

VDIIATDIQT KELQKQITKI QNFRVYYRDS RNPLWKGPAK LLWKGEGAVV

IQDNSDIKVV PRRKAKIIRD YGKQMAGDDC VASRQDED

A polynucleotide that encodes the IN integrase protein of SEQ ID NO:65 is SEQ ID NO:66 (corresponding to residues 1873-2736 of SEQ ID NO:36):

tttttagatg gaatagataa ggcccaagat gaacatgaga

aatatcacag taattggaga gcaatggcta gtgattttaa

cctgccacct gtagtagcaa aagaaatagt agccagctgt

gataaatgtc agctaaaagg agaagccatg catggacaag

tagactgtag tccaggaata tggcaactag attgtacaca

tttagaagga aaagttatcc tggtagcagt tcatgtagcc

agtggatata tagaagcaga agttattcca gcagaaacag

ggcaggaaac agcatatttt cttttaaaat tagcaggaag

atggccagta aaaacaatac atacagacaa tggcagcaat

ttcaccagtg ctacggttaa ggccgcctgt tggtgggcgg

gaatcaagca ggaatttgga attccctaca atccccaaag

tcaaggagta gtagaatcta tgaataaaga attaaagaaa

attataggac aggtaagaga tcaggctgaa catcttaaga

cagcagtaca aatggcagta ttcatccaca attttaaaag

aaaagggggg attggggggt acagtgcagg ggaaagaata

gtagacataa tagcaacaga catacaaact aaagaattac

aaaaacaaat tacaaaaatt caaaattttc gggtttatta

cagggacagc agaaatccac tttggaaagg accagcaaag

ctcctctgga aaggtgaagg ggcagtagta atacaagata

atagtgacat aaaagtagtg ccaagaagaa aagcaaagat

cattagggat tatggaaaac agatggcagg tgatgattgt

gtggcaagta gacaggatga ggat

Polynucleotides capable of encoding mutated IN integrase proteins include those that cause mutations in the catalytic core of the lentiviral integrase (e.g., S81R, D64V, D116I, N120L, N120E, N120G, P145I, P145I/P90D, P145I/F185K, E152G, E152V, K156I, etc.). The D688V pol substitution creates the D64V mutated integrase protein, and is a preferred integrase mutation as it greatly impairs 3′ processing, strand transfer, and disintegration in vitro, but permits the production of high infectious titer (Leavitt. A, D, et al. (1996) “Human Immunodeficiency Virus Type 1 Integrase Mutants Retain In Vitro Integrase Activity Yet Fail To Integrate Viral DNA Efficiently During Infection,” J. Virol. 70(2):721-728; Sayasith, K. et al. (2000) “Characterization Of Mutant HIV-1 Integrase Carrying Amino Acid Changes In The Catalytic Domain,” Mol. Cells 10(5):525-532). The D688V mutation thus attenuates the ability of the lentiviral sequences to integrate into the chromosomes of transfected mammalian cells, and thus attenuates the ability of the lentiviral sequences to integrate into the chromosomes of the cells of recipient subjects.

SEQ ID NO:37 provides the amino acid sequence of an variant pol protein that comprises D249V, D250V and D688V substitutions (relative to SEQ ID NO:35). The sequence of SEQ ID NO:37 is shown below (differences relative to SEQ ID NO:35 are underlined):

MSLPGRWKPK MIGGIGGFIK VRQYDQILIE ICGHKAIGTV

LVGPTPVNII GRNLLTQIGC TLNFPISPIE TVPVKLKPGM

DGPKVKQWPL TEEKIKALVE ICTEMEKEGK ISKIGPENPY

NTPVFAIKKK DSTKWRKLVD FRELNKRTQD FWEVQLGIPH

PAGLKKKKSV TVLDVGDAYF SVPLDEDFRK YTAFTIPSIN

NETPGIRYQY NVLPQGWKGS PAIFQSSMTK ILEPFRKQNP

DIVIYQYMVV LYVGSDLEIG QHRTKIEELR QHLLRWGLTT

PDKKHQKEPP FLWMGYELHP DKWTVQPIVL PEKDSWTVND

IQKLVGKLNW ASQIYPGIKV RQLCKLLRGT KALTEVIPLT

EEAELELAEN REILKEPVHG VYYDPSKDLI AEIQKQGQGQ

WTYQIYQEPF KNLKTGKYAR MRGAHTNDVK QLTEAVQKIT

TESIVIWGKT PKFKLPIQKE TWETWWTEYW QATWIPEWEF

VNTPPLVKLW YQLEKEPIVG AETFYVDGAA NRETKLGKAG

YVTNRGRQKV VTLTDTTNQK TELQAIYLAL QDSGLEVNIV

TDSQYALGII QAQPDQSESE LVNQIIEQLI KKEKVYLAWV

PAHKGIGGNE QVDKLVSAGI RKVLFLDGID KAQDEHEKYH

SNWRAMASDF NLPPVVAKEI VASCDKCQLK GEAMHGQVDC

SPGIWQLVCT HLEGKVILVA VHVASGYIEA EVIPAETGQE

TAYFLLKLAG RWPVKTIHTD NGSNFTSATV KAACWWAGIK

QEFGIPYNPQ SQGVVESMNK ELKKIIGQVR DQAEHLKTAV

QMAVFIHNFK RKGGIGGYSA GERIVDIIAT DIQTKELQKQ

ITKIQNFRVY YRDSRNPLWK GPAKLLWKGE GAVVIQDNSD

IKVVPRRKAK IIRDYGKQMA GDDCVASRQD ED

An exemplary polynucleotide that encodes the D249V/D250V/D688V HIV-1 pol protein has the sequence of SEQ ID NO:38:

atgagtttgc caggaagatg gaaaccaaaa atgatagggg

gaattggagg ttttatcaaa gtaagacagt atgatcagat

actcatagaa atctgtggac ataaagctat aggtacagta

ttagtaggac ctacacctgt caacataatt ggaagaaatc

tgttgactca gattggttgc actttaaatt ttcccattag

ccctattgag actgtaccag taaaattaaa gccaggaatg

gatggcccaa aagttaaaca atggccattg acagaagaaa

aaataaaagc attagtagaa atttgtacag agatggaaaa

ggaagggaaa atttcaaaaa ttgggcctga aaatccatac

aatactccag tatttgccat aaagaaaaaa gacagtacta

aatggagaaa attagtagat ttcagagaac ttaataagag

aactcaagac ttctgggaag ttcaattagg aataccacat

cccgcagggt taaaaaagaa aaaatcagta acagtactgg

atgtgggtga tgcatatttt tcagttccct tagatgaaga

cttcaggaaa tatactgcat ttaccatacc tagtataaac

aatgagacac cagggattag atatcagtac aatgtgcttc

cacagggatg gaaaggatca ccagcaatat tccaaagtag

catgacaaaa atcttagagc cttttagaaa acaaaatcca

gacatagtta tctatcaata catggtcgtg ttgtatgtag

gatctgactt agaaataggg cagcatagaa caaaaataga

ggagctgaga caacatctgt tgaggtgggg acttaccaca

ccagacaaaa aacatcagaa agaacctcca ttcctttgga

tgggttatga actccatcct gataaatgga cagtacagcc

tatagtgctg ccagaaaaag acagctggac tgtcaatgac

atacagaagt tagtggggaa attgaattgg gcaagtcaga

tttacccagg gattaaagta aggcaattat gtaaactcct

tagaggaacc aaagcactaa cagaagtaat accactaaca

gaagaagcag agctagaact ggcagaaaac agagagattc

taaaagaacc agtacatgga gtgtattatg acccatcaaa

agacttaata gcagaaatac agaagcaggg gcaaggccaa

tggacatatc aaatttatca agagccattt aaaaatctga

aaacaggaaa atatgcaaga atgaggggtg cccacactaa

tgatgtaaaa caattaacag aggcagtgca aaaaataacc

acagaaagca tagtaatatg gggaaagact cctaaattta

aactgcccat acaaaaggaa acatgggaaa catggtggac

agagtattgg caagccacct ggattcctga gtgggagttt

gttaataccc ctcctttagt gaaattatgg taccagttag

agaaagaacc catagtagga gcagaaacct tctatgtaga

tggggcagct aacagggaga ctaaattagg aaaagcagga

tatgttacta atagaggaag acaaaaagtt gtcaccctaa

ctgacacaac aaatcagaag actgagttac aagcaattta

tctagctttg caggattcgg gattagaagt aaacatagta

acagactcac aatatgcatt aggaatcatt caagcacaac

cagatcaaag tgaatcagag ttagtcaatc aaataataga

gcagttaata aaaaaggaaa aggtctatct ggcatgggta

ccagcacaca aaggaattgg aggaaatgaa caagtagata

aattagtcag tgctggaatc aggaaagtac tatttttaga

tggaatagat aaggcccaag atgaacatga gaaatatcac

agtaattgga gagcaatggc tagtgatttt aacctgccac

ctgtagtagc aaaagaaata gtagccagct gtgataaatg

tcagctaaaa ggagaagcca tgcatggaca agtagactgt

agtccaggaa tatggcaact agtctgtaca catttagaag

gaaaagttat cctggtagca gttcatgtag ccagtggata

tatagaagca gaagttattc cagcagaaac agggcaggaa

acagcatatt ttcttttaaa attagcagga agatggccag

taaaaacaat acatacagac aatggcagca atttcaccag

tgctacggtt aaggccgcct gttggtgggc gggaatcaag

caggaatttg gaattcccta caatccccaa agtcaaggag

tagtagaatc tatgaataaa gaattaaaga aaattatagg

acaggtaaga gatcaggctg aacatcttaa gacagcagta

caaatggcag tattcatcca caattttaaa agaaaagggg

ggattggggg
gtacagtgca ggggaaagaa tagtagacat

aatagcaaca
gacatacaaa ctaaagaatt acaaaaacaa

attacaaaaa
ttcaaaattt tcgggtttat tacagggaca

gcagaaatcc actttggaaa ggaccagcaa agctcctctg

gaaaggtgaa ggggcagtag taatacaaga taatagtgac

ataaaagtag tgccaagaag aaaagcaaag atcattaggg

attatggaaa acagatggca ggtgatgatt gtgtggcaag

tagacaggat gaggattag

It will be noted that residues 2424-2541 of SEQ ID NO:36 and SEQ ID NO:38 each comprise a lentiviral central polypurine tract and central termination sequence (cPPT/CTS) (shown underlined above).

A further preferred feature of the packaging vectors of the present invention is a polynucleotide that comprises a Rev response element (RRE). An exemplary polynucleotide has the sequence of SEQ ID NO:7.

A further preferred feature of the packaging vectors of the present invention is a polynucleotide that comprises an SV40 small t intron. An exemplary polynucleotide has the sequence of SEQ ID NO:39:

gtaaatataa aatttttaag tgtataatgt gttaaactac

tgattctaat tgtttgtgta ttttag

A further preferred feature of the packaging vectors of the present invention is a polynucleotide that encodes a nuclear localization signal sufficient to promote localization of expressed proteins to the nucleus of a transfected mammalian cell. An exemplary nuclear localization signal is the nuclear localization signal of the SV40 large T antigen (SEQ ID NO:40):

PKKKRKV,

which may be encoded by (SEQ ID NO:41):

ccaaaaaagaagagaaaggta.

A further preferred feature of the packaging vectors of the present invention is a polynucleotide that comprises a polyadenylation signal. An exemplary polynucleotide comprises the SV40 poly(A) signal site (SEQ ID NO:42):

aacttgttta ttgcagctta taatggttac aaataaagca

atagcatcac aaatttcaca aataaagcat ttttttcact

gcattctagt tgtggtttgt ccaaactcat caatgtatct

tatcatgtct ggatc

A further preferred feature of the packaging vectors of the present invention is a polynucleotide that comprises a promoter that will facilitate and mediate transcription in a mammalian host cell. An exemplary polynucleotide comprises the SV40 early promoter (SEQ ID NO:43):

gcatctcaat tagtcagcaa ccatagtccc gcccctaact

ccgcccatcc cgcccctaac tccgcccagt tccgcccatt

ctccgcccca
tggctgacta atttttttta tttatgcaga

ggccgaggcc
gcctcggcct ctgagctatt ccagaagtag

tgaggaggct
tttttggagg cctaggcttt tgcaaa

It will be noted that residues 47-182 of SEQ ID NO:43 (underlined above) correspond to an SV40 origin of replication.

A further preferred feature of the packaging vectors of the present invention is a polynucleotide that comprises a promoter that will facilitate and mediate transcription in a bacterial host. An illustrative polynucleotide that comprises the AmpR promoter has the sequence of SEQ ID NO:16.

A further preferred feature of the packaging vectors of the present invention is a gene that encodes an antibiotic resistance determinant, such as AmpR. Illustrative polynucleotides that encode such a determinant are described above (e.g., SEQ ID NO:22, SEQ ID NO:24).

The double-stranded vector pGAG (FIG. 13) is a preferred packaging vector of the present invention that may be used with the LTR-containing vectors, REV vectors and envelope vectors of the present invention to produce lentiviral particles that array a SARS-CoV-2 S protein on their surface. The polynucleotide sequence of the first strand of vector pGAG is SEQ ID NO:44:

ttcaacattt ccgtgtcgcc cttattccct tttttgcggc attttgcctt
50

cctgtttttg ctcacccaga aacgctggtg aaagtaaaag atgctgaaga
100

tcagttgggt gcacgagtgg gttacatcga actggatctc aacagcggta
150

agatccttga gagttttcgc cccgaagaac gttttccaat gatgagcact
200

tttaaagttc tgctatgtgg cgcggtatta tcccgtgttg acgccgggca
250

agagcaactc ggtcgccgca tacactattc tcagaatgac ttggttgagt
300

actcaccagt cacagaaaag catcttacgg atggcatgac agtaagagaa
350

ttatgcagtg ctgccataac catgagtgat aacactgcgg ccaacttact
400

tctgacaacg atcggaggac cgaaggagct aaccgctttt ttgcacaaca
450

tgggggatca tgtaactcgc cttgatcgtt gggaaccgga gctgaatgaa
500

gccataccaa acgacgagcg tgacaccacg atgcctgcag caatggcaac
550

aacgttgcgc aaactattaa ctggcgaact acttactcta gcttcccggc
600

aacaattaat agactggatg gaggcggata aagttgcagg accacttctg
650

cgctcggccc ttccggctgg ctggtttatt gctgataaat ctggagccgg
700

tgagcgtggg tctcgcggta tcattgcagc actggggcca gatggtaagc
750

cctcccgtat cgtagttatc tacacgacgg ggagtcaggc aactatggat
800

gaacgaaata gacagatcgc tgagataggt gcctcactga ttaagcattg
850

gtaactgtca gaccaagttt actcatatat actttagatt gatttaaaac
900

ttcattttta atttaaaagg atctaggtga agatcctttt tgataatctc
950

atgaccaaaa tcccttaacg tgagttttcg ttccactgag cgtcagaccc
1000

cgtagaaaag atcaaaggat cttcttgaga tccttttttt ctgcgcgtaa
1050

tctgctgctt gcaaacaaaa aaaccaccgc taccagcggt ggtttgtttg
1100

ccggatcaag agctaccaac tctttttccg aaggtaactg gcttcagcag
1150

agcgcagata ccaaatactg tccttctagt gtagccgtag ttaggccacc
1200

acttcaagaa ctctgtagca ccgcctacat acctcgctct gctaatcctg
1250

ttaccagtgg ctgctgccag tggcgataag tcgtgtctta ccgggttgga
1300

ctcaagacga tagttaccgg ataaggcgca gcggtcgggc tgaacggggg
1350

gttcgtgcac acagcccagc ttggagcgaa cgacctacac cgaactgaga
1400

tacctacagc gtgagctatg agaaagcgcc acgcttcccg aagggagaaa
1450

ggcggacagg tatccggtaa gcggcagggt cggaacagga gagcgcacga
1500

gggagcttcc agggggaaac gcctggtatc tttatagtcc tgtcgggttt
1550

cgccacctct gacttgagcg tcgatttttg tgatgctcgt caggggggcg
1600

gagcctatgg aaaaacgcca gcaacgcggc ctttttacgg ttcctggcct
1650

tttgctggcc ttttgctcac atgttctttc ctgcgttatc ccctgattct
1700

gtggataacc gtattaccgc ctttgagtga gctgataccg ctcgccgcag
1750

ccgaacgacc gagcgcagcg agtcagtgag cgaggaagcg gaagagcgcc
1800

tgatgcggta ttttctcctt acgcatctgt gcggtatttc acaccgcata
1850

tggtgcactc tcagtacaat ctgctctgat gccgcatagt taagccagta
1900

tcctcgacat cgctctagtc tagttattaa tagtaatcaa ttacggggtc
1950

attagttcat agcccatata tggagttccg cgttacataa cttacggtaa
2000

atggcccgcc tggctgaccg cccaacgacc cccgcccatt gacgtcaata
2050

atgacgtatg ttcccatagt aacgccaata gggactttcc attgacgtca
2100

atgggtggag tatttacggt aaactgccca cttggcagta catcaagtgt
2150

atcatatgcc aagtacgccc cctattgacg tcaatgacgg taaatggccc
2200

gcctggcatt atgcccagta catgacctta tgggactttc ctacttggca
2250

gtacatctac gtattagtca tcgctattac catggtgatg cggttttggc
2300

agtacatcaa tgggcgtgga tagcggtttg actcacgggg atttccaagt
2350

ctccacccca ttgacgtcaa tgggagtttg ttttggcacc aaaatcaacg
2400

ggactttcca aaatgtcgta acaactccgc cccattgacg caaatgggcg
2450

gtaggcgtgt acggtgggag gtctatataa gcagagctct ctggctaact
2500

agagaaccca ctgcttactg gcttatcgaa attaatacga ctcactatag
2550

ggagacccaa gcttggtacc gagctcggat ccactagagc gcgcacggca
2600

agaggcgagg ggcggcgact ggtgagtacg ccggctagaa ggagagagat
2650

gggtgcgaga gcgtcagtat taagcggggg agaattagat cgatgggaaa
2700

aaattcggtt aaggccaggg ggaaagaaaa aatataaatt aaaacatata
2750

gtatgggcaa gcagggagct agaacgattc gcagttaatc ctggcctgtt
2800

agaaacatca gaaggctgta gacaaatact gggacagcta caaccatccc
2850

ttcagacagg atcagaagaa cttagatcat tatataatac agtagcaacc
2900

ctctattgtg tgcatcaaag gatagagata aaagacacca aggaagcttt
2950

agacaagata gaggaagagc aaaacaaaag taagaaaaaa gcacagcaag
3000

cagcagctga cacaggacac agcaatcagg tcagccaaaa ttaccctata
3050

gtgcagaaca tccaggggca aatggtacat caggccatat cacctagaac
3100

tttaaatgca tgggtaaaag tagtagaaga gaaggctttc agcccagaag
3150

tgatacccat gttttcagca ttatcagaag gagccacccc acaagattta
3200

aacaccatgc taaacacagt ggggggacat caagcagcca tgcaaatgtt
3250

aaaagagacc atcaatgagg aagctgcaga atgggataga gtgcatccag
3300

tgcatgcagg gcctattgca ccaggccaga tgagagaacc aaggggaagt
3350

gacatagcag gaactactag tacccttcag gaacaaatag gatggatgac
3400

aaataatcca cctatcccag taggagaaat ttataaaaga tggataatcc
3450

tgggattaaa taaaatagta agaatgtata gccctaccag cattctggac
3500

ataagacaag gaccaaaaga accctttaga gactatgtag accggttcta
3550

taaaactcta agagccgagc aagcttcaca ggaggtaaaa aattggatga
3600

cagaaacctt gttggtccaa aatgcgaacc cagattgtaa gactatttta
3650

aaagcattgg gaccagcggc tacactagaa gaaatgatga cagcatgtca
3700

gggagtagga ggacccggcc ataaggcaag agttttggct gaagcaatga
3750

gccaagtaac aaattcagct accataatga tgcagagagg caattttagg
3800

aaccaaagaa agattgttaa gtgtttcaat tgtggcaaag aagggcacac
3850

agccagaaat tgcagggccc ctaggaaaaa gggctgttgg aaatgtggaa
3900

aggaaggaca ccaaatgaaa gattgtactg agagacaggc taatttttta
3950

gggaagatct ggccttccta caagggaagg ccagggaatt ttcttcagag
4000

cagaccagag ccaacagccc caccagaaga gagcttcagg tctggggtag
4050

agacaacaac tccccctcag aagcaggagc cgatagacaa ggaactgtat
4100

cctttaactt ccctcagatc actctttggc aacgacccct cgtcacaata
4150

aagatagggg ggcaactaaa ggaagctcta ttagatacag gagcagatga
4200

tacagtatta gaagaaatga gtttgccagg aagatggaaa ccaaaaatga
4250

tagggggaat tggaggtttt atcaaagtaa gacagtatga tcagatactc
4300

atagaaatct gtggacataa agctataggt acagtattag taggacctac
4350

acctgtcaac ataattggaa gaaatctgtt gactcagatt ggttgcactt
4400

taaattttcc cattagccct attgagactg taccagtaaa attaaagcca
4450

ggaatggatg gcccaaaagt taaacaatgg ccattgacag aagaaaaaat
4500

aaaagcatta gtagaaattt gtacagagat ggaaaaggaa gggaaaattt
4550

caaaaattgg gcctgaaaat ccatacaata ctccagtatt tgccataaag
4600

aaaaaagaca gtactaaatg gagaaaatta gtagatttca gagaacttaa
4650

taagagaact caagacttct gggaagttca attaggaata ccacatcccg
4700

cagggttaaa aaagaaaaaa tcagtaacag tactggatgt gggtgatgca
4750

tatttttcag ttcccttaga tgaagacttc aggaaatata ctgcatttac
4800

catacctagt ataaacaatg agacaccagg gattagatat cagtacaatg
4850

tgcttccaca gggatggaaa ggatcaccag caatattcca aagtagcatg
4900

acaaaaatct tagagccttt tagaaaacaa aatccagaca tagttatcta
4950

tcaatacatg gatgatttgt atgtaggatc tgacttagaa atagggcagc
5000

atagaacaaa aatagaggag ctgagacaac atctgttgag gtggggactt
5050

accacaccag acaaaaaaca tcagaaagaa cctccattcc tttggatggg
5100

ttatgaactc catcctgata aatggacagt acagcctata gtgctgccag
5150

aaaaagacag ctggactgtc aatgacatac agaagttagt ggggaaattg
5200

aattgggcaa gtcagattta cccagggatt aaagtaaggc aattatgtaa
5250

actccttaga ggaaccaaag cactaacaga agtaatacca ctaacagaag
5300

aagcagagct agaactggca gaaaacagag agattctaaa agaaccagta
5350

catggagtgt attatgaccc atcaaaagac ttaatagcag aaatacagaa
5400

gcaggggcaa ggccaatgga catatcaaat ttatcaagag ccatttaaaa
5450

atctgaaaac aggaaaatat gcaagaatga ggggtgccca cactaatgat
5500

gtaaaacaat taacagaggc agtgcaaaaa ataaccacag aaagcatagt
5550

aatatgggga aagactccta aatttaaact gcccatacaa aaggaaacat
5600

gggaaacatg gtggacagag tattggcaag ccacctggat tcctgagtgg
5650

gagtttgtta atacccctcc tttagtgaaa ttatggtacc agttagagaa
5700

agaacccata gtaggagcag aaaccttcta tgtagatggg gcagctaaca
5750

gggagactaa attaggaaaa gcaggatatg ttactaatag aggaagacaa
5800

aaagttgtca ccctaactga cacaacaaat cagaagactg agttacaagc
5850

aatttatcta gctttgcagg attcgggatt agaagtaaac atagtaacag
5900

actcacaata tgcattagga atcattcaag cacaaccaga tcaaagtgaa
5950

tcagagttag tcaatcaaat aatagagcag ttaataaaaa aggaaaaggt
6000

ctatctggca tgggtaccag cacacaaagg aattggagga aatgaacaag
6050

tagataaatt agtcagtgct ggaatcagga aagtactatt tttagatgga
6100

atagataagg cccaagatga acatgagaaa tatcacagta attggagagc
6150

aatggctagt gattttaacc tgccacctgt agtagcaaaa gaaatagtag
6200

ccagctgtga taaatgtcag ctaaaaggag aagccatgca tggacaagta
6250

gactgtagtc caggaatatg gcaactagat tgtacacatt tagaaggaaa
6300

agttatcctg gtagcagttc atgtagccag tggatatata gaagcagaag
6350

ttattccagc agaaacaggg caggaaacag catattttct tttaaaatta
6400

gcaggaagat ggccagtaaa aacaatacat acagacaatg gcagcaattt
6450

caccagtgct acggttaagg ccgcctgttg gtgggcggga atcaagcagg
6500

aatttggaat tccctacaat ccccaaagtc aaggagtagt agaatctatg
6550

aataaagaat taaagaaaat tataggacag gtaagagatc aggctgaaca
6600

tcttaagaca gcagtacaaa tggcagtatt catccacaat tttaaaagaa
6650

aaggggggat tggggggtac agtgcagggg aaagaatagt agacataata
6700

gcaacagaca tacaaactaa agaattacaa aaacaaatta caaaaattca
6750

aaattttcgg gtttattaca gggacagcag aaatccactt tggaaaggac
6800

cagcaaagct cctctggaaa ggtgaagggg cagtagtaat acaagataat
6850

agtgacataa aagtagtgcc aagaagaaaa gcaaagatca ttagggatta
6900

tggaaaacag atggcaggtg atgattgtgt ggcaagtaga caggatgagg
6950

attagaacat ggaaaagttt agtaaaacac catatgtata tttcaaggaa
7000

agctaaggac tggttttata gacatcacta tgaaagtact aatccaaaaa
7050

taagttcaga agtacacatc ccactagggg atgctaaatt agtaataaca
7100

acatattggg gtctgcatac aggagaaaga gactggcatt tgggtcaggg
7150

agtctccata gaatggagga aaaagagata tagcacacaa gtagaccctg
7200

acctagcaga ccaactaatt catctgcact attttgattg tttttcagaa
7250

tctgctataa gaaataccat attaggacgt atagttagtc ctaggtgtga
7300

atatcaagca ggacataaca aggtaggatc tctacagtac ttggcactag
7350

cagcattaat aaaaccaaaa cagataaagc cacctttgcc tagtgttagg
7400

aaactgacag aggacagatg gaacaagccc cagaagacca agggccacag
7450

agggagccat acaatgaatg gacactagag cttttagagg aacttaagag
7500

tgaagctgtt agacattttc ctaggatatg gctccataac ttaggacaac
7550

atatctatga aacttacggg gatacttggg caggagtgga agccataata
7600

agaattctgc aacaactgct gtttatccat ttcagaattg ggtgtcgaca
7650

tagcagaata ggcgttactc gacagaggag agcaagaaat ggagccagta
7700

gatcctagac tagagccctg gaagcatcca ggaagtcagc ctaaaactgc
7750

ttgtaccaat tgctattgta aaaagtgttg ctttcattgc caagtttgtt
7800

tcatgacaaa agccttaggc atctcctatg gcaggaagaa gcggagacag
7850

cgacgaagag ctcatcagaa cagtcagact catcaagctt ctctatcaaa
7900

gcagtaagta gtacatgtaa tgcaacctat aatagtagca atagtagcat
7950

tagtagtagc aataataata gcaatagttg tgtggtccat agtaatcata
8000

gaatatagga aaatattaag acaaagaaaa atagacaggt taattgatag
8050

actaatagaa agagcagaag acagtggcaa tgagagtgaa ggagaagtat
8100

cagcacttgt ggagatgggg gtggaaatgg ggcaccatgc tccttgggat
8150

attgatgatc tgtagtgcta cagaaaaatt gtgggtcaca gtctattatg
8200

gggtacctgt gtggaaggaa gcaaccacca ctctattttg tgcatcagat
8250

gctaaagcat atgatacaga ggtacataat gtttgggcca cacatgcctg
8300

tgtacccaca gaccccaacc cacaagaagt agtattggta aatgtgacag
8350

aaaattttaa catgtggaaa aatgacatgg tagaacagat gcatgaggat
8400

ataatcagtt tatgggatca aagcctaaag ccatgtgtaa aattaacccc
8450

actctgtgtt agtttaaagt gcactgattt gaagaatgat actaatacca
8500

atagtagtag cgggagaatg ataatggaga aaggagagat aaaaaactgc
8550

tctttcaata tcagcacaag cataagaggt aaggtgcaga aagaatatgc
8600

atttttttat aaacttgata taataccaat agataatgat actaccagct
8650

ataagttgac aagttgtaac acctcagtca ttacacaggc ctgtccaaag
8700

gtatcctttg agccaattcc catacattat tgtgccccgg ctggttttgc
8750

gattctaaaa tgtaataata agacgttcaa tggaacagga ccatgtacaa
8800

atgtcagcac agtacaatgt acacatggaa ttaggccagt agtatcaact
8850

caactgctgt taaatggcag tctagcagaa gaagaggtag taattagatc
8900

gatcttcaga cctggaggag gagatatgag ggacaattgg agaagtgaat
8950

tatataaata taaagtagta aaaattgaac cattaggagt agcacccacc
9000

aaggcaaaga gaagagtggt gcagagagaa aaaagagcag tgggaatagg
9050

agctttgttc cttgggttct tgggagcagc aggaagcact atgggcgcag
9100

cgtcaatgac gctgacggta caggccagac aattattgtc tggtatagtg
9150

cagcagcaga acaatttgct gagggctatt gaggcgcaac agcatctgtt
9200

gcaactcaca gtctggggca tcaagcagct ccaggcaaga atcctggctg
9250

tggaaagata cctaaaggat caacagctcc tggggatttg gggttgctct
9300

ggaaaactca tttgcaccac tgctgtgcct tggaatgcta gttggagtaa
9350

taaatctctg gaacagattt ggaatcacac gacctggatg gagtgggaca
9400

gagaaattaa caattacaca agcttaatac actccttaat tgaagaatcg
9450

caaaaccagc aagaaaagaa tgaacaagaa ttattggaat tagataaatg
9500

ggcaagtttg tggaattggt ttaacataac aaattggctg tggtatataa
9550

aattattcat aatgatagta ggaggcttgg taggtttaag aatagttttt
9600

gctgtacttt ctatagtgaa tagagttagg cagggatatt caccattatc
9650

gtttcagacc cacctcccaa ccccgagggg acccgacagg cccgaaggaa
9700

tagaagaaga aggtggagag agagacagag acagatccat tcgattagtg
9750

aacggatctt tgtgaaggaa ccttacttct gtggtgtgac ataattggac
9800

aaactaccta cagagattta aagctctaag gtaaatataa aatttttaag
9850

tgtataatgt gttaaactac tgattctaat tgtttgtgta ttttagattc
9900

caacctatgg aactgatgaa tgggagcagt ggtggaatgc ctttaatgag
9950

gaaaacctgt tttgctcaga agaaatgcca tctagtgatg atgaggctac
10000

tgctgactct caacattcta ctcctccaaa aaagaagaga aaggtagaag
10050

accccaagga ctttccttca gaattgctaa gttttttgag tcatgctgtg
10100

tttagtaata gaactcttgc ttgctttgct atttacacca caaaggaaaa
10150

agctgcactg ctatacaaga aaattatgga aaaatattct gtaaccttta
10200

taagtaggca taacagttat aatcataaca tactgttttt tcttactcca
10250

cacaggcata gagtgtctgc tattaataac tatgctcaaa aattgtgtac
10300

ctttagcttt ttaatttgta aaggggttaa taaggaatat ttgatgtata
10350

gtgccttgac tagagatcat aatcagccat accacatttg tagaggtttt
10400

acttgcttta aaaaacctcc cacacctccc cctgaacctg aaacataaaa
10450

tgaatgcaat tgttgttgtt aacttgttta ttgcagctta taatggttac
10500

aaataaagca atagcatcac aaatttcaca aataaagcat ttttttcact
10550

gcattctagt tgtggtttgt ccaaactcat caatgtatct tatcatgtct
10600

ggatcccgcg atgtcgaggc atctcaatta gtcagcaacc atagtcccgc
10650

ccctaactcc gcccatcccg cccctaactc cgcccagttc cgcccattct
10700

ccgccccatg gctgactaat tttttttatt tatgcagagg ccgaggccgc
10750

ctcggcctct gagctattcc agaagtagtg aggaggcttt tttggaggcc
10800

taggcttttg caaaaagctt ggcgagattt tcaggagcta aggaagctaa
10850

aatggagaaa aaaatcactg gatataccac cgttgatata tcccaatggc
10900

atcgtaaaga acattttgag gcatttcagt cagttgctca atgtacctat
10950

aaccagaccg ttcagctgga tattacggcc tttttaaaga ccgtaaagaa
11000

aaataagcac aagttttatc cggcctttat tcacattctt gcccgcctga
11050

tgaatgctca tccggaattc ttgaagacga aagggcctcg tgatacgcct
11100

atttttatag gttaatgtca tgataataat ggtttcttag acgtcaggtg
11150

gcacttttcg gggaaatgtg cgcggaaccc ctatttgttt atttttctaa
11200

atacattcaa atatgtatcc gctcatgaga caataaccct gataaatgct
11250

tcaataatat tgaaaaagga agagtatgag ta
11282

As will be noted, residues 1025-1613 of SEQ ID NO:44 correspond to the high-copy-number ColE1/pMB/pBR322/pUC origin of replication (SEQ ID NO:20). Residues 1981-2284 of SEQ ID NO:44 correspond to the CMV immediate early enhancer site (SEQ ID NO:29). Residues 2285-2488 of SEQ ID NO:44 correspond to the CMV immediate early promoter site (SEQ ID NO:31). Residues 2533-2551 of SEQ ID NO:44 correspond to the T7 promoter site (SEQ ID NO:12). Residues 2649-4151 of SEQ ID NO:44 correspond to a polynucleotide (SEQ ID NO:34) that encodes the HIV-1 gag protein (SEQ ID NO:33). Residues 4217-6955 of SEQ ID NO:44 correspond to a polynucleotide (SEQ ID NO:36) that encodes the HIV-1 pol protein (SEQ ID NO:35), and include a lentiviral central polypurine tract and central termination sequence (cPPT/CTS). Residues 9048-9281 of SEQ ID NO:44 correspond to a Rev response element (RRE) (SEQ ID NO:7). Residues 9831-9896 of SEQ ID NO:44 correspond to an SV40 small t intron (SEQ ID NO:39). Residues 10026-10046 of SEQ ID NO:44 correspond to a polynucleotide (SEQ ID NO:41) that encodes the nuclear localization signal of the SV40 large T antigen (SEQ ID NO:40). The nuclear localization signal is in frame with an open reading frame that encodes a protein having the sequence (SEQ ID NO:45) (the SV40 large T nuclear localization signal is underlined):

PKKKRKV
EDP KDFPSELLSF LSHAVFSNRT LACFAIYTTK

EKAALLYKKI MEKYSVTFIS RHNSYNHNIL FFLTPHRHRV

SAINNYAQKL CTFSFLICKG VNKEYLMYSA LTRDHNQPYH

ICRGFTCFKK PPTPPPEPET

Residues 10471-10605 of SEQ ID NO:44 correspond to an SV40 poly(A) signal site (SEQ ID NO:42). Residues 10619-10814 of SEQ ID NO:44 correspond to an SV40 early promoter (SEQ ID NO:43), which includes an SV40 origin of replication. Residues 11171-11275 of SEQ ID NO:44 correspond to an AmpR promoter (SEQ ID NO:16). Residues 11276-11282 and residues 1-854 of SEQ ID NO:44 correspond to a polynucleotide (SEQ ID NO:24) that encodes an AmpR antibiotic resistance determinant (SEQ ID NO:23).

C. REV Vectors of the Present Invention

As used herein, the term “REV vector” is intended to denote a vector that comprises a polynucleotide that encodes a rev protein and a promoter sufficient to mediate the transcription of such gene in a mammalian cell.

Most preferably, the REV vector of the present invention will be a double-stranded DNA plasmid. The structure of a preferred REV vector (pREV) is shown in FIG. 14, and comprises 5,514 base pairs. The preferred REV vectors of the present invention comprise multiple features.

The first of such preferred features of the REV vectors of the present invention comprises a gene that encodes an antibiotic resistance determinant operably linked to a promoter capable of mediating its expression in a bacterial host. Polynucleotides that encode such antibiotic resistance determinants are described above. An exemplary antibiotic resistance determinant is the AmpR determinant (SEQ ID NO:23), which is encoded by a polynucleotide that comprises the sequence of SEQ ID NO:24. An exemplary AmpR promoter-containing polynucleotide has the sequence of SEQ ID NO:16.

A further preferred feature of the REV vectors of the present invention is an origin of replication capable of mediating the replication of the vector in prokaryotic cells, such as the high-copy-number ColE1/pMB1/pBR322/pUC origin of replication. Illustrative polynucleotides that comprise such an origin of replication are described above (e.g., SEQ ID NO:19, SEQ ID NO:20).

A central feature of the REV vectors of the present invention is a promoter (and an optional upstream transcriptional enhancer site) that will facilitate and mediate transcription in a mammalian host cell. Suitable promoters are described above. An exemplary promoter/enhancer site is the CMV immediate early enhancer site (SEQ ID NO:4) and the CMV immediate early promoter (SEQ ID NO:5).

A second central feature of the REV vectors of the present invention is a polynucleotide encoding a lentiviral Rev protein, operably linked to such promoter. The Rev protein, however, is encoded by a polynucleotide that contains intervening sequences and that is subject to mRNA splicing (Kammler, S. et al. (2006) “The Strength Of The HIV-1 3′ Splice Sites Affects Rev Function,” Retrovirol. 3:89:1-20). The rev gene thus consists of two coding exons that together predict a protein of 116 amino acids. An exemplary lentiviral Rev protein has the amino acid sequence (SEQ ID NO:46):

MAGRSGDSDE ELIRTVRLIK LLYQSNPPPN PEGTRQARRN

RRRRWRERQR QIHSISERIL GTYLGRSAEP VPLQLPPLER

LTLDCNEDCG TSGTQGVGSP QILVESPTVL ESGTKE

An illustrative polynucleotide that is capable of being processed to form Rev protein by transfected mammalian cells has the sequence (SEQ ID NO:47):

atgctgctac cattgtcaga tgtgttttct aaacaagggg

ctcggaattc cccggatccg tcgactctag aggatctgca

tctcctatgg caggaagaag cggagacagc gacgaagacc

tcctcaaggc agtcagactc atcaagtttc tctatcaaag

caacccacct cccaatcccg aggggacccg acaggcccga

aggaatagaa gaagaaggtg gagagagaga cagagacaga

tccattcgat tagtgaacgg atccttagca cttatctggg

acgatctgcg gagcctgtgc ctcttcagct accaccgctt

gagagactta ctcttgattg taacgaggat tgtggaactt

ctgggacgca gggggtggga agccctcaaa tattggtgga

atctcctaca atattggagt caggagctaa agaatagtgc

tgttagcttg ctcaatgcca cagctatagc agtagctgag

gggacagata gggttataga agtagtacaa gaagcttata

gagctattcg ccacatacct agaagaataa gacagggctt

ggaaaggatt ttgctataag atgggtggca agtggtcaaa

aagtagtgtg gttggatggc ctgctgtaag ggaaagaatg

agacgagctg agccagcagc agatggggtg ggagcagcat

ctcgagacct agaaaaacat ggagcaatca caagtagcaa

cacagcagct aacaatgctg cttgtgcctg gctagaagca

caagaggagg agaaggtggg ttttccagtc acacctcagg

taccgagctc gaattcactc ctcaggtgca ggctgcctat

cagaaggtgg tggctggtgt ggccaatgcc ctggctcaca

aataccactg agatctttgt gaaggaacct tacttctgtg

gtgtgacata attggacaaa ctacctacag agatttaaag

ctctaaggta aatataaaat ttttaagtgt ataatgtgtt

aaactactga
ttctaattgt ttgtgtattt tagattccaa

cctatggaac tgatgaatgg gagcagtggt ggaatgcctt

taatgaggaa aacctgtttt gctcagaaga aatgccatct

agtgatgatg aggctactgc tgactctcaa cattctactc

ctccaaaaaa gaagagaaag gtagaagacc ccaaggaactt

tccttcagaa ttgctaagtt ttttgagtca tgctgtgttt

agtaatagaa ctcttgcttg ctttgctatt tacaccacaa

aggaaaaagc tgcactgcta tacaagaaaa ttatggaaaa

atattctgta acctttataa gtaggcataa cagttataat

cataacatac tgttttttct tactccacac aggcatagag

tgtctgctat taataactat gctcaaaaat tgtgtacctt

tagcttttta atttgtaaag gggttaataa ggaatatttg

atgtatagtg ccttgactag agatcataat cagccatacc

acatttgtag aggttttact tgctttaaaa aacctcccac

acctccccct gaacctgaaa ca

As will be recognized, the Rev-encoding polynucleotide (SEQ ID NO:47) comprises an SV40 small t antigen intron (SEQ ID NO:48) (underlined above):

gtaaatataa aatttttaag tgtataatgt gttaaactac

tgattctaat tgtttgtgta ttttag

As will also be realized, the Rev-encoding polynucleotide (SEQ ID NO:47) comprises a polynucleotide (SEQ ID NO:41) (double underlined above) that encodes the nuclear localization signal of the SV40 large T antigen (SEQ ID NO:40). The nuclear localization signal is in frame with an open reading frame (shown in bold above) that encodes a protein having the sequence of SEQ ID NO:45.

A further preferred feature of the REV vectors of the present invention is a polynucleotide that comprises a polyadenylation signal. An exemplary polynucleotide comprises the SV40 poly(A) signal site has the sequence of SEQ ID NO:42.

The double-stranded vector pREV (FIG. 14) is a preferred REV vector of the present invention that may be used with the LTR-containing vectors, packaging vectors and envelope vectors of the present invention to produce lentiviral particles that array a SARS-CoV-2 S protein on their surface. The polynucleotide sequence of the first strand of vector pREV is SEQ ID NO:49:

gagaggacat tccaatcata ggctgcccat ccaccctctg tgtcctcctg
50

ttaattaggt cacttaacaa aaaggaaatt gggtaggggt ttttcacaga
100

ccgctttcta agggtaattt taaaatatct gggaagtccc ttccactgct
150

gtgttccaga agtgttggta aacagcccac aaatgtcaac agcagaaaca
200

tacaagctgt cagctttgca caagggccca acaccctgct catcaagaag
250

cactgtggtt gctgtgttag taatgtgcaa aacaggaggc acattttccc
300

cacctgtgta ggttccaaaa tatctagtgt tttcattttt acttggatca
350

ggaacccagc actccactgg ataagcatta tccttatcca aaacagcctt
400

gtggtcagtg ttcatctgct gactgtcaac tgtagcattt tttggggtta
450

cagtttgagc aggatatttg gtcctgtagt ttgctaacac accctgcagc
500

tccaaaggtt ccccaccaac agcaaaaaaa tgaaaatttg acccttgaat
550

gggttttcca gcaccatttt catgagtttt ttgtgtccct gaatgcaagt
600

ttaacatagc agttacccca ataacctcag ttttaacagt aacagcttcc
650

cacatcaaaa tatttccaca ggttaagtcc tcatttaaat taggcaaagg
700

aattcttgaa gacgaaaggg cctcgtgata cgcctatttt tataggttaa
750

tgtcatgata ataatggttt cttagacgtc aggtggcact tttcggggaa
800

atgtgcgcgg aacccctatt tgtttatttt tctaaataca ttcaaatatg
850

tatccgctca tgagacaata accctgataa atgcttcaat aatattgaaa
900

aaggaagagt atgagtattc aacatttccg tgtcgccctt attccctttt
950

ttgcggcatt ttgccttcct gtttttgctc acccagaaac gctggtgaaa
1000

gtaaaagatg ctgaagatca gttgggtgca cgagtgggtt acatcgaact
1050

ggatctcaac agcggtaaga tccttgagag ttttcgcccc gaagaacgtt
1100

ttccaatgat gagcactttt aaagttctgc tatgtggcgc ggtattatcc
1150

cgtgttgacg ccgggcaaga gcaactcggt cgccgcatac actattctca
1200

gaatgacttg gttgagtact caccagtcac agaaaagcat cttacggatg
1250

gcatgacagt aagagaatta tgcagtgctg ccataaccat gagtgataac
1300

actgcggcca acttacttct gacaacgatc ggaggaccga aggagctaac
1350

cgcttttttg cacaacatgg gggatcatgt aactcgcctt gatcgttggg
1400

aaccggagct gaatgaagcc ataccaaacg acgagcgtga caccacgatg
1450

cctgcagcaa tggcaacaac gttgcgcaaa ctattaactg gcgaactact
1500

tactctagct tcccggcaac aattaataga ctggatggag gcggataaag
1550

ttgcaggacc acttctgcgc tcggcccttc cggctggctg gtttattgct
1600

gataaatctg gagccggtga gcgtgggtct cgcggtatca ttgcagcact
1650

ggggccagat ggtaagccct cccgtatcgt agttatctac acgacgggga
1700

gtcaggcaac tatggatgaa cgaaatagac agatcgctga gataggtgcc
1750

tcactgatta agcattggta actgtcagac caagtttact catatatact
1800

ttagattgat ttaaaacttc atttttaatt taaaaggatc taggtgaaga
1850

tcctttttga taatctcatg accaaaatcc cttaacgtga gttttcgttc
1900

cactgagcgt cagaccccgt agaaaagatc aaaggatctt cttgagatcc
1950

tttttttctg cgcgtaatct gctgcttgca aacaaaaaaa ccaccgctac
2000

cagcggtggt ttgtttgccg gatcaagagc taccaactct ttttccgaag
2050

gtaactggct tcagcagagc gcagatacca aatactgtcc ttctagtgta
2100

gccgtagtta ggccaccact tcaagaactc tgtagcaccg cctacatacc
2150

tcgctctgct aatcctgtta ccagtggctg ctgccagtgg cgataagtcg
2200

tgtcttaccg ggttggactc aagacgatag ttaccggata aggcgcagcg
2250

gtcgggctga acggggggtt cgtgcacaca gcccagcttg gagcgaacga
2300

cctacaccga actgagatac ctacagcgtg agctatgaga aagcgccacg
2350

cttcccgaag ggagaaaggc ggacaggtat ccggtaagcg gcagggtcgg
2400

aacaggagag cgcacgaggg agcttccagg gggaaacgcc tggtatcttt
2450

atagtcctgt cgggtttcgc cacctctgac ttgagcgtcg atttttgtga
2500

tgctcgtcag gggggcggag cctatggaaa aacgccagca acgcggcctt
2550

tttacggttc ctggcctttt gctggccttt tgctcacatg ttctttcctg
2600

cgttatcccc tgattctgtg gataaccgta ttaccgcctt tgagtgagct
2650

gataccgctc gccgcagccg aacgaccgag cgcagcgagt cagtgagcga
2700

ggaagcggaa gagcgcctga tgcggtattt tctccttacg catctgtgcg
2750

gtatttcaca ccgcatatgg tgcactctca gtacaatctg ctctgatgcc
2800

gcatagttaa gccagtatcc tcgaggcctc caaaaaagcc tcctcactac
2850

ttctggaata gctcagaggc cgaggcggcc tcggcctctg cataaataaa
2900

aaaaattagt cagccatgag cttggcccat tgcatacgtt gtatccatat
2950

cataatatgt acatttatat tggctcatgt ccaacattac cgccatgttg
3000

acattgatta ttgactagtt attaatagta atcaattacg gggtcattag
3050

ttcatagccc atatatggag ttccgcgtta cataacttac ggtaaatggc
3100

ccgcctggct gaccgcccaa cgacccccgc ccattgacgt caataatgac
3150

gtatgttccc atagtaacgc caatagggac tttccattga cgtcaatggg
3200

tggagtattt acggtaaact gcccacttgg cagtacatca agtgtatcat
3250

atgccaagta cgccccctat tgacgtcaat gacggtaaat ggcccgcctg
3300

gcattatgcc cagtacatga ccttatggga ctttcctact tggcagtaca
3350

tctacgtatt agtcatcgct attaccatgg tgatgcggtt ttggcagtac
3400

atcaatgggc gtggatagcg gtttgactca cggggatttc caagtctcca
3450

ccccattgac gtcaatggga gtttgttttg gcaccaaaat caacgggact
3500

ttccaaaatg tcgtaacaac tccgccccat tgacgcaaat gggcggtagg
3550

cgtgtacggt gggaggtcta tataagcaga gctcattaaa gtcctgcaac
3600

gagccctttt cacgcacttc agagcaggat gtggccactc aagaattggc
3650

cagacaaggg gaggaaatcc tctctcagct ataccgaccc ctagaaacat
3700

gcaataactc atgctattgt aagcgatgct gctaccattg tcagatgtgt
3750

tttctaaaca aggggctcgg aattccccgg atccgtcgac tctagaggat
3800

ctgcatctcc tatggcagga agaagcggag acagcgacga agacctcctc
3850

aaggcagtca gactcatcaa gtttctctat caaagcaacc cacctcccaa
3900

tcccgagggg acccgacagg cccgaaggaa tagaagaaga aggtggagag
3950

agagacagag acagatccat tcgattagtg aacggatcct tagcacttat
4000

ctgggacgat ctgcggagcc tgtgcctctt cagctaccac cgcttgagag
4050

acttactctt gattgtaacg aggattgtgg aacttctggg acgcaggggg
4100

tgggaagccc tcaaatattg gtggaatctc ctacaatatt ggagtcagga
4150

gctaaagaat agtgctgtta gcttgctcaa tgccacagct atagcagtag
4200

ctgaggggac agatagggtt atagaagtag tacaagaagc ttatagagct
4250

attcgccaca tacctagaag aataagacag ggcttggaaa ggattttgct
4300

ataagatggg tggcaagtgg tcaaaaagta gtgtggttgg atggcctgct
4350

gtaagggaaa gaatgagacg agctgagcca gcagcagatg gggtgggagc
4400

agcatctcga gacctagaaa aacatggagc aatcacaagt agcaacacag
4450

cagctaacaa tgctgcttgt gcctggctag aagcacaaga ggaggagaag
4500

gtgggttttc cagtcacacc tcaggtaccg agctcgaatt cactcctcag
4550

gtgcaggctg cctatcagaa ggtggtggct ggtgtggcca atgccctggc
4600

tcacaaatac cactgagatc tttgtgaagg aaccttactt ctgtggtgtg
4650

acataattgg acaaactacc tacagagatt taaagctcta aggtaaatat
4700

aaaattttta agtgtataat gtgttaaact actgattcta attgtttgtg
4750

tattttagat tccaacctat ggaactgatg aatgggagca gtggtggaat
4800

gcctttaatg aggaaaacct gttttgctca gaagaaatgc catctagtga
4850

tgatgaggct actgctgact ctcaacattc tactcctcca aaaaagaaga
4900

gaaaggtaga agaccccaag gactttcctt cagaattgct aagttttttg
4950

agtcatgctg tgtttagtaa tagaactctt gcttgctttg ctatttacac
5000

cacaaaggaa aaagctgcac tgctatacaa gaaaattatg gaaaaatatt
5050

ctgtaacctt tataagtagg cataacagtt ataatcataa catactgttt
5100

tttcttactc cacacaggca tagagtgtct gctattaata actatgctca
5150

aaaattgtgt acctttagct ttttaatttg taaaggggtt aataaggaat
5200

atttgatgta tagtgccttg actagagatc ataatcagcc ataccacatt
5250

tgtagaggtt ttacttgctt taaaaaacct cccacacctc cccctgaacc
5300

tgaaacataa aatgaatgca attgttgttg ttaacttgtt tattgcagct
5350

tataatggtt acaaataaag caatagcatc acaaatttca caaataaagc
5400

atttttttca ctgcattcta gttgtggttt gtccaaactc atcaatgtat
5450

cttatcatgt ctggatcccc aggaagctcc tctgtgtcct cataaaccct
5500

aacctcctct actt
5514

As will be noted, residues 806-910 of SEQ ID NO:49 correspond to AmpR promoter (SEQ ID NO:16). Residues 911-1771 of SEQ ID NO:49 correspond to a polynucleotide (SEQ ID NO:24) that encodes an AmpR determinant (SEQ ID NO:23). Residues 1942-2530 of SEQ ID NO:49 correspond to a high-copy-number ColE1/pMB/pBR322/pUC origin of replication (SEQ ID NO:20). Residues 3000-3379 of SEQ ID NO:49 correspond to the CMV immediate early enhancer site (SEQ ID NO:4). Residues 3380-3583 of SEQ ID NO:49 correspond to the CMV immediate early promoter site (SEQ ID NO:5). Residues 3726-5310 of SEQ ID NO:49 correspond to a polynucleotide (SEQ ID NO:47) that is processed by mammalian cells to produce the HIV-1 Rev protein (SEQ ID NO:46). Residues 4693-4758 of such sequence includes an SV40 small t intron (SEQ ID NO:48), and residues 4888-4908 of such sequence comprises a polynucleotide (SEQ ID NO:41) that encodes the nuclear localization signal of the SV40 large T antigen (SEQ ID NO:40) and permits transcription of a protein having the sequence of SEQ ID NO:45. Residues 3726-5310 of SEQ ID NO:49 correspond to an SV40 poly(A) signal site (SEQ ID NO:42).

D. Envelope Vectors of the Present Invention

As used herein, the term “Envelope Vector” is intended to denote a vector that comprises a polynucleotide that encodes a heterologous protein (and especially the SARS-CoV-2 S protein) and a promoter sufficient to mediate the transcription of such gene in a mammalian cell.

Most preferably, the envelope vector of the present invention will be a double-stranded DNA plasmid. The structure of a preferred envelope vector (pCMV-SARS-CoV-2 S Protein) is shown in FIG. 15, and comprises 8,602 base pairs. The preferred envelope vectors of the present invention comprise multiple features.

The first of such features is optional and comprises primer binding sites to facilitate sequencing of the vector. Exemplary sites for such purpose are M13 Fwd and Rev primer binding sites. An exemplary M13 Fwd primer binding site comprises the sequence (SEQ ID NO:50):

gtaaaacgacggccagt,

and hybridizes to the first strand of the vector. An exemplary M13 Rev primer binding site comprises the sequence (SEQ ID NO:51):

caggaaacagctatgac,

and hybridizes to the second strand of the vector.

A further feature is a first promoter that will direct transcription in a bacterial host. Suitable promoters are described above. An exemplary promoter is the T7 promoter site, which comprises the sequence of SEQ ID NO:12.

A further feature is a promoter (and an optional upstream transcriptional enhancer site) that will facilitate and mediate transcription in a mammalian host cell. Exemplary polynucleotides that comprise suitable enhancer and promoter sites are discussed above. An exemplary CMV immediate early enhancer site comprises the sequence of SEQ ID NO:1. An exemplary CMV immediate early promoter site comprises the sequence (SEQ ID NO:52):

A further feature is an intron capable of improving gene expression of downstream genes in a mammalian host cell. An exemplary intron capable of such function is a beta-globin intron (Haddad-Mashadrizeh, A. et al. (2009) “A Systematic Study Of The Function Of The Human Beta-Globin Introns On The Expression Of The Human Coagulation Factor IX In Cultured Chinese Hamster Ovary Cells,” J. Gene. Med. 11(10):941-950). An exemplary beta-globin intron comprises the sequence (SEQ ID NO:53):

gtgagtttgg ggacccttga ttgttctttc tttttcgcta

ttgtaaaatt catgttatat ggagggggca aagttttcag

ggtgttgttt agaatgggaa gatgtccctt gtatcaccat

ggaccctcat gataattttg tttctttcac tttctactct

gttgacaacc attgtctcct cttattttct tttcattttc

tgtaactttt tcgttaaact ttagcttgca tttgtaacga

atttttaaat tcacttttgt ttatttgtca gattgtaagt

actttctcta atcacttttt tttcaaggca atcagggtat

attatattgt acttcagcac agttttagag aacaattgtt

ataattaaat gataaggtag aatatttctg catataaatt

ctggctggcg tggaaatatt cttattggta gaaacaacta

caccctggtc atcatcctgc ctttctcttt atggttacaa

tgatatacac tgtttgagat gaggataaaa tactctgagt

ccaaaccggg cccctctgct aaccatgttc atgccttctt

ctctttccta cag

A further feature is a SARS-CoV-2 S protein encoding sequence that is operably controlled by the upstream mammalian-host promoter (e.g., the CMV immediate early promoter and enhancer sites) so that, upon co-transfection with the LTR-containing vectors, packaging vectors and REV vectors of the present invention, recipient host cells will produce lentiviral particles that are pseudotyped to array the SARS-CoV-2 S protein on their surfaces. An exemplary envelope vector is pseudotyped to array the SARS-CoV-2 S protein of GenBank YP_009724390.1 (Wu, F. et al. (2020) “A New Coronavirus Associated With Human Respiratory Disease In China,” Nature 579(7798):265-269), desirably as modified by the deletion of the C-terminal 18 amino acid residues thereof (a potential endoplasmic retention sequence) (SEQ ID NO:54), or to array a polymorphic variant thereof whose sequence differs from the sequence of SEQ ID NO:54 by less than 2%. Exemplary polymorphic variants of the SARS-CoV-2 S protein GenBank YP_009724390.1 are listed in Table 1.

SARS-CoV-2 S protein (derived from GenBank YP_009724390.1 by the removal of the C-terminal 18 amino acid residues thereof) (SEQ ID NO:54) (the S1 domain thereof shown in boldface; the S2 domain thereof is shown double underlined):

MFVFLVLLPL VSSQCVNLTT RTQLPPAYTN SFTRGVYYPD

KVFRSSVLHS TQDLFLPFFS NVTWFHAIHV SGTNGTKRFD

NPVLPFNDGV YFASTEKSNI IRGWIFGTTL DSKTQSLLIV

NNATNVVIKV CEFQFCNDPF LGVYYHKNNK SWMESEFRVY

SSANNCTFEY VSQPFLMDLE GKQGNFKNLR EFVFKNIDGY

FKIYSKHTPI NLVRDLPQGF SALEPLVDLP IGINITRFQT

LLALHRSYLT PGDSSSGWTA GAAAYYVGYL QPRTFLLKYN

ENGTITDAVD CALDPLSETK CTLKSFTVEK GIYQTSNFRV

QPTESIVRFP NITNLCPFGE VFNATRFASV YAWNRKRISN

CVADYSVLYN SASFSTFKCY GVSPTKLNDL CFTNVYADSF

VIRGDEVRQI APGQTGKIAD YNYKLPDDFT GCVIAWNSNN

LDSKVGGNYN YLYRLFRKSN LKPFERDIST EIYQAGSTPC

NGVEGFNCYF PLQSYGFQPT NGVGYQPYRV VVLSFELLHA

PATVCGPKKS TNLVKNKCVN FNFNGLTGTG VLTESNKKFL

PFQQFGRDIA DTTDAVRDPQ TLEILDITPC SFGGVSVITP

GTNTSNQVAV LYQDVNCTEV PVAIHADQLT PTWRVYSTGS

NVFQTRAGCL IGAEHVNNSY ECDIPIGAGI CASYQTQTNS

PRRAR
SVASQ SIIAYTMSLG AENSVAYSNN SIAIPTNFTI

SVTTEILPVS MTKTSVDCTM YICGDSTECS NLLLQYGSFC

TQLNRALTGI AVEQDKNTQE VFAQVKQIYK TPPIKDFGGF

NFSQILPDPS KPSKRSFIED LLFNKVTLAD AGFIKQYGDC

LGDIAARDLI CAQKFNGLTV LPPLLTDEMI AQYTSALLAG

TITSGWTFGA GAALQIPFAM QMAYRFNGIG VTQNVLYENQ

KLIANQFNSA IGKIQDSLSS TASALGKLQD VVNQNAQALN

TLVKQLSSNF GAISSVLNDI LSRLDKVEAE VQIDRLITGR

LQSLQTYVTQ QLIRAAEIRA SANLAATKMS ECVLGQSKRV

DFCGKGYHLM SFPQSAPHGV VFLHVTYVPA QEKNFTTAPA

ICHDGKAHFP REGVFVSNGT HWFVTQRNFY EPQIITTDNT

FVSGNCDVVI GIVNNTVYDP LQPELDSFKE ELDKYFKNHT

SPDVDLGDIS GINASVVNIQ KEIDRLNEVA KNLNESLIDL

QELGKYEQYI KWPWYIWLGF IAGLIAIVMV TIMLCCMTSC

CSCLKGCCSC GSCCK

TABLE 1

GenBank Reference of Polymorphic Variants of

the SARS-CoV-2 S Protein of GenBank YP 009724390.1

QHD43416.1
QIS60930.1
QIZ16197.1
QJD47202.1

(—)
(E96D)
(W258L; D614G)
(M731I)

QHR84449.1
QIS60978.1
QIZ16509.1
QJD47358.1

(S247R)
(D1168H)
(V772I)
(Y423X; D614G)

QHU79173.2
QIS61254.1
QIZ16559.1
QJD47442.1

(H49Y)
(A1078V)
(I197V)
(Y200X; D614G)

QHZ00379.1
QIS61338.1
QIZ64470.1
QJD47718.1

(S221W)
(D111N)
(D614G;
(H49Y; S884F)

A1078S)

QIA20044.1
QIS61422.1
QIZ64530.1
QJD48279.1

(Y28N)
(H519Q)
(D614G; S939F)
(M1237I)

QIA98583.1
QIS61468.1
QIZ64578.1
QJE38426.1

(A930V)
(A942X)
(H146Y; D614G)
(A845S)

QIC53204.1
QIT07011.1
QIZ64624.1
QJE38606.1

(F797C)
(L8V)
(S98F)
(Y145H; D614G)

QII57278.1
QIU78825.1
QIZ97039.1
QJE38822.1

(F157L)
(G910X)
(N148S)
(S704X)

QII87830.1
QIU80913.1
QIZ97051.1
QJF11959.1

(H655Y)
(S5OL)
(Y279X; D614G)
(L752X)

QIJ96493.1
QIU80973.1
QJA17276.1
QJF11971.1

(G181V)
(A27V)
(D614G; I818V)
(H655X)

QIK50427.1
QIU81585.1
QJA17468.1
QJF75467.1

(D614G)
(T240I)
(L5F; D614G)
(N354B)

QIO04367.1
QIU81873.2
QJA17524.1
QJF75779.1

(N74K)
(A653V)
(D614X;
(V503X; D614G)

G1124X)

QIQ08810.1
QIU81885.1
QJA17596.1
QJF76007.1

(K528X)
(A570V)
(D614G; L1203F)
(S704L)

QIQ49882.1
QIV15164.1
QJA42177.1
QJF76438.1

(L5F; G476S)
(Q644X)
(D614G; V1065L)
(L118F; D614G)

QIQ50092.1
QIV65033.1
QJC19491.1
QJF77194.1

(K814X)
(Y265X)
(Q271R; D614G))
(A27S; D614G)

QIS30105.1
QIZ13143.1
QJC20043.1
QJF77846.1

(D614X)
(L1152X))
(K529E; D614G)
(Y28H)

QIS30115.1
QIZ13179.1
QJC20367.1
QJG65949.1

(P427X;
(S71F)
(D614G; S9291)
(G485R)

D614G)

QIS30165.1
QIZ13299.1
QJC20391.1
QJG65951.1

(V483A)
(D80Y)
(D614G; T768I)
(A67S; F1103L)

QIS30295.1
QIZ13765.1
QJC20993.1
QJG65954.1

(L54F; D614G)
(D614G; V615F)
(V367F)
(S750R; L752R)

QIS30335.1
QIZ13789.1
QJD20632.1
QJG65956.1

(A348T)
(D614G; V6221)
(T791I)
(G838S)

QIS30425.1
QIZ13861.1
QJD23273.1
QJG65957.1

(G476S)
(V70F)
(V90F; D614G)
(W152R)

QIS60489.1
QIZ14569.1
QJD23524.1
QJ153955.1

(A520S)
(C1250Y)
(P217X)
(Q239R; D614G)

QIS60546.1
QIZ15585.1
QJD24377.1
QJQ04352.1

(T29I)
(D614G;
(A522S; D614G)
(D614G; T676S)

V1228X)

QIS60582.1
QIZ15717.1
QJD25085.1
QJQ27878.1

(D1259H)
(P9L)
(F220X; D614G)
(K557X)

QIS60906.1
QIZ15969.1
QJD25529.1
QJQ28105.1

(L5F)
(F238X; D614G)
(D614G; P631S)
(T951; D614G)

An exemplary polynucleotide that encodes the SARS-CoV-2 S Protein of SEQ ID NO:54 has the sequence of the S protein of SARS-CoV-2/human/USA/WA-UW-6547/2020 (Genflank: MT461658.1) (SEQ ID NO: 55):

atgtttgttt ttcttgtttt attgccacta gtctctagtc

agtgtgttaa tcttacaacc agaactcaat taccccctgc

atacactaat tctttcacac gtggtgttta ttaccctgac

aaagttttca gatcctcagt tttacattca actcaggact

tgttcttacc tttcttttcc aatgttactt ggttccatgc

tatacatgtc tctgggacca atggtactaa gaggtttgat

aaccctgtcc taccatttaa tgatggtgtt tattttgctt

ccactgagaa gtctaacata ataagaggct ggatttttgg

tactacttta gattcgaaga cccagtccct acttattgtt

aataacgcta ctaatgttgt tattaaagtc tgtgaatttc

aattttgtaa tgatccattt ttgggtgttt attaccacaa

aaacaacaaa agttggatgg aaagtgagtt cagagtttat

tctagtgcga ataattgcac ttttgaatat gtctctcagc

cttttcttat ggaccttgaa ggaaaacagg gtaatttcaa

aaatcttagg gaatttgtgt ttaagaatat tgatggttat

tttaaaatat attctaagca cacgcctatt aatttagtgc

gtgatctccc tcagggtttt tcggctttag aaccattggt

agatttgcca ataggtatta acatcactag gtttcaaact

ttacttgctt tacatagaag ttatttgact cctggtgatt

cttcttcagg ttggacagct ggtgctgcag cttattatgt

gggttatctt caacctagga cttttctatt aaaatataat

gaaaatggaa ccattacaga tgctgtagac tgtgcacttg

accctctctc agaaacaaag tgtacgttga aatccttcac

tgtagaaaaa ggaatctatc aaacttctaa ctttagagtc

caaccaacag aatctattgt tagatttcct aatattacaa

acttgtgccc ttttggtgaa gtttttaacg ccaccagatt

tgcatctgtt tatgcttgga acaggaagag aatcagcaac

tgtgttgctg attattctgt cctatataat tccgcatcat

tttccacttt taagtgttat ggagtgtctc ctactaaatt

aaatgatctc tgctttacta atgtctatgc agattcattt

gtaattagag gtgatgaagt cagacaaatc gctccagggc

aaactggaaa gattgctgat tataattata aattaccaga

tgattttaca ggctgcgtta tagcttggaa ttctaacaat

cttgattcta aggttggtgg taattataat tacctgtata

gattgtttag gaagtctaat ctcaaacctt ttgagagaga

tatttcaact gaaatctatc aggccggtag cacaccttgt

aatggtgttg aaggttttaa ttgttacttt cctttacaat

catatggttt ccaacccact aatggtgttg gttaccaacc

atacagagta gtagtacttt cttttgaact tctacatgca

ccagcaactg tttgtggacc taaaaagtct actaatttgg

ttaaaaacaa atgtgtcaat ttcaacttca atggtttaac

aggcacaggt gttcttactg agtctaacaa aaagtttctg

cctttccaac aatttggcag agacattgct gacactactg

atgctgtccg tgatccacag acacttgaga ttcttgacat

tacaccatgt tcttttggtg gtgtcagtgt tataacacca

ggaacaaata cttctaacca ggttgctgtt ctttatcagg

atgttaactg cacagaagtc cctgttgcta ttcatgcaga

tcaacttact cctacttggc gtgtttattc tacaggttct

aatgtttttc aaacacgtgc aggctgttta ataggggctg

aacatgtcaa caactcatat gagtgtgaca tacccattgg

tgcaggtata tgcgctagtt atcagactca gactaattct

cctcggcggg cacgtagtgt agctagtcaa tccatcattg

cctacactat gtcacttggt gcagaaaatt cagttgctta

ctctaataac tctattgcca tacccacaaa ttttactatt

agtgttacca cagaaattct accagtgtct atgaccaaga

catcagtaga ttgtacaatg tacatttgtg gtgattcaac

tgaatgcagc aatcttttgt tgcaatatgg cagtttttgt

acacaattaa accgtgcttt aactggaata gctgttgaac

aagacaaaaa cacccaagaa gtttttgcac aagtcaaaca

aatttacaaa acaccaccaa ttaaagattt tggtggtttt

aatttttcac aaatattacc agatccatca aaaccaagca

agaggtcatt tattgaagat ctacttttca acaaagtgac

acttgcagat gctggcttca tcaaacaata tggtgattgc

cttggtgata ttgctgctag agacctcatt tgtgcacaaa

agtttaacgg ccttactgtt ttgccacctt tgctcacaga

tgaaatgatt gctcaataca cttctgcact gttagcgggt

acaatcactt ctggttggac ctttggtgca ggtgctgcat

tacaaatacc atttgctatg caaatggctt ataggtttaa

tggtattgga gttacacaga atgttctcta tgagaaccaa

aaattgattg ccaaccaatt taatagtgct attggcaaaa

ttcaagactc actttcttcc acagcaagtg cacttggaaa

acttcaagat gtggtcaacc aaaatgcaca agctttaaac

acgcttgtta aacaacttag ctccaatttt ggtgcaattt

caagtgtttt aaatgatatc ctttcacgtc ttgacaaagt

tgaggctgaa gtgcaaattg ataggttgat cacaggcaga

cttcaaagtt tgcagacata tgtgactcaa caattaatta

gagctgcaga aatcagagct tctgctaatc ttgctgctac

taaaatgtca gagtgtgtac ttggacaatc aaaaagagtt

gatttttgtg gaaagggcta tcatcttatg tccttccctc

agtcagcacc tcatggtgta gtcttcttgc atgtgactta

tgtccctgca caagaaaaga acttcacaac tgctcctgcc

atttgtcatg atggaaaagc acactttcct cgtgaaggtg

tctttgtttc aaatggcaca cactggtttg taacacaaag

gaatttttat gaaccacaaa tcattactac agacaacaca

tttgtgtctg gtaactgtga tgttgtaata ggaattgtca

acaacacagt ttatgatcct ttgcaacctg aattagactc

attcaaggag gagttagata aatattttaa gaatcataca

tcaccagatg ttgatttagg tgacatctct ggcattaatg

cttcagttgt aaacattcaa aaagaaattg accgcctcaa

tgaggttgcc aagaatttaa atgaatctct catcgatctc

caagaacttg gaaagtatga gcagtatata aaatggccat

ggtacatttg gctaggtttt atagctggct tgattgccat

agtaatggtg acaattatgc tttgctgtat gaccagttgc

tgtagttgtc tcaagggctg ttgttcttgt ggatcctgct

gcaaa

A second suitable polynucleotide that encodes the SARS-CoV-2 S Protein of SEQ ID NO: 54 has the sequence of SEQ ID NO:71.

A further feature is a polyadenylation (poly(A)) signal sequence. An illustrative poly(A) signal sequence is a beta-globin poly(A) signal sequence. An exemplary beta-globin poly(A) signal sequence comprises the sequence (SEQ ID NO:56):

aataaaggaa atttattttc attgcaatag tgtgttggaa

ttttttgtgt ctctca

A further feature is a second promoter that will direct transcription in a bacterial host. Suitable promoters are discussed above. An illustrative polynucleotide for such purpose comprises a lac operator and a lac promoter site. An exemplary lac operator site comprises the sequence (SEQ ID NO:57):

ttgtgagcggataacaa

(positioned on the second strand of the vector). An exemplary lac promoter site comprises the sequence (SEQ ID NO:58):

tttacactttatgcttccggctcgtatgttg.

A further feature is an E. coli catabolite activator protein (CAP) binding site that comprises the sequence (SEQ ID NO:59):

taatgtgagttagctcactcat

(positioned on the second strand of the vector).

A further feature is an origin of replication capable of mediating the replication of the vector in prokaryotic cells. An exemplary origin or replication site for this purpose is the high-copy-number ColE1/pMB1/pBR322/pUC origin (SEQ ID NO:19).

A further feature is a gene that encodes an antibiotic resistance determinant, such as AmpR, which confers resistance to ampicillin, carbenicillin, and related antibiotics to bacterial cells transfected with the vector. The antibiotic resistance determinant is operably controlled by a promoter, such as the AmpR promoter, and both polynucleotide sequences are preferably positioned on the second stand of the vector. An exemplary AmpR antibiotic resistance determinant comprises the sequence of SEQ ID NO:21. An exemplary polynucleotide that encodes the AmpR antibiotic resistance determinant of SEQ ID NO:21 has the sequence of SEQ ID NO:22. An exemplary AmpR promoter-containing polynucleotide has the sequence of SEQ ID NO:26.

A further feature is a single-strand origin of replication, such as an origin of replication of the f1 bacteriophage, which is preferably positioned on the second stand of the vector. An exemplary polynucleotide that comprises an f1 bacteriophage origin of replication comprises the sequence (SEQ ID NO:60):

acgcgccctg tagcggcgca ttaagcgcgg cgggtgtggt

ggttacgcgc agcgtgaccg ctacacttgc cagcgcccta

gcgcccgctc ctttcgcttt cttcccttcc tttctcgcca

cgttcgccgg ctttccccgt caagctctaa atcgggggct

ccctttaggg ttccgattta gtgctttacg gcacctcgac

cccaaaaaac ttgattaggg tgatggttca cgtagtgggc

catcgccctg atagacggtt tttcgccctt tgacgttgga

gtccacgttc tttaatagtg gactcttgtt ccaaactgga

acaacactca accctatctc ggtctattct tttgatttat

aagggatttt gccgatttcg gcctattggt taaaaaatga

gctgatttaa caaaaattta acgcgaattt taacaaaata

ttaacgctta caattt

The vector pCMV-SARS-CoV-2 S Protein (FIG. 15) is a preferred envelope vector of the present invention that may be used with the LTR-containing vectors, packaging vectors, and REV vectors of the present invention to produce lentiviral particles that array a SARS-CoV-2 S protein on their surface. The invention contemplates that two or more different vectors may be employed in order to produce pseudotyped lentiviral particles that array both the SARS-CoV-2 S protein and one or more different proteins (e.g., the hemagglutinin (HA) protein of influenza virus, the SARS-CoV S protein, the MERS-CoV S protein, etc.).

The polynucleotide sequence of the SARS-CoV-2 S protein-coding (“first”) strand of vector pCMV-SARS-CoV-2 S Protein is SEQ ID NO:61.

gttttcccag tcacgacgtt gtaaaacgac ggccagtgag cgcgcgtaat 50

acgactcact atagggcgaa ttggagctcc accgcggtgg cggccgctct 100

agagagcttg gcccattgca tacgttgtat ccatatcata atatgtacat 150

ttatattggc tcatgtccaa cattaccgcc atgttgacat tgattattga 200

ctagttatta atagtaatca attacggggt cattagttca tagcccatat 250

atggagttcc gcgttacata acttacggta aatggcccgc ctggctgacc 300

gcccaacgac ccccgcccat tgacgtcaat aatgacgtat gttcccatag 350

taacgccaat agggactttc cattgacgtc aatgggtgga gtatttacgg 400

taaactgccc acttggcagt acatcaagtg tatcatatgc caagtacgcc 450

ccctattgac gtcaatgacg gtaaatggcc cgcctggcat tatgcccagt 500

acatgacctt atgggacttt cctacttggc agtacatcta cgtattagtc 550

atcgctatta ccatggtgat gcggttttgg cagtacatca atgggcgtgg 600

atagcggttt gactcacggg gatttccaag tctccacccc attgacgtca 650

atgggagttt gttttggcac caaaatcaac gggactttcc aaaatgtcgt 700

aacaactccg ccccattgac gcaaatgggc ggtaggcgtg tacggtggga 750

ggtctatata agcagagctc gtttagtgaa ccgtcagatc gcctggagac 800

gccatccacg ctgttttgac ctccatagaa gacaccggga ccgatccagc 850

ctccggtcga ccgatcctga gaacttcagg gtgagtttgg ggacccttga 900

ttgttctttc tttttcgcta ttgtaaaatt catgttatat ggagggggca 950

aagttttcag ggtgttgttt agaatgggaa gatgtccctt gtatcaccat 1000

ggaccctcat gataattttg tttctttcac tttctactct gttgacaacc 1050

attgtctcct cttattttct tttcattttc tgtaactttt tcgttaaact 1100

ttagcttgca tttgtaacga atttttaaat tcacttttgt ttatttgtca 1150

gattgtaagt actttctcta atcacttttt tttcaaggca atcagggtat 1200

attatattgt acttcagcac agttttagag aacaattgtt ataattaaat 1250

gataaggtag aatatttctg catataaatt ctggctggcg tggaaatatt 1300

cttattggta gaaacaacta caccctggtc atcatcctgc ctttctcttt 1350

atggttacaa tgatatacac tgtttgagat gaggataaaa tactctgagt 1400

ccaaaccggg cccctctgct aaccatgttc atgccttctt ctctttccta 1450

cagctcctgg gcaacgtgct ggttgttgtg ctgtctcatc attttggcaa 1500

agaattcctc gacggatccg gtaccgagga gatctgccgc cgcgatcgcc 1550

accatgtttg tttttcttgt tttattgcca ctagtctcta gtcagtgtgt 1600

taatcttaca accagaactc aattaccccc tgcatacact aattctttca 1650

cacgtggtgt ttattaccct gacaaagttt tcagatcctc agttttacat 1700

tcaactcagg acttgttctt acctttcttt tccaatgtta cttggttcca 1750

tgctatacat gtctctggga ccaatggtac taagaggttt gataaccctg 1800

tcctaccatt taatgatggt gtttattttg cttccactga gaagtctaac 1850

ataataagag gctggatttt tggtactact ttagattcga agacccagtc 1900

cctacttatt gttaataacg ctactaatgt tgttattaaa gtctgtgaat 1950

ttcaattttg taatgatcca tttttgggtg tttattacca caaaaacaac 2000

aaaagttgga tggaaagtga gttcagagtt tattctagtg cgaataattg 2050

cacttttgaa tatgtctctc agccttttct tatggacctt gaaggaaaac 2100

agggtaattt caaaaatctt agggaatttg tgtttaagaa tattgatggt 2150

tattttaaaa tatattctaa gcacacgcct attaatttag tgcgtgatct 2200

ccctcagggt ttttcggctt tagaaccatt ggtagatttg ccaataggta 2250

ttaacatcac taggtttcaa actttacttg ctttacatag aagttatttg 2300

actcctggtg attcttcttc aggttggaca gctggtgctg cagcttatta 2350

tgtgggttat cttcaaccta ggacttttct attaaaatat aatgaaaatg 2400

gaaccattac agatgctgta gactgtgcac ttgaccctct ctcagaaaca 2450

aagtgtacgt tgaaatcctt cactgtagaa aaaggaatct atcaaacttc 2500

taactttaga gtccaaccaa cagaatctat tgttagattt cctaatatta 2550

caaacttgtg cccttttggt gaagttttta acgccaccag atttgcatct 2600

gtttatgctt ggaacaggaa gagaatcagc aactgtgttg ctgattattc 2650

tgtcctatat aattccgcat cattttccac ttttaagtgt tatggagtgt 2700

ctcctactaa attaaatgat ctctgcttta ctaatgtcta tgcagattca 2750

tttgtaatta gaggtgatga agtcagacaa atcgctccag ggcaaactgg 2800

aaagattgct gattataatt ataaattacc agatgatttt acaggctgcg 2850

ttatagcttg gaattctaac aatcttgatt ctaaggttgg tggtaattat 2900

aattacctgt atagattgtt taggaagtct aatctcaaac cttttgagag 2950

agatatttca actgaaatct atcaggccgg tagcacacct tgtaatggtg 3000

ttgaaggttt taattgttac tttcctttac aatcatatgg tttccaaccc 3050

actaatggtg ttggttacca accatacaga gtagtagtac tttcttttga 3100

acttctacat gcaccagcaa ctgtttgtgg acctaaaaag tctactaatt 3150

tggttaaaaa caaatgtgtc aatttcaact tcaatggttt aacaggcaca 3200

ggtgttctta ctgagtctaa caaaaagttt ctgcctttcc aacaatttgg 3250

cagagacatt gctgacacta ctgatgctgt ccgtgatcca cagacacttg 3300

agattcttga cattacacca tgttcttttg gtggtgtcag tgttataaca 3350

ccaggaacaa atacttctaa ccaggttgct gttctttatc aggatgttaa 3400

ctgcacagaa gtccctgttg ctattcatgc agatcaactt actcctactt 3450

ggcgtgttta ttctacaggt tctaatgttt ttcaaacacg tgcaggctgt 3500

ttaatagggg ctgaacatgt caacaactca tatgagtgtg acatacccat 3550

tggtgcaggt atatgcgcta gttatcagac tcagactaat tctcctcggc 3600

gggcacgtag tgtagctagt caatccatca ttgcctacac tatgtcactt 3650

ggtgcagaaa attcagttgc ttactctaat aactctattg ccatacccac 3700

aaattttact attagtgtta ccacagaaat tctaccagtg tctatgacca 3750

agacatcagt agattgtaca atgtacattt gtggtgattc aactgaatgc 3800

agcaatcttt tgttgcaata tggcagtttt tgtacacaat taaaccgtgc 3850

tttaactgga atagctgttg aacaagacaa aaacacccaa gaagtttttg 3900

cacaagtcaa acaaatttac aaaacaccac caattaaaga ttttggtggt 3950

tttaattttt cacaaatatt accagatcca tcaaaaccaa gcaagaggtc 4000

atttattgaa gatctacttt tcaacaaagt gacacttgca gatgctggct 4050

tcatcaaaca atatggtgat tgccttggtg atattgctgc tagagacctc 4100

atttgtgcac aaaagtttaa cggccttact gttttgccac ctttgctcac 4150

agatgaaatg attgctcaat acacttctgc actgttagcg ggtacaatca 4200

cttctggttg gacctttggt gcaggtgctg cattacaaat accatttgct 4250

atgcaaatgg cttataggtt taatggtatt ggagttacac agaatgttct 4300

ctatgagaac caaaaattga ttgccaacca atttaatagt gctattggca 4350

aaattcaaga ctcactttct tccacagcaa gtgcacttgg aaaacttcaa 4400

gatgtggtca accaaaatgc acaagcttta aacacgcttg ttaaacaact 4450

tagctccaat tttggtgcaa tttcaagtgt tttaaatgat atcctttcac 4500

gtcttgacaa agttgaggct gaagtgcaaa ttgataggtt gatcacaggc 4550

agacttcaaa gtttgcagac atatgtgact caacaattaa ttagagctgc 4600

agaaatcaga gcttctgcta atcttgctgc tactaaaatg tcagagtgtg 4650

tacttggaca atcaaaaaga gttgattttt gtggaaaggg ctatcatctt 4700

atgtccttcc ctcagtcagc acctcatggt gtagtcttct tgcatgtgac 4750

ttatgtccct gcacaagaaa agaacttcac aactgctcct gccatttgtc 4800

atgatggaaa agcacacttt cctcgtgaag gtgtctttgt ttcaaatggc 4850

acacactggt ttgtaacaca aaggaatttt tatgaaccac aaatcattac 4900

tacagacaac acatttgtgt ctggtaactg tgatgttgta ataggaattg 4950

tcaacaacac agtttatgat cctttgcaac ctgaattaga ctcattcaag 5000

gaggagttag ataaatattt taagaatcat acatcaccag atgttgattt 5050

aggtgacatc tctggcatta atgcttcagt tgtaaacatt caaaaagaaa 5100

ttgaccgcct caatgaggtt gccaagaatt taaatgaatc tctcatcgat 5150

ctccaagaac ttggaaagta tgagcagtat ataaaatggc catggtacat 5200

ttggctaggt tttatagctg gcttgattgc catagtaatg gtgacaatta 5250

tgctttgctg tatgaccagt tgctgtagtt gtctcaaggg ctgttgttct 5300

tgtggatcct gctgcaaata acctcaggtg caggctgcct atcagaaggt 5350

ggtggctggt gtggccaatg ccctggctca caaataccac tgagatcttt 5400

ttccctctgc caaaaattat ggggacatca tgaagcccct tgagcatctg 5450

acttctggct aataaaggaa atttattttc attgcaatag tgtgttggaa 5500

ttttttgtgt ctctcactcg gaaggacata tgggagggca aatcatttaa 5550

aacatcagaa tgagtatttg gtttagagtt tggcaacata tgcccatatg 5600

ctggctgcca tgaacaaagg ttggctataa agaggtcatc agtatatgaa 5650

acagccccct gctgtccatt ccttattcca tagaaaagcc ttgacttgag 5700

gttagatttt ttttatattt tgttttgtgt tatttttttc tttaacatcc 5750

ctaaaatttt ccttacatgt tttactagcc agatttttcc tcctctcctg 5800

actactccca gtcatagctg tccctcttct cttatggaga tccctcgacg 5850

gatcggccgc aattcgtaat catgtcatag ctgtttcctg tgtgaaattg 5900

ttatccgctc acaattccac acaacatacg agccggaagc ataaagtgta 5950

aagcctgggg tgcctaatga gtgagctaac tcacattaat tgcgttgcgc 6000

tcactgcccg ctttccagtc gggaaacctg tcgtgccagc tgcattaatg 6050

aatcggccaa cgcgcgggga gaggcggttt gcgtattggg cgctcttccg 6100

cttcctcgct cactgactcg ctgcgctcgg tcgttcggct gcggcgagcg 6150

gtatcagctc actcaaaggc ggtaatacgg ttatccacag aatcagggga 6200

taacgcagga aagaacatgt gagcaaaagg ccagcaaaag gccaggaacc 6250

gtaaaaaggc cgcgttgctg gcgtttttcc ataggctccg cccccctgac 6300

gagcatcaca aaaatcgacg ctcaagtcag aggtggcgaa acccgacagg 6350

actataaaga taccaggcgt ttccccctgg aagctccctc gtgcgctctc 6400

ctgttccgac cctgccgctt accggatacc tgtccgcctt tctcccttcg 6450

ggaagcgtgg cgctttctca tagctcacgc tgtaggtatc tcagttcggt 6500

gtaggtcgtt cgctccaagc tgggctgtgt gcacgaaccc cccgttcagc 6550

ccgaccgctg cgccttatcc ggtaactatc gtcttgagtc caacccggta 6600

agacacgact tatcgccact ggcagcagcc actggtaaca ggattagcag 6650

agcgaggtat gtaggcggtg ctacagagtt cttgaagtgg tggcctaact 6700

acggctacac tagaagaaca gtatttggta tctgcgctct gctgaagcca 6750

gttaccttcg gaaaaagagt tggtagctct tgatccggca aacaaaccac 6800

cgctggtagc ggtggttttt ttgtttgcaa gcagcagatt acgcgcagaa 6850

aaaaaggatc tcaagaagat cctttgatct tttctacggg gtctgacgct 6900

cagtggaacg aaaactcacg ttaagggatt ttggtcatga gattatcaaa 6950

aaggatcttc acctagatcc ttttaaatta aaaatgaagt tttaaatcaa 7000

tctaaagtat atatgagtaa acttggtctg acagttacca atgcttaatc 7050

agtgaggcac ctatctcagc gatctgtcta tttcgttcat ccatagttgc 7100

ctgactcccc gtcgtgtaga taactacgat acgggagggc ttaccatctg 7150

gccccagtgc tgcaatgata ccgcgagacc cacgctcacc ggctccagat 7200

ttatcagcaa taaaccagcc agccggaagg gccgagcgca gaagtggtcc 7250

tgcaacttta tccgcctcca tccagtctat taattgttgc cgggaagcta 7300

gagtaagtag ttcgccagtt aatagtttgc gcaacgttgt tgccattgct 7350

acaggcatcg tggtgtcacg ctcgtcgttt ggtatggctt cattcagctc 7400

cggttcccaa cgatcaaggc gagttacatg atcccccatg ttgtgcaaaa 7450

aagcggttag ctccttcggt cctccgatcg ttgtcagaag taagttggcc 7500

gcagtgttat cactcatggt tatggcagca ctgcataatt ctcttactgt 7550

catgccatcc gtaagatgct tttctgtgac tggtgagtac tcaaccaagt 7600

cattctgaga atagtgtatg cggcgaccga gttgctcttg cccggcgtca 7650

atacgggata ataccgcgcc acatagcaga actttaaaag tgctcatcat 7700

tggaaaacgt tcttcggggc gaaaactctc aaggatctta ccgctgttga 7750

gatccagttc gatgtaaccc actcgtgcac ccaactgatc ttcagcatct 7800

tttactttca ccagcgtttc tgggtgagca aaaacaggaa ggcaaaatgc 7850

cgcaaaaaag ggaataaggg cgacacggaa atgttgaata ctcatactct 7900

tcctttttca atattattga agcatttatc agggttattg tctcatgagc 7950

ggatacatat ttgaatgtat ttagaaaaat aaacaaatag gggttccgcg 8000

cacatttccc cgaaaagtgc cacctaaatt gtaagcgtta atattttgtt 8050

aaaattcgcg ttaaattttt gttaaatcag ctcatttttt aaccaatagg 8100

ccgaaatcgg caaaatccct tataaatcaa aagaatagac cgagataggg 8150

ttgagtgttg ttccagtttg gaacaagagt ccactattaa agaacgtgga 8200

ctccaacgtc aaagggcgaa aaaccgtcta tcagggcgat ggcccactac 8250

gtgaaccatc accctaatca agttttttgg ggtcgaggtg ccgtaaagca 8300

ctaaatcgga accctaaagg gagcccccga tttagagctt gacggggaaa 8350

gccggcgaac gtggcgagaa aggaagggaa gaaagcgaaa ggagcgggcg 8400

ctagggcgct ggcaagtgta gcggtcacgc tgcgcgtaac caccacaccc 8450

gccgcgctta atgcgccgct acagggcgcg tcccattcgc cattcaggct 8500

gcgcaactgt tgggaagggc gatcggtgcg ggcctcttcg ctattacgcc 8550

agctggcgaa agggggatgt gctgcaaggc gattaagttg ggtaacgcca 8600

gg 8602

As will be noted, residues 21-37 of SEQ ID NO:61 correspond to the M13 Fwd primer binding site (SEQ ID NO:50). Residues 47-65 of SEQ ID NO:61 correspond to the T7 promoter site (SEQ ID NO:12). Residues 186-565 of SEQ ID NO:61 correspond to the CMV immediate early enhancer site (SEQ ID NO:1). Residues 566-769 of SEQ ID NO:61 correspond to the CMV immediate early promoter site (SEQ ID NO:52). Residues 881-1453 of SEQ ID NO:61 correspond to the beta-globin intron site (SEQ ID NO:53). Residues 1554-5318 of SEQ ID NO:61 correspond to a polynucleotide sequence (SEQ ID NO:55) that encodes the SARS-CoV-2 S protein (SEQ ID NO:54). Residues 5461-5516 of SEQ ID NO:61 correspond to the beta-globin poly(A) signal site (SEQ ID NO:56). Residues 5874-5890 of SEQ ID NO:61 are complementary to the M13 Rev primer binding site (SEQ ID NO:51). Residues 5898-5914 of SEQ ID NO:61 are complementary to the lac operator site (SEQ ID NO:57). Residues 5922-5952 of SEQ ID NO:61 are complementary to the lac promoter site (SEQ ID NO:58). Residues 5967-5988 of SEQ ID NO:61 are complementary to the CAP binding site (SEQ ID NO:59). Residues 6276-6864 of SEQ ID NO:61 are complementary to the ColE1/pMB1/pBR322/pUC origin of replication (SEQ ID NO:19). Residues 7035-7895 of SEQ ID NO:61 are complementary to the AmpR antibiotic resistance determinant (SEQ ID NO:22). Residues 7896-8000 of SEQ ID NO:61 are complementary to the AmpR promoter (SEQ ID NO:26). Residues 8026-8481 of SEQ ID NO:61 are complementary to the f1 origin of replication (SEQ ID NO:60).

II. Methods for Producing the SARS-CoV-2 S Protein Lentiviral Particles of the Present Invention

Any cell type capable of propagating a lentivirus may be employed to produce the SARS-CoV-2 S Protein Lentiviral Particle of the present invention. However, the use of HEK293 (ATCC® CRL-1573™), HEK293T, and SJ293TS human embryonic kidney cells are preferred. Such cells are widely known (e.g., Merten, O.-W. et al. (2016) “Production Of Lentiviral Vectors,” Molec. Ther. Meth. Clin. Develop. 3:16017:1-14; Bauler, M. et al. (2020) “Production of Lentiviral Vectors Using Suspension Cells Grown in Serum-Free Media,” Molec. Ther.: Meth. Clin. Develop. 17:58-68; Hu, J. et al. (2018) “Human Embryonic Kidney 293 Cells: A Vehicle for Biopharmaceutical Manufacturing, Structural Biology, and Electrophysiology,” Cells Tissues Organs 205:1-8; Thomas, P. et al. (2005) “HEK293 Cell Line: A Vehicle For The Expression Of Recombinant Proteins,” J. Pharmacol. Toxicol. Meth. 51(3):187-200; Pear, W. S. et al. (1994) “Production Of High-Titer Helper-Free Retroviruses By Transient Transfection,” Proc. Natl. Acad. Sci. (U.S.A.) 90:8392-8396), and are available commercially (Antibody Research Corp.; ATCC; Thermo-Fisher Scientific; Life Technologies; etc.).

Cells may be transfected with the above-described lentiviral plasmids and cultured to produce the SARS-CoV-2 S Protein Lentiviral Particle of the present invention using any of a variety of methods (Bauler, M. et al. (2020) “Production of Lentiviral Vectors Using Suspension Cells Grown in Serum-Free Media,” Molec. Ther.: Meth. Clin. Develop. 17:58-68; Merten, O.-W. et al. (2016) “Production Of Lentiviral Vectors,” Molec. Ther. Meth. Clin. Develop. 3:16017:1-14; Gandara, C. et al. (2018) “Manufacture of Third-Generation Lentivirus for Preclinical Use, with Process Development Considerations for Translation to Good Manufacturing Practice,” Hum. Gene Ther. Meth. 29(1):1-15). For example, in the method of Gandara, C. et al. (2018) (“Manufacture of Third-Generation Lentivirus for Preclinical Use, with Process Development Considerations for Translation to Good Manufacturing Practice,” Hum. Gene Ther. Meth. 29(1):1-15), HEK293 cells are coated onto the surfaces of tissue culture dishes or flasks using poly-L-lysine and cultured at 37° C. (3% CO₂) to confluency in Dulbecco's modified Eagle's medium containing high glucose and containing 10% fetal bovine serum, 2 mM L-glutamine, 1 mM sodium pyruvate and 100 IU/mL of penicillin/streptomycin. Cells are then detached from the surface through the addition of Trypsin-EDTA (0.5%) and phosphate buffer. The cells are then resuspended in fresh media, cultured overnight at 37° C. (3% CO₂) and incubated in a 200 mM calcium chloride transfection buffer and borate-buffered saline transfection reagent for 30 minutes at room temperature in the presence of the lentiviral plasmids, and then incubated at 37° C. and 3% CO₂overnight in culture media. Culture media is replaced after 18 hours, and the cells are permitted to grow for an additional 24 hours.

The amount of plasmid to be provided to such cells will vary depending on their respective lengths. Table 2 provides the mass, copy numbers and typical lengths of such plasmids that may be used to calculate the amount (μg) of plasmid that is to be provided for any particular transfection (thus, for example, if a vector has a smaller length that that indicated in Table 2, the employed amount of the plasmid will be decreased in order to maintain the indicated copy number).

TABLE 2

Mass
Typical
DNA Copy

Vector
(μg)
Length
Number

LTR-containing Vector
300
7,537
3.9 × 10¹³

Packaging Vector
250
8,890
2.7 × 10¹³

REV Vector
125
4,180
2.9 × 10¹³

Envelope Vector
150
5,822
2.5 × 10¹³

After such culturing, the culture media is filtered using a 0.45 μm or 0.22 μm filter to obtain a culture media that comprises physical titers of between 10¹¹and 10¹²particles/mL and functional titers of between 10⁷and 10¹⁰particles/mL. Additional purification can be obtained using ultracentrifugation or tangential flow filtration (Cooper, A. R. et al. (2011) “Highly Efficient Large-Scale Lentiviral Vector Concentration By Tandem Tangential Flow Filtration,” J. Virol. Methods. 177(1):1-9; Busatto, S. et al. (2018) “Tangential Flow Filtration for Highly Efficient Concentration of Extracellular Vesicles from Large Volumes of Fluid,” Cells 7(12):1-11; Musumeci, T. et al. (2018) “Tangential Flow Filtration Technique: An Overview on Nanomedicine Applications,” Pharm. Nanotechnol. 6(1):48-60; Nordin, J. Z. et al. (2019) “Tangential Flow Filtration with or Without Subsequent Bind-Elute Size Exclusion Chromatography for Purification of Extracellular Vesicles,” Methods Mol. Biol. 1953:287-299; Tinch, S. et al. (2019) “A Scalable Lentiviral Vector Production and Purification Method Using Mustang Q Chromatography and Tangential Flow Filtration,” Methods Mol. Biol. 1937:135-153).

III. Pharmaceutical Compositions

The invention provides SARS-CoV-2 S Protein Lentiviral Vaccine pharmaceutical compositions that comprise the SARS-CoV-2 S Protein Lentiviral Particles of the present invention and a pharmaceutically acceptable carrier.

In a first preferred embodiment, the SARS-CoV-2 S protein lentiviral vaccine pharmaceutical compositions of the present invention will comprise lentiviral particles that array the SARS-CoV-2 S protein on their surface. Such vaccines may be produced by transfecting cells with the packaging, REV, and envelope vectors of the present invention in concert with any of the LTR-containing vectors of the invention. In general, the lentiviral particles of such vaccines mimic the external structure of SARS-CoV-2 and thus permit the recipient subject to develop immunity to the virus.

In a second preferred embodiment, the SARS-CoV-2 S protein lentiviral vaccine pharmaceutical compositions of the present invention will comprise lentiviral particles that array the SARS-CoV-2 S protein on their surface and additionally comprise a genome that encodes all or a portion of one or more SARS-CoV-2 proteins (e.g., all or part of the SARS-CoV-2 S protein, and/or all or part of the SARS-CoV-2 N protein, etc.) (“SARS-CoV-2 Transgene-Containing SARS-CoV-2 S Protein Lentiviral Vaccines). Such vaccines may be produced by transfecting cells with the packaging, REV, and envelope vectors of the present invention in concert with an LTR-containing vector of the invention that comprises a SARS-CoV-2 protein-encoding transgene polynucleotide sequence. Such vaccines operate in multiple ways to provide enhanced immunity to recipient subjects. In a first manner, the lentiviral particles of such vaccines mimic the external structure of SARS-CoV-2 and thus permit the recipient subject to develop immunity to the virus. In a second manner, the lentiviral particles of such vaccines, particularly where the SARS-CoV-2 proteins are expressed with a secretory signal sequence (such as the IL-2 signal sequence), mediate the production and release of SARS-CoV-2 proteins into the extracellular environment, and thus provide additional antigen for eliciting immunity. In particular, lentiviral particles of such vaccines that express two or more proteins (e.g., the SARS-CoV-2 S and N proteins) would better mimic the environment seen in an actual SARS-CoV-2 infection, and thus would be expected to provide more effective immunity to recipient subjects. Even more effective immunity is anticipated to be provided by lentiviral particles of such vaccines that array two or more proteins (e.g., the SARS-CoV-2 S and N proteins) on the particle's surface.

The pharmaceutical compositions of the present invention comprise an amount of such SARS-CoV-2 S Protein Lentiviral Particles sufficient to permit the immune system of a recipient subject to initiate and preferably persistently maintain immunity to SARS-CoV-2 infection (“effective amount”).

The term “pharmaceutically acceptable” means approved by a regulatory agency of the Federal or a state government or listed in the US Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term “carrier” refers to a diluent, adjuvant (e.g., Freund's adjuvant complete and incomplete), excipient, or vehicle with which the therapeutic is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained-release formulations and the like. Suitable pharmaceutical excipients are described in U.S. Pat. Nos. 8,852,607; 8,192,975; 6,764,845; 6,759,050; and 7,598,070. The SARS-CoV-2 S Protein Lentiviral Vaccine pharmaceutical compositions of the present invention may also include one or more adjuvants to boost the immune response of a recipient so as to produce more antibodies and/or provide longer-lasting immunity. Suitable adjuvants are known in the art, and include alum, aluminum hydroxide, aluminum phosphate, calcium phosphate hydroxide, mineral oil (e.g., paraffin oil), killed Bordetella pertussis, killed Mycobacterium bovis, plant saponins from Quillaja, soybean, cytokines (e.g., IL-1, IL-2, IL-12, etc.), Freund's complete adjuvant, Freund's incomplete adjuvant, etc. Pharmaceutically acceptable carriers or diluents, adjuvants and excipients are disclosed in REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY, 21^stEdition (2005) Hauber, Ed., Lippincott Williams & Wilkins.

Generally, the ingredients of compositions of the invention are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water-free concentrate, or as an aqueous solution in a hermetically sealed container such as a vial, an ampoule or sachette indicating the quantity of active agent. Where the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water for injection or saline, or other diluent can be provided so that the ingredients may be mixed prior to administration.

The invention also provides a pharmaceutical pack or kit comprising one or more containers of such pharmaceutical composition and instructions for the use of the included SARS-CoV-2 S Protein Lentiviral Vaccine pharmaceutical composition. Optionally associated with such container(s) can be a notice in a form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.

The SARS-CoV-2 S Protein Lentiviral Vaccine pharmaceutical compositions of the present invention are preferably packaged in sterile containers, such as vials, ampoules or sachettes, indicating the provided dose. In one embodiment, such SARS-CoV-2 S Protein Lentiviral Vaccine pharmaceutical compositions are supplied as a dry sterilized lyophilized powder or water-free concentrate in a hermetically sealed container and can be reconstituted, e.g., with water, saline, or other diluent to the appropriate concentration for administration to a subject. The lyophilized material should be stored at between 2° C. and 8° C. in their original container and the material should be administered within 12 hours, preferably within 6 hours, within 5 hours, within 3 hours, or within 1 hour after being reconstituted. In another embodiment, the SARS-CoV-2 S Protein Lentiviral Vaccine pharmaceutical compositions of the present invention are supplied as an aqueous solution in a hermetically sealed container and can be diluted, e.g., with water, saline, or other diluent, to the appropriate concentration for administration to a subject.

The SARS-CoV-2 S Protein Lentiviral Vaccine pharmaceutical compositions of the present invention may further comprise one or more additional prophylactic and/or therapeutic agents useful for the treatment of the disease or condition, in one or more containers; and/or such kits can further comprise one or more additional antiviral agents or one or more anti-SARS-CoV-2 antibodies.

Thus, the invention specifically contemplates pharmaceutical compositions and kits thereof that comprise the SARS-CoV-2 S Protein Lentiviral Vaccine pharmaceutical compositions of the present invention and one or more anti-SARS-CoV-2 antiviral agents, such as, for example, Actemra (Roche), AmnioBoost (Lattice Biologics), APN01 (APEIRON Biologics), AT-100 (Airway Therapeutics), BPI-002 (BeyondSpring), Brilacidin (Innovation Pharmaceuticals), BXT-25 (BIOXYTRAN), Chloroquine and Hydroxychloroquine/Plaquenil, Darunavir (Janssen Pharmaceutical), Favilavir, Galidesivir (Biocryst Pharma), Gimsilumab (Roivant Sciences), Kevzara (Regeneron), leronlimab (CytoDyn), lopinavir (Abbvie), NP-120 (Ifenprodil) (Algernon Pharmaceuticals), OYA1 (OyaGen), PREZCOBIX® HIV (Janssen Pharmaceutical), REGN3048-3051 (Regeneron), Remdesivir (GS-5734) (Gilead Sciences), SNG001 (Synairgen Research), TJM2 (I-Mab Biopharma), TZLS-501 (Tiziana Life Sciences) be provided in prophylactically effective, or therapeutically effective, amounts. The use of such a combined composition permits a synergistic response to COVID-19 infection.

The invention also specifically contemplates pharmaceutical compositions and kits thereof that comprise the SARS-CoV-2 S Protein Lentiviral Vaccine pharmaceutical compositions of the present invention and one or more additional SARS-CoV-2 vaccines. Such additional vaccine compositions include one or more of, for example, AdCOVID (Altimmune), AdCoVID™ (Altimmune), Avian Coronavirus Infectious Bronchitis Virus (IBV) vaccine (MIGAL Research Institute), ChAdOx1 (Jenner Institute), Fusogenix DNA vaccine (Entos Pharmaceuticals), INO-4700 (GLS-5300) (Inovio Pharma), INO-4800 (Inovio Pharmaceuticals), MERS coronavirus vaccine (Novavax), mRNA-1273 (Moderna), Plant-Derived Virus-Line Particle (Medicago), TNX-1800 (Tonix Pharmaceuticals), or Trimer-Tag© recombinant subunit vaccine (Clover Biopharmaceuticals) provided in prophylactically effective, or therapeutically effective, amounts. The use of such a combined vaccine composition permits a synergistic response to COVID-19 infection.

IV. Administration and Dosage

The SARS-CoV-2 S Protein Lentiviral Particle pharmaceutical compositions of the present invention can be administered by parenteral, topical, oral or intranasal means for prophylactic and/or therapeutic treatment. Intramuscular injection (for example, into the arm or leg muscles) and intravenous infusion are preferred methods of administration of the molecules of the present invention. In some methods, such molecules are administered as a sustained release composition or device. In some methods, the SARS-CoV-2 S Protein Lentiviral Particles of the present invention are provided directly into a particular tissue, for example, into the gastrointestinal tract (small intestine, colon, etc.), or into the trachea, bronchi, lungs, or pulmonary arteries that provide oxygen to the lungs, etc.

In one embodiment, a pharmaceutical composition of the present invention is administered parenterally. The phrases “parenteral administration” and “administered parenterally” as used herein denote modes of administration other than enteral and topical administration, usually by injection, and include epidermal, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intracranial, intraorbital, intracardiac, intradermal, intraperitoneal, intratendinous, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, intracranial, intrathoracic, epidural and intrasternal injection, subcutaneous and infusion. In one embodiment that pharmaceutical composition is administered by intravenous or subcutaneous injection or infusion. Intranasal administration is preferred for eliciting IgA2 secretory antibodies. Intramuscular administration is preferred for eliciting IgG or IgM antibodies.

Such pharmaceutical compositions may be administered to a patient who does not have COVID-19 but is susceptible to, or otherwise at risk of, COVID-19. When provided for such prophylactic use, the SARS-CoV-2 S Protein Lentiviral Particle pharmaceutical compositions of the present invention are administered to a subject in an amount sufficient to initiate a protective immune response against SARS-CoV-2 and to maintain such a protective immune response for an extended period (e.g., at least about 1 month, at least about 2 months, at least about 3 months, at least about 4 months, at least about 6 months, at least about 8 months, at least about 1 year, at least about 1.5 years, at least about 2 years, at least about 2.5 years, at least about 3 years, at least about 5 years, or more than five years. As used herein, the term “protective immune response,” denotes an immune response that includes the eliciting and production of neutralizing antibodies to SARS-CoV-2, so that the health of the subject is substantially preserved. Such pharmaceutical compositions may be alternatively or additionally administered to a patient who has been confirmed to suffer from SARS-CoV-2 infection, or who has been diagnosed as exhibiting COVID-19. When provided for such therapeutic use, the SARS-CoV-2 S Protein Lentiviral Particle pharmaceutical compositions of the present invention are administered to a subject in an amount sufficient to initiate a rapid protective immune response against SARS-CoV-2.

Effective doses of the SARS-CoV-2 S Protein Lentiviral Particle pharmaceutical compositions of the present invention for such prophylactic or therapeutic use may vary depending upon many different factors, including means of administration, target site, physiological state of the patient, other medications administered, and whether treatment is prophylactic or therapeutic. Treatment dosages are typically titrated to optimize their safety and efficacy. On any given day that a dosage is given, the dosage may range from about 0.0001 to about 100 mg/kg, and more usually from about 0.01 to about 10 mg/kg, of the host body weight. For example, dosages can be 1 mg/kg body weight or 10 mg/kg body weight or within the range of 1-10 mg/kg body weight. Exemplary dosages thus include: from about 0.1 to about 10 mg/kg/body weight, from about 0.1 to about 5 mg/kg/body weight, from about 0.1 to about 2 mg/kg/body weight, from about 0.1 to about 1 mg/kg/body weight, for instance about 0.15 mg/kg/body weight, about 0.2 mg/kg/body weight, about 0.5 mg/kg/body weight, about 1 mg/kg/body weight, about 1.5 mg/kg/body weight, about 2 mg/kg/body weight, about 5 mg/kg/body weight, or about 10 mg/kg/body weight

A physician or veterinarian having ordinary skill in the art may readily determine and prescribe the effective amount of the pharmaceutical composition required. For example, the physician or veterinarian could start doses of the SARS-CoV-2 S Protein Lentiviral Particle pharmaceutical compositions of the present invention at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved. In general, a suitable daily dose of a composition of the present invention will be that amount of the compound which is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above. Administration may, e.g., be intravenous, intramuscular, intraperitoneal, or subcutaneous, and for instance administered proximal to the site of the target. If desired, the effective daily dose of a pharmaceutical composition may be administered as two, three, four, five, six or more sub-doses administered separately at appropriate intervals, optionally, in unit dosage forms. While the SARS-CoV-2 S Protein Lentiviral Particle pharmaceutical compositions of the present invention may be administered alone, they may be administered with other compounds, e.g., an adjuvant, an antiviral agent, etc.

The therapeutic or prophylactic dosage may be administered repeatedly in order to ensure the continued immunity of the recipient. Relative to the initial administration of the vaccine, such subsequent administrations may be made after about 6 months, after about 1 year, after about 1.5 years, after about 2 years, after about 2.5 years, after about 3 years, after about 5 years, or after more than five years.

V. Diagnostic Utility

In addition to their therapeutic utility, the lentiviral particles of the present invention may be used diagnostically to provide antigen (e.g., SARS-CoV-2 S and/or N protein) that may be used to detect the presence of antibody in immune individuals or recovering COVID-19 patients. Such particles are superior to purified SARS-CoV-2 S and/or N protein, which may not adopt the conformation that such proteins adopt when attached to the SARS-CoV-2 surface. The conformations adopted by the SARS-CoV-2 S and/or N protein of the lentiviral particles of the present invention is expected to be closer to the native conformations of such proteins on a coronavirus.

VI. Embodiments of the Invention

Having now generally described the invention, the same will be more readily understood through reference to the following numbered Embodiments (“E”), which are provided by way of illustration and are not intended to be limiting of the present invention unless specified:

E1. A lentiviral particle that comprises a recombinantly engineered lentiviral genome and that arrays a SARS-CoV-2 spike (S) protein on its surface.
E2. The lentiviral particle of E1, wherein the recombinantly engineered lentiviral genome is non-integrating.
E3. The lentiviral particle of E1, wherein the recombinantly engineered lentiviral genome is incapable of being reverse transcribed.
E4. The lentiviral particle of E1, wherein the recombinantly engineered lentiviral genome is non-integrating and incapable of being reverse transcribed.
E5. The lentiviral particle of any one of E1-E4, wherein the recombinantly engineered lentiviral genome encodes a heterologous transgene protein.
E6. The lentiviral particle of any one of E1-E5, wherein the encoded heterologous transgene protein is an antibiotic resistance determinant, a reporter protein, a protein drug effective in treating SARS-CoV-2 infection, or a protein that comprises the epitope binding domain of an antibody that binds to a SARS-CoV-2 antigen.
E7. The lentiviral particle of E5, wherein the encoded heterologous transgene protein is a SARS-CoV-2 protein.
E8. The lentiviral particle of E7, wherein the encoded SARS-CoV-2 heterologous transgene protein is a SARS-CoV-2 Spike (S) protein or a SARS-CoV-2 Nucleocapsid (N) protein.
E9. A vaccine for the treatment of COVID-19, wherein the vaccine comprises a prophylactically effective dose of a pharmaceutical composition that comprises the lentiviral particle of any one of E1-E8 and a pharmaceutically acceptable carrier.
E10. The vaccine of E9, wherein the recombinantly engineered lentiviral genome of the lentiviral particle is non-integrating.
E11. The vaccine of E9, wherein the recombinantly engineered lentiviral genome of the lentiviral particle is incapable of being reverse transcribed.
E12. The vaccine of E9, wherein the recombinantly engineered lentiviral genome of the lentiviral particle is non-integrating and incapable of being reverse transcribed.
E13. The vaccine of E9, wherein the recombinantly engineered lentiviral genome of the lentiviral particle encodes a heterologous transgene protein.
E14. The vaccine of E13, wherein the encoded heterologous transgene protein is a SARS-CoV-2 Spike (S) protein or a SARS-CoV-2 Nucleocapsid (N) protein.
E15. The vaccine of any one of E9-E14, wherein the pharmaceutically acceptable carrier is adapted for intramuscular administration.
E16. The vaccine of any one of E9-E14, wherein the pharmaceutically acceptable carrier is adapted for intranasal administration.
E17. A method for producing the recombinant lentiviral particle of any one of E1-E16, wherein the method comprises:

(A) transfecting HEK293 cells with:

- (1) an LTR-containing vector that comprises a deleted 5′ LTR U3 region and a self-inactivating 3′ LTR region;
- (2) a packaging vector that comprises a polynucleotide that encodes gag and pol proteins;
- (3) a REV vector that comprises a polynucleotide that encodes a rev protein; and
- (4) an envelope vector that comprises a polynucleotide that encodes a SARS-CoV-2 spike (S) protein; and
- (B) permitting the cells to produce the recombinant lentiviral particle.
E18. The method of E17, wherein the packaging vector comprises a genome that encodes a mutated integrase, wherein the transfection produces a recombinant lentiviral particle that comprises a genome that is non-integrating.
E19. The method of E17, wherein the packaging vector comprises a genome that encodes a mutated reverse transcriptase, wherein the transfection produces a recombinant lentiviral particle that comprises a genome that is incapable of being reverse transcribed.
E20. The method of E19, wherein the packaging vector comprises a genome that additionally encodes a mutated integrase, wherein the transfection produces a recombinant lentiviral particle that comprises a genome that is non-integrating and incapable of being reverse transcribed.
E21. The method of any one of E17-E20, wherein the LTR-containing vector comprises the features of any of the LTR-containing vectors: pLenti-SV40-puro (SEQ ID NO:27);
- pLenti-SV40-puro (-att) (SEQ ID NO:28);
- pLenti-CMV-IRES-empty (-att) (SEQ ID NO:67);
- pLenti-CMV-IRES-Spike (SEQ ID NO:70);
- pLenti-IgGκ-nCoV-Spike-CD8-TM (-att) (SEQ ID NO:83);
- pLenti-IgGκ-nCoV-N-CD8-TM (-att) (SEQ ID NO:84); or
- pLenti-IL-2 n-CoV-N(-att) (SEQ ID NO:85).
E22. The method of any one of E17-E21, wherein the packaging vector comprises the features of pGAG (SEQ ID NO:44).
E23. The method of any one of E17-E22, wherein the REV vector comprises the features of pREV (SEQ ID NO:49).
E24. The method of any one of E17-E23, wherein the envelope vector comprises the features of pCMV-SARS-CoV-2 S Protein (SEQ ID NO:61).

EXAMPLES

Having now generally described the invention, the same will be more readily understood through reference to the following examples, which are provided by way of illustration and are not intended to be limiting of the present invention unless specified.

Example 1
Production of Recombinant Lentiviral Particles that Array the SARS-CoV-2 Spike (S) Protein on their Surface

HEK293 cells are co-transfected with the above-described pLenti-SV40-puro (-att), pGAG, pREV, and pCMV-SARS-CoV-2 S Protein vectors substantially as described by Gandara, C. et al. (2018) (“Manufacture of Third-Generation Lentivirus for Preclinical Use, with Process Development Considerations for Translation to Good Manufacturing Practice,” Hum. Gene Ther. Meth. 29(1):1-15). The co-transfection yields recombinant lentiviral particles that array the SARS-CoV-2 spike (S) protein on their surface.

Example 2
Vaccine Use of Lentiviral Particles that Array the SARS-CoV-2 Spike (S) Protein on their Surface

Therapeutically effective amounts of the lentiviral particles of Example 1 are injected intramuscularly or are applied intranasally to recipient human subjects. Neutralizing antibodies to SARS-CoV-2 are elicited and detected in such immunized subjects. The neutralizing antibodies protect the immunized subjects from COVID-19.

All publications and patents mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference in its entirety. While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth.

Non-integrating HIV-1 comprising mutant RT/IN proteins and the SARS-CoV-2 spike protein

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

Field of Search

CPC

International Classifications

Abstract

Description

Claims

Foreign Referenced Citations (1)

Non-Patent Literature Citations (70)